Genotypic and phenotypic effects of c-Ha-ras oncogene transfection on human colorectal carcinoma cell lines

Citation for published version (APA):

de Vries, J. E. (1993). *Genotypic and phenotypic effects of c-Ha-ras oncogene transfection on human colorectal carcinoma cell lines*. [Doctoral Thesis, Maastricht University]. Rijksuniversiteit Limburg. <https://doi.org/10.26481/dis.19931210jd>

Document status and date:

Published: 01/01/1993

DOI:

[10.26481/dis.19931210jd](https://doi.org/10.26481/dis.19931210jd)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

GENOTYPIC AND PHENOTYPIC EFFECTS
OF C-HA-RAS ONCOGENE TRANSFECTION ON
HUMAN COLORECTAL CARCINOMA CELLS

De druk van dit proefschrift werd financieel ondersteund door de Stichting Klinische Pathologie Zuid-Limburg en BioRad.

**GENOTYPIC AND PHENOTYPIC EFFECTS
OF C-HA-RAS ONCOGENE TRANSFECTION ON
HUMAN COLORECTAL CARCINOMA CELLS**

PROEFSCHRIFT

ter verkrijging van de graad van doctor
aan de Rijksuniversiteit Limburg te Maastricht,
op gezag van de Rector Magnificus, Prof.dr. H. Philipsen,
volgens het besluit van het College van Dekanen,
in het openbaar te verdedigen
op vrijdag, 10 december 1993 om 16.00 uur

door

Johannes Erik de Vries

Promotores:

Prof.dr. F.T. Bosman

Prof.dr. J.P.M. Geraedts

Co-promotor:

Dr. J. ten Kate

Beoordelingscommissie:

Prof.dr. F.C.S. Ramaekers (voorzitter)

Prof.dr. C.H.C.M. Buys (Rijksuniversiteit Groningen)

Prof.dr. D.J. Ruiter (Katholieke Universiteit Nijmegen)

Prof.dr. J.F.M. Smits

Prof.dr. R.W. Stockbrügger

*"De essentie is dat een mens in wezen niet verandert, nog steeds het jongetje van
zeventien is dat de wereld met grote belangstelling en nieuwsgierigheid gadeslaat"*

Opland, 1993.

In herinnering aan mijn vader
Aan mijn moeder

Voor Mieke

CONTENTS

Chapter 1

GENERAL INTRODUCTION.....	11
1.1 Introduction.....	12
1.2 Invasion and metastasis.....	12
1.2.1 Characteristics of the invasive and metastatic cell.....	12
<i>Proliferation, genetic instability, and tumor cell heterogeneity</i>	13
<i>Proteases</i>	15
<i>Cell adhesion molecules</i>	16
<i>Dissemination of tumor cells</i>	19
1.2.2 Tools to investigate invasion and metastasis.....	20
<i>Patient material</i>	20
<i>Cell lines</i>	20
<i>In vitro models</i>	21
<i>In vivo models</i>	21
1.3 The c-Ha-ras oncogene.....	21
1.3.1 Structure, function, and expression of the c-Ha-ras gene.....	21
1.3.2 Regulation of the c-Ha-ras protein activity.....	24
1.3.3 Growth factors and p21ras proteins in signal transduction pathways.....	26
1.3.4 Mutations in the c-Ha-ras gene.....	29
1.3.5 Effects of the introduction of the c-Ha-ras oncogene in cell lines.....	30
<i>Fibroblasts</i>	30
<i>Mammary, prostate, and bladder cells</i>	31
<i>Keratinocytes and hepatocytes</i>	32
<i>Lymphocytes</i>	32
<i>Neuroendocrine cells</i>	32
<i>Muscle cells and melanocytes</i>	32
1.3.6 The c-Ha-ras oncogene in colorectal cancer.....	33
1.4 Aim and design of the study.....	34
1.5 References.....	36

Chapter 2

BEHAVIOR OF ORTHOTOPIC HUMAN COLORECTAL CARCINOMA XENOGRAPTS IN RELATION TO IN VITRO INVASION.....	53
---	----

Chapter 3

CHROMOSOMAL LOCALIZATION OF TRANSFECTED GENES BY A COMBINATION OF HOT BANDING AND FLUORESCENCE IN SITU HYBRIDIZATION.....	67
---	----

Chapter 4

TRANSFECTED C-HA-RAS ONCOGENE ENHANCES KARYOTYPIC INSTABILITY AND INTEGRATES PREDOMINANTLY IN ABERRANT CHROMOSOMES.....	79
---	----

Chapter 5

PHENOTYPIC ANALYSIS OF CACO 2 AND SW480 CELL LINES TRANSFECTED WITH THE C-HA-RAS ONCOGENE.....	95
---	----

Chapter 6

HUMAN CACO 2 CELLS TRANSFECTED WITH C-HA-RAS AS A MODEL FOR ENDOCRINE DIFFERENTIATION IN THE LARGE INTESTINE.....	111
---	-----

Chapter 7

GENERAL DISCUSSION.....	131
7.1 Introduction.....	132
7.2 Orthotopic xenografts: <i>Suitable to study the behavior of human colorectal carcinoma cell lines....</i>	132
7.3 Genetic instability in colorectal carcinoma: The influence of the c-Ha-ras oncogene.....	133
7.4 The role of the c-Ha-ras oncogene in colorectal carcinoma: Effects on growth and differentiation.....	135
7.5 Conclusions.....	136
7.6 References.....	137

SUMMARY.....	141
--------------	-----

SAMENVATTING VOOR DE LEEK.....	143
--------------------------------	-----

DANKWOORD.....	147
CURRICULUM VITAE.....	149
PUBLICATIONS.....	151

CHAPTER 1

GENERAL INTRODUCTION

1.1 INTRODUCTION

Colorectal cancer is one of the most common forms of cancer in Western Europe. It is third next to lung cancer and prostate cancer in males, and second to breast cancer in females (1, 2). In the Netherlands colorectal cancer accounts for 10% and 14% of the cancer deaths in men and women, respectively (2). The development of metastatic lesions from primary tumors is the main cause of failure in the treatment of colorectal tumors. The lack of fundamental understanding as to how tumor invasion, which precedes metastasis, and metastasis itself occur is one of the factors which hamper further advancement in therapy. Therefore, in current cancer research much attention is paid to the molecular mechanisms of tumor progression, including mechanisms of invasion and metastasis.

It has been demonstrated that genes, which normally regulate cellular proliferation and differentiation such as the family of the ras oncogenes, are involved in carcinogenesis. Also, in some aspects of tumor progression these genes play a role. Whether or not they also function in the development of invasion and/or the metastatic phenotype is largely unknown. The family of ras genes, which comprises of N-, Ki-, and Ha-ras, is frequently pointmutated in human colorectal carcinomas but their exact role in carcinogenesis and tumor progression is not understood (3, 4). In this thesis model studies on the possible role of the pointmutated c-Ha-ras gene in tumor progression in human colorectal carcinoma are reported.

This introductory chapter starts with a brief survey of the characteristics of the invasive and metastatic cell and of the tools to investigate invasion and metastasis. Subsequently, the structure, regulation, and function of the c-Ha-ras protein, the effects of its pointmutated counterpart on cell lines, and the occurrence of pointmutations in the c-ras gene family in colorectal cancer are discussed. The final part of this chapter briefly outlines the aims and strategies of the reported studies.

1.2 INVASION AND METASTASIS

1.2.1 Characteristics of the invasive and metastatic cell

The development of a metastatic lesion is the terminal stage of a dynamic proces during which a normal cell gradually acquires a phenotype that enables the cell to grow outside its normal microenvironment. The mechanisms behind this conversion have not been fully elucidated yet, but disorders in the control of the cell cycle, leading to genetic instability and genetic abnormalities, appear to be involved in the onset of cancer (5-7). The final steps of carcinogenesis encompass the invasive and metastatic cascade of events.

The metastatic cascade, the dissemination of carcinoma cells from the primary site to distant organs, can be divided in several steps (8, 9). First, the epithelial basement membrane, a specialized structure of the extracellular matrix which separates tissue

compartments, must be traversed (10). Increased proteolytic activity at the leading edge of invading carcinoma cells might be required at this stage (11). Second, carcinoma cells must detach from the primary tumor, implicating involvement of cell-cell adhesion molecules, which regulate tissue architecture (12). Third, carcinoma cells must express cell adhesion molecules, which are able to interact with extracellular matrix components, in order to migrate through the extracellular matrix (13). Migration of carcinoma cells at this stage might be facilitated by the secretion of autocrine factors that increase cell motility (14-16). Fourth, the carcinoma cell must gain access to lymphatics or blood vessels for further dissemination, and thereby must be able to penetrate the endothelial basement membrane. Fifth, carcinoma cells have to survive the circulation in order to lodge elsewhere. Sixth, they should again traverse the endothelial basement membrane, migrate through extracellular matrix and grow at ectopic sites in order to develop metastases.

Although every step in the metastatic cascade is essential for a metastatic lesion to develop, tumor cell invasion defined as the ability of a tumor cell to traverse the basement membrane, detach from the primary tumor, and migrate through the extracellular matrix in an abnormal tissue compartment, marks the transition from benign to malignant behavior. For this reason, the molecular mechanisms of basement membrane remodeling by proteases and the interactions of the cell with its microenvironment through cell adhesion molecules will be discussed briefly. Subsequently, the possible mechanisms which influence the dissemination of carcinoma cells are reviewed.

Proliferation, genetic instability, and tumor cell heterogeneity

Cell proliferation is required to substitute cells lost either by physiological mechanisms, such as programmed cell death, or by non-physiological mechanisms, such as injury. Physiological cell proliferation is strictly controlled and in balance with cell loss. During DNA replication genetic errors may be introduced into genomic DNA (17). Increased cell proliferation has been associated with an increased probability of cancer (6, 17-20). Because genetic alterations are crucial in carcinogenesis (21) it is conceivable that increased genetic instability due to the introduction of errors in replicated DNA of proliferating cells can contribute to the generation of cancer (5, 7). An argument in favor of this mechanism is the recent genetic mapping of a locus, which predisposes to human familial colorectal cancer (22). The presence of widespread alterations in short repeated DNA sequences in these familial colorectal cancers suggested that numerous replication errors were introduced during tumor development. It was therefore postulated that this locus contains a gene involved in DNA replication (23).

Genetic errors occur during the replication of DNA in the S-phase of the cell-cycle and during the chromosomal segregation in the mitosis or M-phase of the cell-cycle (7). Cell-cycle checkpoints ensure that faults in the replication of DNA and in chromosomal segregation are minimized (7). They do so by functioning as feed-back controls in

eukaryotic cells. An important cell-cycle checkpoint is the start of the M-phase, which is inhibited if DNA replication in S-phase is not finished yet (7, 24). The maturation promoting factor (MPF) is essential in this regulation (7). Inactive MPF, a complex of cyclin B and a tyrosine phosphorylated protein kinase $p34^{cdc2}$, blocks the entry of the cell into the M-phase (7). MPF is maintained in the inactive form by the presence of unreplicated DNA or damaged DNA (7). After completion of the S-phase, tyrosine dephosphorylation activates MPF, which in turn initiates the start of the M-phase, where chromosomes condense and become aligned at the metaphase plane (7). Segregation of the chromosomes proceeds after MPF is inactivated by the degradation of cyclin B, leaving $p34^{cdc2}$ intact for the next round of cell division (7). Various mechanisms for repair of DNA damage are known, which correct genetic errors occurring during DNA replication or which are induced by non-physiological agents, such as UV-light. Defects in these repair mechanisms increase the number of genetic errors during cell proliferation and make cells susceptible to carcinogenesis (21, 25). Indeed, skin cells from *Xeroderma pigmentosum* patients, which are defective in DNA repair mechanisms, are vulnerable for the development of cancer induced by sun light, most likely because of the accumulation of pyrimidine dimers (26, 27). Such skin tumor cells from *Xeroderma pigmentosum* patients contain twice as many mutated *c-ras* genes than skin tumor cells from normal patients (28). Furthermore, human colorectal tumors have been shown to harbour mutations in the catalytic domain of DNA polymerase β , which is involved in DNA repair (29). The product of the p53 tumor suppressor gene, which is the gene most frequently mutated in human tumors (30), is involved in a mechanism to delay entrance of cycling cells into the M-phase if DNA damage occurs, allowing DNA repair before the cell-cycle progresses (31). Therefore, when the p53 gene harbours a pointmutation, the cell-cycle may progress with unrepaired DNA-lesions, thereby increasing the number of genetic abnormalities. Thus, defects in DNA repair pathways increase genetic instability and may result in the multiple mutations which accumulate during carcinogenesis (21, 25).

Given the relation between cell proliferation and carcinogenesis it might not be surprising that a considerable proportion of the known oncogenes are truncated or altered forms of genes, which function in the regulation of cell proliferation. These include growth factors, such as PDGF and CSF-1, and their respective receptors, signal transducing proteins, such as the *c-ras* genes, and non-receptor tyrosine kinase proteins, such as the *src* gene family, and transcription factors, such as *c-fos* (32).

Although it is generally believed that a primary tumor derives from the clonal expansion of one progenitor cell, carcinomas tend to be heterogenous with regard to their genotypical and phenotypical characteristics. It is plausible to assume that continuous proliferation of a progenitor cell with insufficient control of DNA replication and chromosome segregation, increases genetic instability of its offspring. This might be the driving force behind the generation of tumor cell heterogeneity. The ongoing genetic instability may affect the expression of genes or even cause loss of genes. This implies that gene expression in cancer cells is partly autonomous rather than strictly regulated

by the microenvironment. Especially in the later stages of cancer development, when genetic alterations are frequent, this mechanism might contribute to the autonomous growth of carcinomas.

Proteases

One of the first obstacles that carcinoma cells encounter is the basement membrane. The epithelial basement membrane consists of a thin sheet of macromolecules (reviewed in 33, 34). The most prominent components are type IV collagen, which functions as a scaffolding protein, and laminin, adhering to type IV collagen and mediating cell binding (34). Continuous remodeling of the basement membrane is observed in neoplasia, and it has been proposed that imbalance between breakdown and synthesis determines invasive behavior of carcinoma cells (33).

Breakdown of the basement membrane involves degradation of type IV collagen. Metalloproteases have been detected, which degrade type IV collagen, whereas interstitial type I and III collagens are degraded by other metalloproteases (8, and references therein). Under physiological conditions the activity of metalloproteases must be controlled tightly to prevent excessive degradation of the extracellular matrix. Tissue inhibiting metalloproteases (TIMP-1 and -2) bind irreversibly to active metalloproteases rendering them inactive (35, 36), and may thus be involved in the regulation of collagenolytic activity.

Metalloproteases are found in active and latent forms (8). The latent form of type IV collagen specific metalloproteases can be activated by cleavage via plasmin (37, 38). Plasmin is a serine protease and is formed after proteolytic activation of the inactive precursor plasminogen (39), which is able to bind to collagen type IV (39). The activation of plasminogen into plasmin is mediated by plasminogen activators, of which two forms are known, the urokinase-type (u-PA) and the tissue-type (t-PA) (reviewed in 40). Studies indicate that the physiological function of plasminogen activators, and particularly u-PA, involves tissue degradation in the normal organism (40). u-PA is secreted as an inactive, single chain 55 kDa protein (41), and is activated after cleavage at position 157 into a two chain (A and B) molecule (42). A high affinity receptor for u-PA has been reported, which binds the A chain so as to orient the B chain with proteolytic activity toward its target plasminogen (43), converting it into plasmin (44). In this way, catalytic activity is confined to a small region at the cellular surface, which allows local breakdown of the basement membrane.

Active u-PA is rendered inactive after binding to plasminogen activator inhibitors (PAI's), of which two forms are known (45). If active u-PA is attached to the u-PA receptor (u-PAR) and PAI-1 binds to u-PA, then the whole complex is internalized (46, 47), a process mediated by the low density lipoprotein receptor-related protein (LRP) (48). The u-PA-PAI-1 complex is degraded in the lysosomes and the u-PA receptor recycles back to the cell surface (48).

Collectively these proteins allow controlled degradation of the basement membrane in the following way. Degradation is initiated by the secretion of u-PA. After binding of

active u-PA to u-PAR, plasminogen is converted into plasmin. In turn, plasmin mediates the conversion of the latent form of type IV collagenase into the active form. Proteolytic activity is terminated after the binding of either TIMP-1 to type IV collagenase or PAI-1 to u-PA. Another round of the proteolytic cascade may start when the recycled u-PA receptor again binds u-PA. The presence of PAI-1 (49) and most likely TIMP-1 (50, 51) in the extracellular matrix might prevent excessive degradation of the basement membrane.

The ability of carcinoma cells to traverse the basement membrane and leave the compartment to which they are normally confined implies that a local imbalance between membrane degradation and synthesis occurs. Indeed, invasive and metastatic behavior has been correlated repeatedly with increased expression of u-PA (52-59) and type IV collagenase (60-62). Further, increased numbers of u-PAR saturated with u-PA positively correlated with invasive (63, 64) and metastatic capacity (65). This latter mechanism might contribute also to the induction of tissue invasiveness by macrophage colony-stimulating factor (CSF-1), in CSF-1-receptor positive carcinoma cells (66, 67). Inhibition at each step in the proteolytic cascade reduces the invasive potential of tumor cells (68-70) and expression of TIMP-1 is inversely correlated with invasive and/or metastatic behavior of tumor cells (36, 71).

The expression of several components in the proteolytic cascade has been investigated in colon cancer. It was found that mRNA encoding for type IV collagenases (72 and 92 kDa) is expressed in fibroblasts and tissue macrophages in stroma surrounding invasive cancer tissue, but not by carcinoma cells (72). u-PA mRNA and u-PAR mRNA has been detected in fibroblast-like stromal cells and in carcinoma cells at invasive foci of human colon adenocarcinomas (73). However, u-PA has been demonstrated histochemically in the cytoplasm of neoplastic columnar epithelial cells in carcinomas and adenomas of the colorectum (74). Both studies reported absence or low expression of u-PA in normal colonic tissue. Expression of PAI-1 mRNA was noted in endothelial cells in the stroma surrounding invasive tumor glands in colon adenocarcinomas (75). These results indicate that the components of the proteolytic cascade are in close proximity of each other at the invasive edges of human adenocarcinoma of the colon. This suggests a role for the u-PA induced proteolytic activity in invasion of carcinoma cells. However, the interactions between the participating cells and proteins are not yet clear, though an excess of u-PA over PAI and the concentration of u-PA proteolytic activity by u-PAR to a small area of the cell surface may contribute to tumor progression in the colon (63, 64, 76, 77).

Cell adhesion molecules

In the interactions between carcinoma cells and their microenvironment cell adhesion molecules play a prominent role. Detachment of a carcinoma cell from the primary tumor mass most likely involves a particular class of cell-cell adhesion molecules, the cadherins (13, 78). In the migration of a carcinoma cell through the extracellular matrix

a prominent role is probably played by integrins, more specifically the family of β_1 integrins, a family of cell-extracellular matrix adhesion molecules (13).

Cadherins.

The interactions between epithelial cells in a parenchymatous organ are mediated by cadherins, transmembrane calcium dependent cell-cell adhesion molecules. Cadherins show homophilic interactions: they bind selectively to identical cadherin molecules. For example, E-cadherin binds only to E-cadherin. This might provide a mechanism for the preferential adhesion between homotypic cells and implies an important role for cadherins in maintaining tissue integrity (12).

The family of cadherins as yet comprises four members: E-, P-, N-, and R-cadherin (12). The extracellular domain of cadherins is responsible for homophilic binding (79). The intracellular domain is the most conserved region in the cadherin family, which implies an important function for this domain. Deletion of this domain, even while the extracellular domain is intact, abrogates the function of cadherin as cell-cell adhesion receptor (12, 80, 81).

Cadherins are concentrated at special zones in the plasma membrane, the adhesion belts, where the intracellular domain interacts with the cytoplasmic proteins α -, β - and γ -catenins (12, 81). The catenin-associated form of E-cadherin can bind to actin. This association is most likely a prerequisite for the function of cadherins (81) and might include a morphoregulatory role. This is suggested by the following observations. Monoclonal antibodies specific for E-Cadherin disperse cell monolayers (82) and cells lacking α -catenin grow as isolated cells, but after transfection with α N-catenin cDNA cellular aggregates are formed (83). In both cases the morphology of the cells changes. Morphological changes paralleling invasive behavior of carcinoma cells have been demonstrated after loss of E-cadherin mediated cell-cell adhesion (82). Re-expression of E-cadherin inhibited invasive behavior (84).

Alteration of cell morphology most likely results from rearrangements in the actin cytoskeleton. Actin filament bundles are attached to adhesion belts by the proteins vinculin and α -actinin (85). Proteins of the *src* proto-oncogene family, *src*, *yes*, and *lyn* are concentrated also in adhesion belts (12). These membrane proteins are tyrosine kinases and might regulate the function of the cadherin-cytoskeleton complex or mediate transmission of intercellular signals at adhesion belts. The suggestion that the acquisition of invasive potential involves increased phosphorylation of E-cadherin-associated β -catenin by *src* (86) lends support to this postulation.

In cancer tissue, the loss of E-cadherin expression is correlated with tumor progression in human breast carcinoma and squamous cell carcinoma of head and neck (87, 88), human high-grade prostate and rat prostate cancer (89, 90), and mouse squamous cell carcinomas of the skin (91), but is less obvious in human carcinomas of the colon and the lung (92-94).

Thus, although in experimental systems cadherins appear to be involved in carcinoma cell invasion and therefore in tumor progression. Such a relation, however, is less clear in human colorectal cancer tissue.

Integrins.

Major components of the extracellular matrix, such as collagen, laminin and fibronectin, are recognized by cells through specific receptors, which belong to a versatile class of heterotypic cell adhesion molecules, the integrins (78, 95, 96). Integrins are heterodimers of noncovalently associated α and β subunits (96), and especially the subclass of integrins with β_1 subunits are involved in cell-extracellular matrix interactions (78). Most individual integrins bind to more than one ligand and individual ligands in general are mostly recognized by more than one integrin species. The specificity of an integrin further depends on the cell type, e.g. the $\alpha_2\beta_1$ integrin on platelets is specific for collagen and not for laminin, whereas when present on other cell types it can recognize both ligands. These modifications make the pattern of interactions between integrins and their ligands rather complicated (96).

Both subunits of most β_1 integrins are transmembrane glycoproteins with a short cytoplasmic domain and a single hydrophobic transmembrane segment (96). The extracellular domains of both subunits are involved in the recognition of specific amino acid sequences in their ligands, for example the Arg-Gly-Asp (RGD) sequence in fibronectin for $\alpha_5\beta_1$ integrin and Asp-Gly-Glu-Ala (DGEA) in type I collagen for $\alpha_2\beta_1$ integrin (96). Peptides containing these sequences have the ability to inhibit cell adhesion of integrins to certain of these extracellular matrix proteins (78). The cytoplasmic domain of the β_1 subunit is most likely associated with the cytoskeleton via talin and α -actinin (85, 96, 97). In contrast, the cytoplasmic domain of the α subunit does probably not interact with the cytoskeleton. The different α subunits instead may serve to mediate the different responses of cells to common extracellular ligands (96). This possibility is supported by the fact that chimeric integrin α subunits with different cytoplasmic domains but similar extracellular domains triggered either collagen gel contraction or increased the migratory behavior of cells on a collagen substratum after transfection (98, 99).

The effects of extracellular matrix proteins on the behavior of tumor cells are mediated by β_1 integrins and include induction of collagenase expression, differentiation, and proliferation (100-105). However, β_1 integrins lack the characteristics one would expect to find in a signal-generating receptor, such as kinase- or phosphatase-domains or sequences suitable for interactions with G-proteins (106-108). Therefore, other mechanisms must be involved. It has been suggested that signal transduction by integrins may be preceded by cytoskeleton rearrangements, thus regulating the cell shape and the biosynthetic capacity of cells, which may contribute to cell growth and differentiation (109 and references therein). Alternatively, enhanced tyrosine phosphorylation of a complex of proteins of ≈ 120 -130 kDa is observed after clustering of integrin receptors, which occurs during the formation of adhesive contacts on a substratum (46, 110). One of these proteins, a 125 kDa protein, was identified as a substrate for the *src* family of tyrosine kinases (111, 112) and also accumulates in focal adhesive contacts of cells, allowed to spread on fibronectin (113). It turned out to be a novel tyrosine kinase, activated upon phosphorylation, and was named "pp125 Focal

Adhesion Kinase" or pp125^{fak} (113). Thus, integrin mediated signal transduction might involve phosphorylation of pp125^{fak} by *src*, which may complement rather than exclude signal transduction by cytoskeleton rearrangements (109).

The expression of β_1 integrins in normal human colon tissue was readily demonstrated for α_1 , α_2 , α_3 and α_6 integrins (114-117). The laminin receptor $\alpha_6\beta_1$ was found on the basal plane of epithelial cells, facing the basement membrane (117). The integrin receptors for collagen ($\alpha_2\beta_1$) and both collagen and laminin ($\alpha_3\beta_1$) were found at the basolateral surface (117), in agreement with their putative function as homophilic intercellular receptors (118, 119). Downregulation of the β_1 integrins α_2 and α_3 is generally observed in colon carcinomas (78, 115, 120, 121) and is associated with poor differentiation (102, 120). The $\alpha_6\beta_1$ integrin is expressed in colonic adenomas as well as in carcinomas (115), though in general downregulation is observed in carcinomas (117). Thus, decreased expression of a subset of integrins goes along with invasive properties of colorectal carcinoma cells.

Experimental systems also support a role for several β_1 integrins in invasion and metastasis. RGD-containing peptides injected simultaneously with metastatic B16-F10 murine melanoma cells in the tail vein of mice markedly reduced the number of lung metastases (122). Increased expression of $\alpha_2\beta_1$ integrin in rat rhabdomyosarcoma cells augmented metastatic behavior (123) and increased expression of $\alpha_6\beta_1$ and $\alpha_3\beta_1$ integrins in chemically transformed human osteosarcoma cells was associated with increased tumorigenic potential (124), whilst increased levels of $\alpha_5\beta_1$ integrin correlated with decreased tumorigenicity in chinese hamster ovary cells (125).

Apparently, the cell type involved in these studies, the stage at which the metastatic cascade was investigated, and the experimental method which was applied, may influence the results. However, it has been suggested that in the early stages of tumor growth, decreased adhesion to extracellular matrix proteins by downregulation of integrin expression is favored, in contrast to later steps in the metastatic cascade, when lodging of carcinoma cells might profit from increased expression of integrins (78).

Dissemination of carcinoma cells

The pattern of metastatic spread of carcinoma cells is currently regarded to be determined by mechanical factors and by site-specific interactions of carcinoma cells with organ tissue (reviewed in 126).

Site-specific interactions may contribute to the preference of e.g. prostatic carcinoma cells to metastasize to bone tissue (126). Several mechanisms may contribute to site-specific metastasis. The presence of specific growth stimulating conditions in the target organ may promote cell-division of carcinoma cells (127). Organ-specific adhesion molecules on vascular endothelium may interact with adhesion molecules expressed by the carcinoma cell. The different constitution of the extracellular matrix in various organs (128) may inhibit invasion of carcinoma cells, unless they express specific proteolytic enzymes (126).

The mechanical theory considers the various tissues to be passive receptacles for carcinoma cells. The first organ encountered after shedding in the venous circulation would arrest the greatest number of carcinoma cells, and consequently, be the organ with the highest number of metastatic colonies. This would for instance explain the colonization of the liver by colorectal cancer (126).

Most likely, both mechanisms complement each other (126).

1.2.2 Tools to investigate invasion and metastasis

In the preceding paragraphs it was outlined that colorectal carcinoma cells are able to 1) traverse the basement membrane, 2) migrate through the extracellular matrix, 3) enter and survive the circulation, 4) lodge elsewhere in the circulation and extravasate, and 5) resume growth at a distant site forming a metastatic lesion. This complexity of the metastatic cascade makes it necessary to investigate the separate steps in different in vitro and in vivo models with various techniques. A brief description is presented of models and methods, which have been used in our studies.

Patient material

An important source of information, concerning the role of specific proteins in tumor progression, comes from patient material, which is also used to validate concepts developed in basic research. Tissue sections can be used to perform immunohistochemical or in situ hybridization studies and fresh tumor material to analyze the expression of genes at the protein- and mRNA-level and to detect mutations at the DNA-level. With knowledge of these parameters it can be investigated whether specific patterns of expression or mutations are correlated with survival of the patient, recurrence after resection, or the chance of development of distant metastatic lesions.

Cell lines

Tumor cells, isolated from either a primary tumor or a metastatic lesion, can be cultured in vitro and may yield a permanent cell line. The relative ease of handling cell lines makes them suitable for use in in vitro and in vivo model systems. However, for most tumor types a subset of around 30% of the primary tumors can be successfully cultured in vitro (129). This approach may therefore not be representative for all tumors. Furthermore, cell monolayers constitute a two-dimensional model system, which does not resemble the three-dimensional in vivo situation.

Nonetheless, cell lines are highly amenable to genetic modification. The introduction of exogenous genes by various transfection methods can be used to establish a putative role for the transfected gene by investigating cell behavior after transfection in various assays. However, the different techniques for transfection and the different plasmid constructs together with the lack of standard protocols and the fact that each transfectant is unique with respect to the site of integration, may complicate comparison of transfection experiments. This may be the cause of conflicting results with regard to the function of transfected genes (130).

In vitro models

The first two steps of the metastatic cascade can be studied with a variety of in vitro models (131). The effects of proteolytic activity can be studied by analyzing the degradation of reconstituted basement membranes by cancer cells (131). Attachment assays to various components of the extracellular matrix measure the potential of the carcinoma cell to interact with the extracellular matrix. The invasion of carcinoma cells into collagen gels measures invasive potential (132). Most models constitute two-dimensional systems. In contrast, the confrontation of tumor cells with embryonic chick heart fragments is a three-dimensional model (133) and mimicks the in vivo situation more closely than two-dimensional models do. It is amenable to in vitro manipulation, thus providing a suitable model for the study of the first two steps in the metastatic cascade (84, 133).

In vivo models

Later steps in the metastatic cascade, such as survival and lodging elsewhere in the circulation, can be studied more appropriately in in vivo models. Prominent models are injection of tumor cells into the chorioallantoic membrane veins of chick embryos (134), and injection of tumor cells at various sites in nu/nu mice (135, 136). Immunodeficient chick embryos and athymic T-cell deficient nu/nu mice allow growth of human cancer cells and therefore are suited to study metastasis formation (134, 135). The capacity of cancer cells to survive in the circulation and their ability to lodge elsewhere, can be assessed by measuring the lung colonization potential of cancer cells after injection in the tail vein of nu/nu mice, known as the experimental metastasis assay. Injection of cancer cells in the subcutis is relatively easy, results in most cases in solid tumor growth and is applied to measure the tumorigenic potential of cancer cells. However, spontaneous metastases in this model are rare with the exception of melanoma xenografts (135). Metastasis formation is increased when tumor cells are injected orthotopically, which for colorectal cancer cells implies that they are injected in the cecum. Orthotopic xenografting allows the study of the entire metastatic cascade (136).

1.3 THE C-HA-RAS ONCOGENE

1.3.1 Structure, function, and expression of the c-Ha-ras protein

Structure. The N-, Ki- and Ha-ras genes encode similar proteins of 21 kDa, structurally homologous with the α -subunit of heterotrimeric $\alpha\beta\gamma$ G-proteins, which function in signal transduction (137). The α -subunit of a G-protein has intrinsic GTPase activity. By binding GTP, the G-protein is activated, deactivation follows through hydrolysis of GTP into GDP, which is regulated by the intrinsic GTPase activity. The activity of the p21^{ras} proteins is regulated similarly (Fig. 1), but their rate of GTP hydrolysis is two orders of magnitude lower than that of G-proteins (138).

Figure 1. Schematic representation of the regulation of p21^{ras} protein activity.

GAP increases the intrinsic GTPase activity of p21^{ras} proteins. GNRP increases the exchange rate of guanine nucleotides bound to p21^{ras} proteins.

The p21^{ras} proteins from different organisms contain several highly conserved regions, which appear to be essential for their normal function. These regions are involved in the binding of GTP and GDP, in the hydrolysis of GTP into GDP, in the attachment to the plasma membrane, and in the biological activity of the p21^{ras} proteins (139, 140). The guanine base of GTP and GDP is bound with high specificity in a "deep narrow groove" which is formed by the amino acid residues 116-119 and 145-147 (139, 141). The β - and γ -phosphates of GDP and GTP interact with a Mg^{2+} ion and form hydrogen bonds with amino acid residues 13-17, 32, 35, 60, 172-175 and 189. The many interactions explain the high affinity of p21^{ras} proteins for GDP and GTP. The paucity of interactions with the α -phosphate most likely explains the low affinity of p21^{ras} proteins for GMP (139, 142). The catalytic mechanism of the hydrolysis of GTP to GDP involves the Mg^{2+} ion and the amino acid residues 35 and 53-61 (138, 139), but the exact mechanism has not yet been elucidated (143).

In the C-terminus the amino acid residues 165-185 compose the region with the least similarity between N-, Ki- and Ha-ras proteins (144-147). The four C-terminal residues 186-189, however, are conserved in all p21^{ras} proteins and contain a CAAX-box, where C is cysteine, A is any aliphatic amino acid and X is any amino acid. CAAX is a signal sequence for postranslational modification and ensures translocation of cytosolic p21^{ras} proteins to the plasma membrane, after the subsequent action of farnesyl transferase,

protease and methyl transferase (139). A basic region of six lysine residues in the C-terminus of the Ki-ras protein, together with farnesylation, allows firm anchoring of the c-Ki-ras protein to the inner side of the plasma membrane (148). The N- and Ha-ras proteins, however, lack these lysine residues in the C-terminus, but contain one or two cysteine residues, which need to be palmitoylated before firm anchoring in the plasma membrane is achieved (148). It has been suggested that the variation in membrane anchoring might target different ras proteins to specific sites in the plasma membrane. Whether or not this has functional consequences (139, 146) remains to be determined. The biological activity of the p21^{ras} proteins is mediated by the amino acid residues 32-40, the so-called "effector region", which is exposed on the surface of the molecule. The structural difference between GDP- and GTP-bound states is most marked in this region, in particular the amino acid residue 35 (139). However, the conformational changes in amino acid residues 60-63 also differ dramatically between GTP- and GDP-bound forms of p21^{ras} proteins, and therefore this domain might also have a role in the biological activity (138). Furthermore, the amino acid residues 26, 27, 30, 31, 45, flanking the effector region, seem to be required also for normal protein-protein interaction and biological activity (149).

Function. The p21^{ras} proteins have different functions in different organisms (150). The p21^{ras} homolog, ste5, in *S. Pombe* is involved in mating (151) and the p21^{ras} homolog, RAS1, in *S. Cerevisiae* stimulates adenylate cyclase, which leads to proliferation (150). The p21^{ras} proteins function in other cell systems at crucial points in the pathway towards cellular differentiation. The p21^{ras} homolog, let-60, in *C. elegans* is needed in the signal transduction pathway, by which epidermal precursor cells are activated to differentiate into mature vulva cells (152, 153) and a similar role is observed in eye development of *Drosophila melanogaster*, where the precursor cell of the R7 photoreceptor cell requires increased activity of the Ras1 protein in order to differentiate into neuronal cells instead of nonneuronal cone cells (154-156). Thus, p21^{ras} proteins function in pathways leading to proliferation as well as to differentiation, depending on the cell system.

The similarity of p21^{ras} proteins with G-proteins suggests that they play a role in a second messenger system. In mammalian cells, the phosphoinositide second messenger system has been implicated in signal transduction by p21^{ras} proteins. Especially the roles of phospholipase C (PLC) and protein kinase C (PKC) have been investigated, but a coherent picture has not emerged yet (reviewed in 139).

Expression. In most human tissues expression has been observed of p21^{ras} proteins (157, 158). The level of expression varies among different cell types, e.g. melanocytes lack expression of p21^{ras} completely, whereas endocrine cells in the pancreas and thyroid express p21^{ras} proteins abundantly. Expression in fetal tissue matches with expression in adult tissue, though not completely. E.g. specialized cells from the nervous system stain strongly for p21^{ras} protein in fetal and adult tissue, whereas in the lymphoid system high expression is observed in the fetal thymus, but not in adult lymph nodes.

Immunohistochemical studies of mature colon tissue demonstrate that p21^{ras} proteins are expressed in the basal cells of the crypts, which have proliferative capacity (158). Immunoreactivity decreases towards the lumen, but strong immunoreactivity is again detected in the apical brush border of the highly differentiated cells lining the lumen of the intestine (158). A major limitation of these immunohistochemical studies has been the use of monoclonal antibodies (e.g. Y13-259) which recognize both normal and pointmutated forms of the c-N-, c-Ki- and c-Ha-ras proteins. Therefore, which of the p21^{ras} proteins are expressed exactly, cannot be determined (157, 158). In homogenates of normal colorectal tissue expression of both c-Ki- and c-Ha-ras genes have been detected. The expression of the c-N-ras gene was not investigated in these studies (159, 160). A limitation of the latter studies is the fact that in tissue homogenates the individual contribution of different cell types to the total expression of the c-ras genes cannot be determined. Nevertheless, the high level of expression of p21^{ras} proteins in cells with proliferative capacity as well as in fully differentiated cells might indicate that p21^{ras} proteins fulfill functions in regulating cell proliferation as well as specialized cell functions (158).

1.3.2 Regulation of the c-Ha-ras protein activity

The high affinity for GTP and GDP along with the low intrinsic dissociation constant and GTPase activity of p21^{ras} proteins allows precise control of p21^{ras} activity by regulatory proteins (138, 150), which either increase the rate of exchange of GDP for GTP or alter the intrinsic GTPase activity of p21^{ras} proteins (Fig. 1) (138, 150).

Proteins which increase the rate of nucleotide exchange are termed Guanine Nucleotide Releasing Proteins or GNRPs and have been isolated by several groups from cytosolic pools of mammalian cells (161-163). Normally, p21^{ras} proteins are found in the inactive GDP-bound form (150). About 95% of the cytosolic guanine nucleotide pool consists of GTP. The binding of p21^{ras} with a GNP promotes GDP release, thus most likely results in the replacement of GDP by GTP, thereby activating p21^{ras} proteins (150).

Two proteins (GAP and NF-1) are known to increase the intrinsic GTPase activity of p21^{ras} proteins and are termed GTPase Activating Proteins or GAP's, which are found in the cytoplasm (139, 164-166). GAP's convert the active GTP.p21^{ras} complex into the inactive GDP-bound form of p21^{ras}, thus down-regulating p21^{ras} protein activity (139). GAP and NF-1 interact with GTP.p21^{ras} proteins at the effector region (167, 168). This region is essential for the biological activity of GTP.p21^{ras} and it therefore leaves open the possibility that GAP and NF-1 are not only down-regulators, but possibly also effectors of GTP.p21^{ras} proteins (168).

The primary structure of GAP has been determined (Fig. 2) (169). The N-terminus is highly hydrophobic and followed by a proline-rich sequence, possibly indicating a flexible hinge region. Adjacent to the hydrophobic domain are regions similar to a module of 100 and a module of 50 amino acid residues of the proto-oncogene *src*, the so-called Src Homology domain 2 (SH2) and Src Homology domain 3 (SH3) respectively. SH2 and SH3 domains are found in several cytoplasmic signaling proteins

and function as adapter modules (170), coupling receptor tyrosine kinases with their down-stream targets (171-177). The C-terminal part of GAP is the binding site for GTP.p21^{ras} and contains the GTPase stimulating activity (169). The activity of GAP is inhibited by some lipids, which function as second messengers in the phosphoinositide pathway (178, 179), such as arachidonic acid (180). The putative role for GAP as a target for GTP.p21^{ras} is supported by the fact that the biological effects of GTP.p21^{ras} require the SH2/SH3 domains of GAP (181-184). NF-1 is similar to GAP with regard to the GTPase activating sequence but lacks the SH2/SH3 domains (168). It seems to be that NF-1 is not required for the biological effects of p21^{ras} proteins, which makes it unlikely that NF-1 functions as a downstream effector of GTP.p21^{ras} (185). Possibly, NF-1 acts as a constitutive downregulator of GTP.p21^{ras} (186), whereas GAP is involved in downstream signaling of GTP.p21^{ras} (187).

Figure 2. Structural resemblance of GAP and GAP-related proteins.

The black box contains the p21^{ras} binding domain and the GTPase activating domain, the shaded box contains a domain with a high degree of similarity in all GAP-related proteins (modified from ref. 168).

As yet, one protein has been isolated which inhibits the intrinsic GTPase activity of GTP.p21^{ras} proteins. This protein can interact directly with p21^{ras} proteins but the mechanism of inhibition is not known (179). Its activity is increased by phospholipids from the phosphoinositide pathway (179). The dual effect of these lipids, which activate GTPase inhibiting protein and inactivate GAP, tends to increase the biological activity of p21^{ras} proteins and thus stimulates cell proliferation (179).

Similar regulatory proteins are also found in other organisms (139, 150), indicating that the control of p21^{ras} activity is conserved and important for proper functioning of cells. Homologs of GNRPs are ste6 in *S. pombe* (188), CDC25 in *S. cerevisiae* (189), and Son of sevenless in *Drosophila* (154, 190). Homologs of mammalian GAP are the gap/sar1 gene in *S. pombe* (191, 192), the IRA1 and IRA2 genes in *S. cerevisiae* (150), and GAP1 in *Drosophila* (193).

1.3.3 Growth Factors and p21^{ras} proteins in signal transduction pathways

Increased cell proliferation is a crucial element in carcinogenesis (6, 17). Knowledge about the function of the p21^{ras} proteins in the mitogenic signal transduction pathway may elucidate the role of pointmutated p21^{ras} proteins in carcinogenesis.

Growth factors, such as the epidermal growth factor (EGF), the platelet derived growth factor (PDGF), or CSF-1, induce transcription of genes and elicit a mitogenic response in receptor positive cells (194). Increased levels of the active GTP.p21^{ras} complex, sufficiently high to support mitogenic stimulation (195), are found in EGF- and PDGF-stimulated cells (196, 197). This suggests a role for p21^{ras} proteins in the signal transduction pathway of Growth Factors, which is supported also by the observation that GAP binds specifically to ligand-activated CSF-1-, EGF- and PDGF-receptors (198-202).

The first event in the signal transduction pathway is ligand-activation of EGF- or PDGF-receptors. The activated receptors dimerize and cross-phosphorylate on cytoplasmic tyrosine residues, which increases their kinase activity toward other substrates (106, 203). Substrates for the receptor tyrosine kinases attach to the phosphorylated tyrosine residues by means of their SH2 domain(s) (172). Several substrates, including phospholipase C- γ 1 (PLC- γ 1) and GAP, bind to the PDGF-receptor but at different phosphorylated tyrosine residues (201, 204, 205).

In unstimulated cells the level of GTP.p21^{ras} might be downregulated by NF1, which is supported by the observation that lack of functional NF-1 in cells from neurofibromatosis type 1 patients goes along with increased levels of GTP.p21^{ras} in the presence of functional wild type GAP (206). In growth factor stimulated cells GAP is translocated from the cytosol to the plasma membrane upon binding to ligand-activated growth factor receptors (201, 205) and GNP activity is stimulated, which increases the level of GTP.p21^{ras} (Fig. 3) (207, 208). Lipids, generated by activated tyrosine kinase receptor-bound PLC- γ 1, may inhibit the GTPase activity of GAP but do not interfere with the binding of GAP to the effector region of GTP.p21^{ras}. This GTP.p21^{ras}.GAP complex has been postulated to expose the SH2 and SH3 domains of GAP, which are normally hidden (Fig. 4) (184). Two tyrosine phosphorylated proteins, p62 and p190, associate with GAP in mitogenically stimulated cells (209). P62 encodes a putative heterogenous nuclear ribonucleoprotein particle, which belongs to a family of proteins involved in mRNA processing (210). P190 encodes a remarkable combination of a GTPase like protein at the N-terminus, a GAP like protein at the C-terminus, and in between a protein highly similar to a transcriptional repressor of the glucocorticoid receptor gene (211). P62 and p190, might thus provide a link between growth factors and transcriptional control of genes, mediated by the GTP.p21^{ras}.GAP complex. Termination of the mitogenic stimulus decreases the generation of lipids, restores the GTPase activity of GAP, and inactivates GTP.p21^{ras} to GDP.p21^{ras}. In this model GAP acts both as effector and as negative regulator of GTP.p21^{ras}.

Figure 3. Coupling of p21^{ras} proteins to receptor protein tyrosine kinases.
A. Unstimulated cells. **B.** Stimulated cells. Proteins with SH2/SH3 domains function as adapter proteins and link receptor protein tyrosine kinases with GNRPs.

A second signal transduction pathway, which links growth factors and gene transcription via $p21^{\text{ras}}$ proteins, involves Mitogen-Activated Protein Kinases (MAPKs). These are serine/threonine protein kinases (212), which are activated during mitogenic stimulation of cells by several growth factors (213) and most likely have a role in the regulation of gene transcription factors (reviewed in 214), such as c-myc (215, 216). Activation of MAPKs is controlled by another serine/threonine protein kinase, the proto-oncogene c-Raf-1 (217, 218). It has recently been demonstrated that c-Raf-1 interacts directly with GTP. $p21^{\text{ras}}$ but not with GDP. $p21^{\text{ras}}$, most likely at the effector region of the $p21^{\text{ras}}$ protein. It was therefore postulated that c-Raf-1 might be a direct effector of the active $p21^{\text{ras}}$ protein (219-221).

Considering the pleiotropic functions of the $p21^{\text{ras}}$ proteins, it is reasonable to assume that more signal transduction pathways will be elucidated in which $p21^{\text{ras}}$ proteins play a prominent role.

Figure 4. Interaction between GAP and activated $p21^{\text{ras}}$ proteins.

The SH2 and SH3 domains of GAP are accessible to effector proteins after binding of $p21^{\text{ras}}$ proteins with GAP (modified from ref. 184).

1.3.4 Mutations in the c-Ha-ras gene

Human tumors frequently harbor pointmutations in one of the c-ras genes (4). The frequency varies in different tumors, ranging from none in neural crest tumors, such as pheochromocytomas (222), to more than 90% in carcinomas of the exocrine pancreas (223). The pointmutations are generally found in amino acid residues 12, 13 and 61 (137, 145, 224-226). Amino acid residue 61 is implicated in the catalytic mechanism of the hydrolysis of GTP into GDP (139 and references therein). The glycines at positions 12 and 13 are not involved in the catalytic mechanism. However, the substitution of these amino acids leads to displacement of other amino acids, which have a role in GTP hydrolysis (139). These pointmutations decrease the intrinsic GTPase activity of p21^{ras} in vitro (227) and inhibit GAP activity under physiological conditions (164), but do not affect the binding of GAP to the effector region (139). In this way, a permanently stimulating GTP.p21^{ras}.GAP complex is formed, which might explain the transforming capacity of pointmutated p21^{ras} genes in cancer cells.

Pointmutations introduced by site directed mutagenesis provide further insight in the mechanism of transformation by pointmutated p21^{ras} proteins. Mutations in the carboxyl terminal region prevent the anchoring of p21^{ras} proteins to the inner side of the plasma membrane with concomitant loss of transforming ability (148, 228). The reason for this loss is not clear yet. Possibly, the exchange of GDP for GTP in normal and mutant p21^{ras} proteins might exclusively involve membrane bound GNRP, as has been demonstrated in *S. Cerevisiae*. GDP.p21 RAS associates with membrane-bound CDC25 (229), which catalyzes GDP/GTP exchange specifically at the cell membrane (230).

The substitution of asparagine for serine at position 17 generates a mutant p21^{ras} protein with decreased affinity for GTP, without affecting the affinity for GDP. This mutant blocks the induction of genes, activated in NIH 3T3 cells by stimulation with insulin (231). Most likely, this pointmutated p21^{ras} protein acts as an inhibitor of GNRP, thus preventing the activation of endogenous p21^{ras} proteins (207, 232).

As mentioned before pointmutations in codons 12, 13 and 61 decrease the intrinsic GTPase activity, but do not affect the interaction with GAP, the putative effector, thus rendering all p21^{ras} proteins similar when mutated (4). Nevertheless, some tumor types harbor pointmutations in one member of the p21^{ras} family only (4). Tumors from the genitourinary tract, such as prostate and bladder carcinoma, contain pointmutations only in the c-Ha-ras gene, whereas exocrine pancreas carcinomas most frequently harbor pointmutations in the c-Ki-ras gene, and hematopoietic disorders have pointmutations predominantly in the c-N-ras gene. This suggests differential expression of the members of the p21^{ras} family in different tissues. In some tumor types, such as pheochromocytomas, pointmutations in the c-ras genes have not been found (222). This might be related to the normal function of p21^{ras} proteins in these cells, because the high expression of p21^{ras} in differentiated cells of the nervous system suggests a role in a specialized cellular function rather than in cell growth (4, 158).

However, the fundamentally different responses seem to be mediated by a similar set of proteins (Fig. 3) (233-235). Recent studies suggest that activated receptor protein-

tyrosine kinases bind the SH2 domains of cytoplasmic SH2/SH3 adapter proteins. The SH3 domains of the adapter proteins mediate binding to a GNRP, which in turn increases the level of GTP.p21^{ras} protein (171, 173, 175, 176, 236, 237). The GTP.p21^{ras} complex may then couple to its effector proteins, such as GAP and/or c-Raf-1. Whether or not a cell responds to extracellular stimuli depends on the available receptors, what the response will be may depend on the cellular "repertoire", but the signal transducing pathway involved may be similar.

1.3.5 Effects of the introduction of the c-Ha-ras oncogene into cell lines

In the last decade transfection of the c-Ha-ras oncogene with a pointmutation in codon 12 and other pointmutated members of the p21^{ras} protein family has been applied to investigate the role of these proteins in carcinogenesis and differentiation. For reasons of convenience, the data reviewed here describe the effects of pointmutated p21^{ras} proteins per investigated cell type, but when similar effects were noted in other cell types these are mentioned also.

Fibroblasts

NIH 3T3

The mouse fibroblast-like cell line NIH 3T3 is immortal but non-tumorigenic in nude mice (238). The introduction of either cellular or viral forms of the Ha-ras oncogene morphologically transforms these cells (239, 240). Synthesis of DNA can then be initiated in the absence of serum, indicating a reduced requirement for exogenous growth factors (239, 240). The morphologically transformed cells are tumorigenic (238), either with (241-247) or without acquiring spontaneous metastatic capacity (130, 248, 249) when xenografted into nude mice. The variability in metastatic capacity is most likely due to variations in applied methodology (130). The acquisition of metastatic capacity has been correlated with increased expression of the proteases collagenase type IV and u-PA (247, 248), with expression of an autocrine motility factor (250) and with increased sialic acid content at the cell surface (251), which supposedly confer new matrix degrading, migratory and adhesive properties to transfected NIH 3T3 cells (15, 252).

Rat Fibroblasts

Introduction of the c-Ha-ras oncogene into second passage rat embryo fibroblasts (REF) induces experimental and spontaneous metastatic capacity in morphologically transformed REF, which is paralleled by increased proteolytic activity (55, 253-255). Cytogenetic analysis revealed that metastatic behavior is acquired without chromosomal rearrangements, implying that a diploid cell can be tumorigenic and metastatic (256). Cotransfection of the c-Ha-ras oncogene with the v-myc oncogene also induced metastatic behavior in REF cells, in parallel with the emergence of chromosomal rearrangements, and site-specific integration of the c-Ha-ras oncogene close to the centromere of chromosome 3 (254, 257). This may indicate that not only the

characteristics of the oncogene, but also the site of its integration may contribute to the transfection induced effects (258).

Non-tumorigenic Rat-1 fibroblasts demonstrated a reduced requirement for growth factors after transfection with the pointmutated c-Ha-ras gene or with the wild type c-Ha-ras gene. Tumorigenic potential was induced in either case, although a modest expression of the c-Ha-ras oncogene was far more effective than overexpression of the wild type c-Ha-ras gene (259). Overexpression of the wild type c-Ha-ras gene also induced tumorigenicity in NIH 3T3 cells (244).

Human fibroblasts

Whether or not different ras oncogenes exert similar effects was investigated in non-tumorigenic human MSU 1.1 fibroblasts, immortalized by v-myc transfection. The introduction of pointmutated c-Ha-, v-Ki-, or c-N-ras genes morphologically transformed MSU 1.1 cells, which became tumorigenic and invasive in nu/nu mice (260-262). Spontaneous metastasis was not observed, but it was suggested that nu/nu mice do not survive the xenograft long enough for metastases to develop (261). Furthermore, reduced growth factor requirement and higher levels of secretion of u-PA and t-PA were observed (260, 261, 263). The karyotype of the transfected cell lines was identical to that of the parental diploid karyotype (260-262). The similarity of the effects on MSU 1.1 cells of either viral or cellular pointmutated N-, Ki- and Ha-ras genes, supports the hypothesis that the functional differences between the members of the p21^{ras} protein family are lost upon mutation.

In the experiments described so far, ras oncogenes were introduced into immortal human fibroblasts or in embryonic rodent fibroblasts. Non-immortalized human fibroblasts can be transformed morphologically by the c-N- or the c-Ha-ras oncogene, but the transformed cells do not acquire tumorigenic potential (264-266). Thus, the effects of ras oncogene transfection is determined partly by the recipient cell.

Mammary, prostate, and bladder cells

Mouse mammary carcinoma and rat prostate adenocarcinoma cells with intrinsic low metastatic capacity became highly metastatic after transfection with pointmutated forms of the c-Ha-ras gene (267-271), without a simple dose-effect relationship between the level of c-Ha-ras expression and metastatic ability (268, 272, 273). Cytogenetic analysis revealed that genetic instability is increased and it was suggested that this contributes to the increased metastatic ability (273, 274). In human mammary cancer cells reduced requirement for growth factors (275), and conversion of non-tumorigenic HBL100 cells into tumorigenic cells was observed (276).

Human tumorigenic non-invasive papillary transitional cell carcinoma cells became invasive upon overexpression of wild type and pointmutated forms of the c-Ha-ras gene (277, 278), which was accompanied with increased expression of EGFR (279). However, non-immortalized human urothelial cells could not be converted into tumorigenic cells (278). Thus, the c-Ha-ras oncogene induces neoplastic behavior not

only in fibroblasts, but also in other cell types, while the recipient cell partly determines the effect of the c-Ha-ras oncogene.

Keratinocytes and hepatocytes

Transfection of the pointmutated c-Ha-ras gene into immortalized but non-tumorigenic human keratinocytes induced tumorigenicity and invasive behavior. In these cells expression of the cytokeratins K1 and K10 was not impaired (280, 281). Also, SV40-immortalized rat hepatocytes transfected with the c-Ha-ras oncogene become tumorigenic while cell differentiation, as reflected in the expression of genes associated with hepatocyte function such as albumin, was not impaired (282, 283). These findings indicate that induction of tumorigenic and invasive behavior by the c-Ha-ras oncogene does not necessarily alter cell differentiation.

Lymphocytes

Normal human lymphocytes were refractory to transformation after transfection with a pointmutated c-Ha-ras gene (284). In contrast, mouse lymphoma cells became invasive (285) and EBV-immortalized human B-lymphocytes became tumorigenic (286, 287). Interestingly, in the latter experiment concomitant induction of plasmacytoid differentiation was observed (287). It was suggested that the c-Ha-ras oncogene stimulates uncontrolled proliferation and triggers terminal differentiation, which is normally blocked in EBV-infected B-cells (287).

Neuroendocrine cells

The v-Ha-ras oncogene has been reported to induce differentiation in tumor cell lines derived from neural crest tumors (288, 289). Increased expression of the peptide hormone calcitonin along with a decrease in cell proliferation and DNA-synthesis, suggested enhanced neuroendocrine differentiation in human medullary thyroid carcinoma cells (288). In the rat pheochromocytoma cell line, PC12, induction of sympathetic neuronal differentiation with concomitant cessation of cell proliferation was reported (289).

Transfection of the pointmutated c-Ha-ras gene into a human small cell lung cancer cell line or in fibroblast-like murine 3T3-L1 cells induced neuroendocrine differentiation and adipocyte differentiation respectively (290, 291), which extends the induction of differentiation after transfection with the c-Ha-ras oncogene to other cell types. Hence, these experiments suggest a role for the c-Ha-ras oncogene not only in neoplastic progression, but also in differentiation.

Muscle and melanocytes

Transfection of the c-Ha-ras oncogene into tumorigenic rat rhabdomyosarcoma cells neither altered growth potential nor induced invasive or metastatic behavior (292). Low metastatic murine K-1735 melanoma cells did not become highly metastatic after transfection with the pointmutated c-Ha-ras gene (293). Also, tumorigenic but non-

metastatic mouse LTA fibroblast-like cells did not become metastatic after transfection with the pointmutated c-Ha-ras gene (294). These studies suggest that the c-Ha-ras oncogene, at least in these cell lines, is not essential for further malignant progression.

In conclusion, the introduction of the c-Ha-ras oncogene reduces the growth factor requirement in a variety of tumor cells. It is plausible to link this effect to the putative role of the c-Ha-ras gene in the transduction pathway of several growth factors. Immortality of the recipient cell seems to be required for malignant transformation and after transformation the cells retain expression of genes associated with differentiation. In some cells, differentiation can be induced with a concomitant stop of proliferation. The pleiotropic effects of the c-Ha-ras oncogene most likely reflect the putative roles of normal p21^{ras} proteins in proliferation as well as in differentiation.

1.3.6 The c-Ha-ras oncogene in colorectal cancer

Pointmutations within the ras genes frequently occur in colon adenomas and carcinomas. They mainly concern the Ki-ras gene (4, 295-298) and constitute mostly G to A transitions (297). The finding that pointmutated Ki-ras genes in adenomas of the lung and the exocrine pancreas are G to T transitions, suggests a specific mechanism for the induction of pointmutations (299). The nature of the inducing agents is as yet obscure, but these may include tissue-specific factors, related to susceptibility to specific carcinogens or activity of certain DNA repair mechanisms, and could also involve chemical mutagens. For all three these tumor types (colon, lung, pancreas) it has to be assumed that the c-Ki-ras gene and not the c-N- or the c-Ha-ras gene is expressed, in order to explain the high specificity for pointmutations in the c-Ki-ras gene.

In about 50% of colorectal adenomas pointmutations are detected in the c-ras genes and a similar percentage is observed in colorectal carcinomas (297). This prompted the suggestion that pointmutations develop in the adenoma stage and may be involved in the progression to carcinomas (3, 4). However, pointmutated ras genes have been observed also in early stages of colorectal carcinogenesis (296), and are absent in the other 50% of the colon carcinomas, indicating that the route to a carcinoma can involve more than one pathway.

Pointmutations in the Ki-ras gene were observed with higher frequency in primary colon tumors with metastasis, than in those without (300, 301). Moreover, the primary tumor and the metastasis contained the same pointmutation or, when the primary tumor did not harbor a pointmutation, it was not detected either in the metastasis (300, 301). This suggests that the pointmutated c-Ki-ras gene must be present in the primary tumor, which renders a clonal selection of c-Ki-ras mutated cells during the metastatic process unlikely. Furthermore, aneuploid colorectal carcinomas have c-Ki-ras pointmutations more frequently than diploid tumors, implicating ras mutations in the development of aneuploidy (301). As mentioned before, genetic errors, including aneuploidy, may result from defects in the control of the cell-cycle. One of the factors involved in this regulation, particularly in the onset to mitosis, is the maturation promoting factor

(MPF). It is therefore of interest to note that MPF can be activated by the introduction of a pointmutated c-Ha-ras gene in *Xenopus oocytes* (302, 303). This indicates a role for p21^{ras} in the regulation of cell-cycle control.

Data on the mRNA expression of c-ras genes in colorectal cancer is confusing. Elevated mRNA levels of c-Ha- and c-Ki-ras have been observed in tissue homogenates of premalignant and malignant tumors of the colorectum (160). Other studies detected similar levels of c-Ki-ras mRNA in normal colon and colorectal cancer tissue (159, 295). Also, data on p21^{ras} protein in colorectal cancer tissue are difficult to interpret. Immunoblotting with the p21^{ras} monoclonal antibody Y13-259 showed an increased level of p21^{ras} proteins in primary colorectal tumors, classified as Dukes B and C, whereas p21^{ras} protein level was not increased in most tumors classified as Dukes D and their metastases (304). Radioimmunoassays with Y13-259 showed increased expression of p21^{ras} proteins in most biopsy specimens from colorectal tumors (305). However, the number of colorectal tumors analyzed in both studies was rather small (304, 305).

Fairly extensive immunohistochemical studies have been performed to analyze p21^{ras} protein expression at the tissue level. Again, data are difficult to interpret. One study reported no difference in p21^{ras} protein levels between cancer tissue and normal tissue (157). Others detected increased immunoreactivity of p21^{ras} proteins in normal mucosa in the vicinity of tumors or in inflammation (306). The highest immunostaining was noted in villoglandular adenomas, dysplastic adenomas, and carcinomas *in situ*, and was not related with Dukes stage but rather with the degree of differentiation (306). Taken together, the level of p21^{ras} proteins seems to increase in premalignant tissue, whereas in malignant tissue the level of p21^{ras} proteins may vary.

Thus, the relation between p21^{ras} protein level and carcinogenesis or tumor progression remains obscure. Nevertheless, it is clear that p21^{ras} proteins are components of signal transduction pathways, which are utilized in different cell types of an organism and are evolutionary conserved. It is used by cells to respond to extracellular signals from the microenvironment, and is involved in proliferation as well as in differentiation, depending on the type of cell. Increased proliferation may be central to carcinogenesis, but most likely, can still be regulated by the microenvironment in the early stage of carcinogenesis. This regulation may end when pointmutations in the c-ras genes are present. Constitutive proliferation caused by pointmutated c-ras genes may then increase the genetic instability and speed up the evolution of a premalignant cell into a malignant cancer cell.

1.4 AIM AND DESIGN OF THE STUDY

The reviewed literature indicates that p21^{ras} proteins play a role in colorectal carcinogenesis and cancer progression but the exact mechanism of its involvement is not yet clear. The aim of this study was to gain more insight in the role of the c-Ha-ras oncogene in colorectal carcinogenesis and cancer progression.

In chapter 2 a study on the behavior of 9 human colorectal carcinoma cell lines in nu/nu mice, after ectopic and orthotopic xenografting, and in the embryonic chick heart fragment assay is described. Cancer cell behavior was correlated with the expression of proteases and cell-adhesion molecules, which have been implicated in invasion and metastasis. Based on the obtained results the cell lines CaCo 2 and SW480 were selected for further transfection experiments with the c-Ha-ras oncogene in an attempt to elucidate the role of this oncogene in progression of colorectal cancer.

To establish the effects of transfection on the genome it was investigated whether or not integration occurs at specific sites and whether genetic instability increased. In chapter 3 a method is described to identify the chromosomal integration sites of transfected plasmid DNA. In chapter 4 the application of this method is described for the identification of the chromosomal integration sites of plasmid DNA in transfected SW480 cell lines along with a detailed cytogenetic analysis to assess the genetic instability after transfection.

In chapter 5 and 6 the data are presented concerning the phenotypic effects, which were observed in CaCo 2 and SW480 cells after transfection with the c-Ha-ras oncogene, with emphasis on tumorigenic behavior, expression of proteases and cell-adhesion molecules, and degree of differentiation.

1.5 REFERENCES

1. Silverberg E: **Cancer Statistics**. Cancer. 1981; 31: 13.
2. **Incidence of cancer in The Netherlands 1989**. First report of The Netherlands Cancer Registry. Hoonte-Holland bv, Utrecht 1992.
3. Fearon ER, Vogelstein B: **A genetic model for colorectal tumorigenesis**. Cell. 1990; 61: 759-767.
4. Bos JL: **Ras oncogenes in human cancer: A review**. Cancer. Res. 1989; 49: 4682-4689.
5. Hartwell L: **Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells**. Cell. 1992; 71: 543-546.
6. Lipkin M: **Biomarkers of increased susceptibility to gastrointestinal cancer: new application to studies of cancer prevention in human subjects**. Cancer. Res. 1988; 48: 235-245.
7. Murray AW: **Creative blocks: Cell-cycle checkpoints and feedback controls**. Nature. 1992; 359: 599-604.
8. Liotta LA, Rao CN, Barsky SH: **Tumor invasion and the extracellular matrix**. Lab. Invest. 1983; 49: 636-649.
9. Bastida E: **The metastatic cascade: potential approaches for the inhibition of metastasis**. Semin. Thromb. Hemost. 1988; 14: 66-72.
10. Liotta LA: **Tumor invasion and metastases: role of the basement membrane**. Warner-Lambert Parke-Davis Award lecture. Am. J. Pathol. 1984; 117: 339-348.
11. Barsky SH, Togo S, Garbisa S, Liotta LA: **Type IV collagenase immunoreactivity in invasive breast carcinoma**. The Lancet 1983; i: 296-297.
12. Takeichi M: **Cadherin cell adhesion receptors as a morphogenetic regulator**. Science. 1991; 251: 1451-1455.
13. Evans CW: **Cell adhesion and metastasis**. Cell. Biol. Int. Rep. 1992; 16: 1-10.
14. Liotta LA, Mandler R, Murano G, *et al*: **Tumor cell autocrine motility factor**. Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 3302-3306.
15. Liotta LA, Steeg PS, Stetler-Stevenson WG: **Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation**. Cell. 1991; 64: 327-336.
16. Starkey JR: **Cell-matrix interactions during tumor invasion**. Cancer. Metastasis. Rev. 1990; 9: 113-123.
17. Cohen SM, Ellwein LB: **Genetic errors, cell proliferation, and carcinogenesis**. Cancer. Res. 1991; 51: 6493-6505.
18. Ames BN, Gold LS: **Chemical carcinogenesis: too many rodent carcinogens**. Proc. Natl. Acad. Sci. U. S. A. 1990; 87: 7772-7776.
19. Cohen SM, Ellwein LB: **Cell proliferation in carcinogenesis**. Science. 1990; 249: 1007-1011.
20. Farber E, Rubin H: **Cellular adaptation in the origin and development of cancer**. Cancer. Res. 1991; 51: 2751-2761.
21. Strauss BS: **The origin of point mutations in human tumor cells**. Cancer. Res. 1992; 52: 249-253.
22. Peltomaki P, Aaltonen LA, Sistonen P, *et al*: **Genetic mapping of a locus predisposing to human colorectal cancer**. Science. 1993; 260: 810-812.
23. Aaltonen LA, Peltomaki P, Leach FS, *et al*: **Clues to the pathogenesis of familial colorectal cancer**. Science. 1993; 260: 812-816.
24. Enoch T, Nurse P: **Coupling M phase and S phase: controls maintaining the dependence of mitosis on chromosome replication**. Cell. 1991; 65: 921-923.

25. Loeb LA: **Mutator phenotype may be required for multistage carcinogenesis.** *Cancer. Res.* 1991; 51: 3075-3079.
26. Hanawalt PC, Sarasin A: **Cancer-prone hereditary diseases with DNA processing abnormalities.** *TIG* 1986; 2: 124-129.
27. Cleaver JE, Karentz D: **DNA repair in man: Regulation by a multigene family and association with human disease.** *BioEssays* 1987; 6: 122-127.
28. Daya-Grosjean L, Robert C, Drougard C, Suarez H, Sarasin A: **High mutation frequency in ras genes of skin tumors isolated from DNA repair deficient Xeroderma pigmentosum patients.** *Cancer. Res.* 1993; 53: 1625-1629.
29. Wang L, Patel U, Ghosh L, Banerjee S: **DNA polymerase beta mutations in human colorectal cancer.** *Cancer. Res.* 1992; 52: 4824-4827.
30. Vogelstein B: **A deadly inheritance.** *Nature.* 1990; 348: 681-682.
31. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: **Participation of p53 protein in the cellular response to DNA damage.** *Cancer. Res.* 1991; 51: 6304-6311.
32. Cooper GM, ed: **Oncogenes.** first ed. Boston: Jones and Bartlett Publishers, 1990
33. Bosman FT, Havenith MG, Visser R, Cleutjens JPM: **Basement membranes in neoplasia.** *Progr. Histochem. Cytochem.* 1992; 24: 1-92.
34. Paulsson M: **Basement membrane proteins: structure, assembly, and cellular interactions.** *Crit. Rev. Biochem. Mol. Biol.* 1992; 27: 93-127.
35. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG: **Tumor cell invasion inhibited by TIMP-2.** *J. Natl. Cancer. Inst.* 1991; 83: 775-779.
36. Khokha R, Zimmer MJ, Graham CH, Lala PK, Waterhouse P: **Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells.** *J. Natl. Cancer. Inst.* 1992; 84: 1017-1022.
37. Salo T, Liotta LA, Keski-Oja J, Turpeenniemi-Hujanen T, Tryggvason K: **Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells - Role in metastasis.** *Int. J. Cancer.* 1982; 30: 669-673.
38. He CS, Wilhelm SM, Pentland AP, *et al*: **Tissue cooperation in a proteolytic cascade activating human interstitial collagenase.** *Proc. Natl. Acad. Sci. U. S. A.* 1989; 86: 2632-2636.
39. Stack MS, Moser TL, Pizzo SV: **Binding of human plasminogen to basement-membrane (type IV) collagen.** *Biochem. J.* 1992; 284: 103-108.
40. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: **Plasminogen activators, tissue degradation, and cancer.** *Adv. Cancer. Res.* 1985; 44: 139-266.
41. Petersen LC, Lund LR, Nielsen LS, Dano K, Skriver L: **One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity.** *J. Biol. Chem.* 1988; 263: 11189-11195.
42. Kasai S, Arimura H, Nishida M, Suyama T: **Primary structure of single-chain pro-urokinase.** *J. Biol. Chem.* 1985; 260: 12382-12389.
43. Blasi F, Vassalli JD, Dano K: **Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors.** *J. Cell. Biol.* 1987; 104: 801-804.
44. Ronne E, Behrendt N, Ellis V, Ploug M, Dano K, Hoyer-Hansen G: **Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor.** *FEBS. Lett.* 1991; 288: 233-236.
45. Sprengers ED, Kluft C: **Plasminogen activator inhibitors.** *Blood.* 1987; 69: 381-387.

46. Olson D, Pollanen J, Hoyer-Hansen G, *et al*: **Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.** *J. Biol. Chem.* 1992; 267: 9129-9133.
47. Cubellis MV, Wun TC, Blasi F: **Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.** *Embo. J.* 1990; 9: 1079-1085.
48. Herz J, Clouthier DE, Hammer RE: **LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation.** *Cell.* 1992; 71: 411-421.
49. Cohen RL, Niclas J, Lee WM, *et al*: **Effects of cellular transformation on expression of plasminogen activator inhibitors 1 and 2. Evidence for independent regulation.** *J. Biol. Chem.* 1989; 264: 8375-8383.
50. Welgus HG, Stricklin GP: **Human skin fibroblast collagenase inhibitor.** *J. Biol. Chem.* 1983; 258: 12259-12264.
51. Lu XQ, Levy M, Weinstein IB, Santella RM: **Immunological quantitation of levels of tissue inhibitor of metalloproteinase-1 in human colon cancer.** *Cancer. Res.* 1991; 51: 6231-6235.
52. Cajot JF, Sordat B, Bachmann F: **Human primary colon carcinomas xenografted into nude mice. II. Modulation of tumor plasminogen activator activity by the host tissue environment.** *J. Natl. Cancer. Inst.* 1986; 77: 1099-1107.
53. Axelrod JH, Reich R, Miskin R: **Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells.** *Mol. Cell. Biol.* 1989; 9: 2133-2141.
54. Hearing VJ, Law LW, Corti A, Appella E, Blasi F: **Modulation of metastatic potential by cell surface urokinase of murine melanoma cells.** *Cancer. Res.* 1988; 48: 1270-1278.
55. Bernhard EJ, Muschel RJ, Hughes EN: **Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells.** *Cancer. Res.* 1990; 50: 3872-3877.
56. Quax PHA, van Muijen GNP, Weening-Verhoeff EJD, *et al*: **Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase mediated matrix degradation.** *J. Cell. Biol.* 1991; 115: 191-199.
57. Henderson BR, Tansey WP, Phillips SM, Ramshaw IA, Kefford RF: **Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells.** *Cancer. Res.* 1992; 52: 2489-2496.
58. Garbisa S, Scagliotti G, Masiero L, *et al*: **Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy.** *Cancer. Res.* 1992; 52: 4548-4549.
59. Hendrix MJ, Wood WR, Seftor EA, *et al*: **Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor.** *Cancer. Res.* 1990; 50: 4121-4130.
60. Turpeenniemi-Hujanen T, Thorgeirsson UP, Hart IR, Grant SS, Liotta LA: **Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential.** *J. Natl. Cancer. Inst.* 1985; 75: 99-103.
61. Nakajima M, Welch DR, Belloni PN, Nicolson GL: **Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials.** *Cancer. Res.* 1987; 47: 4869-4876.
62. Watanabe H, Nakanishi I, Yamashita K, Hayakawa T, Okada Y: **Matrix metalloproteinase-9 (92 kDa gelatinase/type IV collagenase) from U937 monoblastoid cells: Correlation with cellular invasion.** *J. Cell Sci.* 1993; 104: 991-999.
63. Hollas W, Blasi F, Boyd D: **Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.** *Cancer. Res.* 1991; 51: 3690-3695.

64. Reiter LS, Kruthof EKO, Cajot J-F, Sordat B: **The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells.** *Int. J. Cancer.* 1993; 53: 444-450.
65. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA: **Prevention of metastasis by inhibition of the urokinase receptor.** *Proc. Natl. Acad. Sci. USA* 1993; 90: 5021-5025.
66. Filderman AE, Bruckner A, Kacinski BM, Deng N, Remold HG: **Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1 receptor-positive carcinoma cell lines.** *Cancer. Res.* 1992; 52: 3661-3666.
67. Bruckner A, Filderman AE, Kirchheimer JC, Binder BR, Remold HG: **Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.** *Cancer. Res.* 1992; 52: 3043-3047.
68. Ossowski L: **Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo.** *Cell.* 1988; 52: 321-328.
69. Reich R, Thompson EW, Iwamoto Y, *et al*: **Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells.** *Cancer. Res.* 1988; 48: 3307-3312.
70. Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T, Terao T: **Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B.** *Cancer. Res.* 1992; 52: 3610-3614.
71. Khokha R, Waterhouse P, Yagel S, *et al*: **Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells.** *Science.* 1989; 243: 947-950.
72. Pyke C, Ralfkiaer E, Tryggvason K, Dano K: **Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer.** *Am. J. Pathol.* 1993; 142: 359-365.
73. Pyke C, Kristensen P, Ralfkiaer E, *et al*: **Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.** *Am. J. Pathol.* 1991; 138: 1059-1067.
74. Sier CF, Fellbaum C, Verspaget HW, *et al*: **Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum.** *Histopathology.* 1991; 19: 231-237.
75. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Dano K: **The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.** *Cancer. Res.* 1991; 51: 4067-4071.
76. Sier CFM, Verspaget HW, Griffioen G, *et al*: **Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia.** *Gastroenterology* 1991; 101: 1522-1528.
77. Ossowski L, Clunie G, Masucci MT, Blasi F: **In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion.** *J. Cell. Biol.* 1991; 115: 1107-1112.
78. Albelda SM: **Role of integrins and other cell adhesion molecules in tumor progression and metastasis.** *Lab. Invest.* 1993; 68: 4-17.
79. Nose A, Tsuji K, Takeichi M: **Localization of specificity determining sites in cadherin cell adhesion molecules.** *Cell.* 1990; 61: 147-155.
80. Fujimori T, Miyatani S, Takeichi M: **Ectopic expression of N-cadherin perturbs histogenesis in *Xenopus* embryos.** *Development* 1990; 110: 97-104.
81. Ozawa M, Ringwald M, Kemler R: **Uvomorulin-catenin complex formation is regulated by a specific domain in the cytoplasmic region of the cell adhesion molecule.** *Proc. Natl. Acad. Sci. U. S. A.* 1990; 87: 4246-4250.

82. Behrens J, Mareel MM, Van-Roy FM, Birchmeier W: **Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion.** *J. Cell. Biol.* 1989; 108: 2435-2447.
83. Hirano S, Kimoto N, Shimoyama Y, Hirohashi S, Takeichi M: **Identification of a neural alpha-catenin as a key regulator of cadherin function and multicellular organization.** *Cell.* 1992; 70: 293-301.
84. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van-Roy F: **Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role.** *Cell.* 1991; 66: 107-119.
85. Horwitz A, Duggan K, Buck C, Beckerle MC, Burridge K: **Interaction of plasma membrane fibronectin receptor with talin - a transmembrane linkage.** *Nature.* 1986; 320: 531-533.
86. Behrens J, Vakaet L, Friis R, *et al*: **Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-Cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-Src gene.** *J. Cell. Biol.* 1993; 120: 757-766.
87. Oka H, Shiozaki H, Kobayashi K, *et al*: **Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis.** *Cancer. Res.* 1993; 53: 1696-1701.
88. Schipper JH, Frixen UH, Behrens J, Unger A, Jahnke K, Birchmeier W: **E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis.** *Cancer. Res.* 1991; 51: 6328-6337.
89. Umbas R, Schalken JA, Aalders TW, *et al*: **Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.** *Cancer. Res.* 1992; 52: 5104-5109.
90. Bussemakers MJ, van-Moorselaar RJ, Girolodi LA, *et al*: **Decreased expression of E-cadherin in the progression of rat prostatic cancer.** *Cancer. Res.* 1992; 52: 2916-2922.
91. Ruggeri B, Caamano J, Slaga TJ, Conti CJ, Nelson WJ, Klein-Szanto AJ: **Alterations in the expression of uvomorulin and Na⁺,K⁺-adenosine triphosphatase during mouse skin tumor progression.** *Am. J. Pathol.* 1992; 140: 1179-1185.
92. Shimoyama Y, Hirohashi S, Hirano S, *et al*: **Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas.** *Cancer. Res.* 1989; 49: 2128-2133.
93. van der Wurff AA, ten Kate J, van der Linden EPM, Dinjens WNM, Arends J-W, Bosman FT: **L-CAM expression in normal, premalignant, and malignant colon mucosa.** *J. Pathol.* 1992; 168: 287-291.
94. Dorudi S, Sheffield JP, Poulson R, Northover JMA, Hart IR: **E-cadherin expression in colorectal cancer; An immunohistochemical and in situ hybridization study.** *Am. J. Pathol.* 1993; 142: 981-986.
95. Hynes RO: **Integrins: a family of cell surface receptors.** *Cell.* 1987; 48: 549-554.
96. Hynes RO: **Integrins: versatility, modulation, and signaling in cell adhesion.** *Cell.* 1992; 69: 11-25.
97. Tapley P, Horwitz A, Buck C, Duggan K, Rohrschneider L: **Integrins isolated from Rous sarcoma virus-transformed chicken embryo fibroblasts.** *Oncogene.* 1989; 4: 325-333.
98. Schiro JA, Chan BM, Roswit WT, *et al*: **Integrin alpha 2 beta 1 (VLA-2) mediates reorganization and contraction of collagen matrices by human cells.** *Cell.* 1991; 67: 403-410.
99. Chan BM, Kassner PD, Schiro JA, Byers HR, Kupper TS, Hemler ME: **Distinct cellular functions mediated by different VLA integrin alpha subunit cytoplasmic domains.** *Cell.* 1992; 68: 1051-1060.

100. Azzam HS, Thompson EW: **Collagen-induced activation of the M(r) 72,000 type IV collagenase in normal and malignant human fibroblastoid cells.** *Cancer. Res.* 1992; 52: 4540-4544.
101. Pignatelli M, Bodmer WF: **Genetics and biochemistry of collagen binding-triggered glandular differentiation in a human colon carcinoma cell line.** *Proc. Natl. Acad. Sci. U. S. A.* 1988; 85: 5561-5565.
102. Pignatelli M, Bodmer WF: **Integrin cell adhesion molecules and colorectal cancer.** *J. Pathol.* 1990; 162: 95-97.
103. Werb Z, Tremble PM, Behrendtsen O, Crowley E, Damsky CH: **Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression.** *J. Cell. Biol.* 1989; 109: 877-889.
104. Mortarini R, Gismondi A, Santoni A, Parmiani G, Anichini A: **Role of the alpha 5 beta 1 integrin receptor in the proliferative response of quiescent human melanoma cells to fibronectin.** *Cancer. Res.* 1992; 52: 4499-4506.
105. Pignatelli M, Bodmer WF: **Integrin-receptor-mediated differentiation and growth inhibition are enhanced by transforming growth factor-beta in colorectal tumour cells grown in collagen gel.** *Int. J. Cancer.* 1989; 44: 518-523.
106. Ullrich A, Schlessinger J: **Signal transduction by receptors with tyrosine kinase activity.** *Cell.* 1990; 61: 203-212.
107. Fischer EH, Charbonneau H, Tonks NK: **Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes.** *Science.* 1991; 253: 401-406.
108. Gilman AG: **G proteins: transducers of receptor-generated signals.** *Annu. Rev. Biochem.* 1987; 56: 615-649.
109. Juliano RL, Haskill S: **Signal transduction from the extracellular matrix.** *J. Cell. Biol.* 1993; 120: 577-585.
110. Kornberg LJ, Earp HS, Turner CE, Prockop C, Juliano RL: **Signal transduction by integrins: increased protein tyrosine phosphorylation caused by clustering of beta 1 integrins.** *Proc. Natl. Acad. Sci. U. S. A.* 1991; 88: 8392-8396.
111. Kanner SB, Reynolds AB, Vines RR, Parsons JT: **Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases.** *Proc. Natl. Acad. Sci. U. S. A.* 1990; 87: 3328-3332.
112. Guan JL, Shalloway D: **Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation.** *Nature.* 1992; 358: 690-692.
113. Hanks SK, Calalb MB, Harper MC, Patel SK: **Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin.** *Proc. Natl. Acad. Sci. U. S. A.* 1992; 89: 8487-8491.
114. Choy MY, Richman PI, Horton MA, MacDonald TT: **Expression of the VLA family of integrins in human intestine.** *J. Pathol.* 1990; 160: 35-40.
115. Koretz K, Schlag P, Bousmell L, Moller P: **Expression of VLA-alpha 2, VLA-alpha 6, and VLA-beta 1 chains in normal mucosa and adenomas of the colon, and in colon carcinomas and their liver metastases.** *Am. J. Pathol.* 1991; 138: 741-750.
116. Sonnenberg A, Linders CJT, Daams JH, Kennel SJ: **The alpha-6-beta-1 (VLA-6) and alpha-6-beta-4 protein complexes: tissue distribution and biochemical properties.** *J. Cell Sci.* 1990; 96: 207-217.
117. Bosman FT, de Bruine A, Flohil C, van der Wurff A, ten Kate J, Dinjens WWM: **Epithelial-stromal interactions in colon cancer.** *Int. J. Dev. Biol.* 1993; 37: 203-211.
118. Larjava H, Peltonen J, Akiyama SK, *et al*: **Novel function for beta 1 integrins in keratinocyte cell-cell interactions.** *J. Cell. Biol.* 1990; 110: 803-815.

119. Symington BE, Takada Y, Carter WG: **Interaction of integrins alpha3 beta1 and alpha2 beta1: Potential role in keratinocyte intercellular adhesion.** J. Cell. Biol. 1993; 120: 523-535.
120. Pignatelli M, Smith ME, Bodmer WF: **Low expression of collagen receptors in moderate and poorly differentiated colorectal adenocarcinomas.** Br. J. Cancer. 1990; 61: 636-638.
121. Stallmach A, van Lampe B, Matthes H, Bornhoft G, Riecken EO: **Diminished expression of integrin adhesion molecules on human colonic epithelial cells during the benign to malign transformation.** Gut. 1992; 33: 342-346.
122. Humphries MJ, Olden K, Yamada KM: **A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells.** Science. 1986; 233: 467-470.
123. Chan BMC, Matsuura N, Takada Y, Zetter BR, Hemler ME: **In vitro and in vivo consequences of VLA-2 expression on rhabdomyosarcoma cells.** Science. 1991; 251: 1600-1602.
124. Dedhar S, Saulnier R: **Alterations in integrin receptor expression on chemically transformed human cells: specific enhancement of laminin and collagen receptor complexes.** J. Cell. Biol. 1990; 110: 481-489.
125. Giancotti FG, Ruoslahti E: **Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells.** Cell. 1990; 60: 849-859.
126. Zetter BR: **The cellular basis of site-specific tumor metastasis.** N. Engl. J. Med. 1990; 322: 605-612.
127. Sargent NS, Oestreicher M, Haidvogel H, Madnick HM, Burger MM: **Growth regulation of cancer metastases by their host organ.** Proc. Natl. Acad. Sci. U. S. A. 1988; 85: 7251-7255.
128. Cleutjens JP, Havenith MG, Vallinga M, Beek C, Bosman FT: **Monoclonal antibodies to native basement membranes reveal heterogeneous immunoreactivity patterns.** Histochemistry. 1989; 92: 407-412.
129. McBain JA, Weese JL, Meisner LF, Wolberg WH, Willson JK: **Establishment and characterization of human colorectal cancer cell lines.** Cancer. Res. 1984; 44: 5813-5821.
130. Wallace JS, Hayle AJ, Syms AJ, *et al*: **The ras oncogene and tumour metastasis: observations on murine cells transfected with activated human c-Ha-ras.** Differentiation. 1989; 41: 208-215.
131. Mareel MM, Van-Roy FM, Messiaen LM, Boghaert ER, Bruyneel EA: **Qualitative and quantitative analysis of tumour invasion in vivo and in vitro.** J. Cell. Sci. Suppl. 1987; 8: 141-163.
132. Schor SL, Schor AM, Winn B, Rushton G: **The use of three-dimensional collagen gels for the study of tumour cell invasion in vitro: experimental parameters influencing cell migration into the gel matrix.** Int. J. Cancer. 1982; 29: 57-62.
133. Mareel MM, De Bruyne GK, Vandesande F, Dragonetti C: **Immunohistochemical study of embryonic chick heart invaded by malignant cells in three-dimensional culture.** Invasion. Metastasis. 1981; 1: 195-204.
134. Chambers AF, Tuck AB: **Oncogene transformation and the metastatic phenotype.** Anticancer. Res. 1988; 8: 861-871.
135. Fidler IJ: **Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis.** Cancer. Metastasis. Rev. 1986; 5: 29-49.
136. Fidler IJ, Naito S, Pathak S: **Orthotopic implantation is essential for the selection, growth and metastasis of human renal cell cancer in nude mice.** Cancer. Metastasis. Rev. 1990; 9: 149-165.
137. Barbacid M: **ras genes.** Annu. Rev. Biochem. 1987; 56: 779-827.

138. Bourne HR, Sanders DA, McCormick F: **The GTPase superfamily: conserved structure and molecular mechanism.** *Nature.* 1991; 349: 117-127.
139. Grand RJA, Owen D: **The biochemistry of ras p21.** *Biochem. J.* 1991; 279: 609-631.
140. Polakis P, McCormick F: **Structural requirements for the interaction of p21 ras with GAP, Exchange factors, and its biological effector target.** *J. Biol. Chem.* 1993; 268: 9157-9160.
141. Tong LA, de-Vos AM, Milburn MV, Kim SH: **Crystal structures at 2.2 Å resolution of the catalytic domains of normal ras protein and an oncogenic mutant complexed with GDP.** *J. Mol. Biol.* 1991; 217: 503-516.
142. John J, Sohmen R, Feuerstein J, Linke R, Wittinghofer A, Goody RS: **Kinetics of interaction of nucleotides with nucleotide-free H-ras p21.** *Biochemistry.* 1990; 29: 6058-6065.
143. Chung H-H, Benson DR, Schultz PG: **Probing the structure and mechanism of ras protein with an expanded genetic code.** *Science.* 1993; 259: 806-809.
144. Capon DJ, Chen EY, Levinson AD, Seeburg PH, Goeddel DV: **Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue.** *Nature.* 1983; 302: 33-37.
145. McGrath JP, Capon DJ, Smith DH, *et al*: **Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene.** *Nature.* 1983; 304: 501-506.
146. Shimizu K, Birnbaum D, Ruley MA, *et al*: **Structure of the Ki-ras gene of the human lung carcinoma cell line Calu-1.** *Nature.* 1983; 304: 497-500.
147. Taparowsky E, Shimizu K, Goldfarb M, Wigler M: **Structure and activation of the human N-ras gene.** *Cell.* 1983; 34: 581-586.
148. Hancock JF, Paterson H, Marshall CJ: **A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane.** *Cell.* 1990; 63: 133-139.
149. Marshall MS, Davis LJ, Keys RD, *et al*: **Identification of amino acid residues required for Ras p21 target activation.** *Mol. Cell. Biol.* 1991; 11: 3997-4004.
150. Haubruck H, McCormick F: **Ras p21: effects and regulation.** *Biochim. Biophys. Acta.* 1991; 1072: 215-229.
151. Fukui Y, Kozasa T, Kaziro Y, Takeda T, Yamamoto M: **Role of a ras homolog in the life cycle of Schizosaccharomyces pombe.** *Cell.* 1986; 44: 329-336.
152. Han M, Sternberg PW: **let-60, a gene that specifies cell fates during C. elegans vulval induction, encodes a ras protein.** *Cell.* 1990; 63: 921-931.
153. Beitel GJ, Clark SG, Horvitz R: **Caenorhabditis elegans ras gene let-60 acts as a switch in the pathway of vulval induction.** *Nature.* 1990; 348: 503-509.
154. Simon MA, Bowtell DD, Dodson GS, Lavery TR, Rubin GM: **Ras1 and a putative guanine nucleotide exchange factor perform crucial steps in signaling by the sevenless protein tyrosine kinase.** *Cell.* 1991; 67: 701-716.
155. Fortini ME, Simon MA, Rubin GM: **Signalling by the sevenless protein tyrosine kinase is mimicked by Ras1 activation.** *Nature.* 1992; 355: 559-561.
156. Greenwald I, Rubin GM: **Making a difference: the role of cell-cell interactions in establishing separate identities for equivalent cells.** *Cell.* 1992; 68: 271-281.
157. Chesa PG, Rettig WJ, Melamed MR, Old LJ, Niman HL: **Expression of p21ras in normal and malignant human tissues: lack of association with proliferation and malignancy.** *Proc. Natl. Acad. Sci. U. S. A.* 1987; 84: 3234-3238.
158. Furth ME, Aldrich TH, Cordon-Cardo C: **Expression of ras proto-oncogene proteins in normal human tissues.** *Oncogene.* 1987; 1: 47-58.
159. Untawale S, Blick M: **Oncogene expression in adenocarcinomas of the colon and in colon tumor-derived cell lines.** *Anticancer. Res.* 1988; 8: 1-7.

160. Spandidos DA, Kerr IB: **Elevated expression of the human ras oncogene family in premalignant and malignant tumours of the colorectum.** *Br. J. Cancer.* 1984; 49: 681-688.
161. West M, Kung HF, Kamata T: **A novel membrane factor stimulates guanine nucleotide exchange reaction of ras proteins.** *FEBS. Lett.* 1990; 259: 245-248.
162. Wolfman A, Macara IG: **A cytosolic protein catalyzes the release of GDP from p21ras.** *Science.* 1990; 248: 67-69.
163. Downward J, Riehl R, Wu L, Weinberg RA: **Identification of a nucleotide exchange-promoting activity for p21ras.** *Proc. Natl. Acad. Sci. U. S. A.* 1990; 87: 5998-6002.
164. Trahey M, McCormick F: **A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants.** *Science.* 1987; 238: 542-545.
165. Xu GF, O'Connell P, Viskochil D, *et al*: **The neurofibromatosis type 1 gene encodes a protein related to GAP.** *Cell.* 1990; 62: 599-608.
166. Ballester R, Marchuk D, Boguski M, *et al*: **The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins.** *Cell.* 1990; 63: 851-859.
167. de-Vos AM, Tong L, Milburn MV, *et al*: **Three-dimensional structure of an oncogene protein: catalytic domain of human c-H-ras p21.** *Science.* 1988; 239: 888-893.
168. Hall A: **Signal transduction through small GTPases—a tale of two GAPs.** *Cell.* 1992; 69: 389-391.
169. Vogel US, Dixon RA, Schaber MD, *et al*: **Cloning of bovine GAP and its interaction with oncogenic ras p21.** *Nature.* 1988; 335: 90-93.
170. Koch CA, Anderson D, Moran MF, Ellis C, Pawson T: **SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins.** *Science.* 1991; 252: 668-674.
171. Pawson T, Gish GD: **SH2 and SH3 domains: from structure to function.** *Cell.* 1992; 71: 359-362.
172. Cantley L, Auger KR, Carpenter C, *et al*: **Oncogenes and signal transduction.** *Cell.* 1991; 64: 281-302.
173. Songyang Z, Shoelson SE, Chaudhuri M, *et al*: **SH2 domains recognize specific phosphopeptide sequences.** *Cell.* 1993; 72: 767-778.
174. Simon MA, Dodson GS, Rubin GM: **An SH3-SH2-SH3 protein is required for p21ras1 activation and binds to sevenless and sos proteins in vitro.** *Cell.* 1993; 73: 169-177.
175. Olivier JP, Raabe T, Henkemeyer M, *et al*: **A drosophila SH2-SH3 adaptor protein implicated in coupling the sevenless tyrosine kinase to an activator of ras guanine nucleotide exchange, sos.** *Cell.* 1993; 73: 179-191.
176. Buday L, Downward J: **Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor.** *Cell.* 1993; 73: 611-620.
177. Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D: **The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos.** *Nature.* 1993; 363: 83-85.
178. Tsai MH, Yu CL, Wei FS, Stacey DW: **The effect of GTPase activating protein upon ras is inhibited by mitogenically responsive lipids.** *Science.* 1989; 243: 522-526.
179. Tsai MH, Yu CL, Stacey DW: **A cytoplasmic protein inhibits the GTPase activity of H-Ras in a phospholipid-dependent manner.** *Science.* 1990; 250: 982-985.
180. Majerus PW: **Inositol phosphate biochemistry.** *Annu. Rev. Biochem.* 1992; 61: 225-250.
181. Yatani A, Okabe K, Polakis P, Halenbeck R, McCormick F, Brown AM: **ras p21 and GAP inhibit coupling of muscarinic receptors to atrial K⁺ channels.** *Cell.* 1990; 61: 769-776.

182. Gideon P, John J, Frech M, *et al*: **Mutational and kinetic analyses of the GTPase-activating protein (GAP)-p21 interaction: the C-terminal domain of GAP is not sufficient for full activity.** *Mol. Cell. Biol.* 1992; 12: 2050-2056.
183. Medema RH, de-Laat WL, Martin GA, McCormick F, Bos JL: **GTPase-activating protein SH2-SH3 domains induce gene expression in a Ras-dependent fashion.** *Mol. Cell. Biol.* 1992; 12: 3425-3430.
184. Martin GA, Yatani A, Clark R, *et al*: **GAP domains responsible for Ras p21-dependent inhibition of muscarinic atrial K⁺ channel currents.** *Nature.* 1992; 255: 192-194.
185. Marshall MS, Hettich LA: **Characterization of Ras effector mutant interactions with the NF1-GAP related domain.** *Oncogene.* 1993; 8: 425-431.
186. Bollag G, McCormick F, Clark R: **Characterization of full-length neurofibromin: Tubulin inhibits Ras GAP activity.** *The EMBO Journal* 1993; 12: 1923-1927.
187. McGlade J, Brunkhorst B, Anderson D, *et al*: **The N-terminal region of GAP regulates cytoskeletal structure and cell adhesion.** *The EMBO Journal* 1993; 12: 3073-3081.
188. Hughes DA, Fukui Y, Yamamoto M: **Homologous activators of ras in fission and budding yeast.** *Nature.* 1990; 344: 355-357.
189. Jones S, Vignais M-L, Broach JR: **The CDC25 protein of *Saccharomyces cerevisiae* promotes exchange of guanine nucleotides bound to Ras.** *Mol. Cell. Biol.* 1991; 11: 2641-2646.
190. Rogge RD, Karlovich CA, Banerjee U: **Genetic dissection of a neurodevelopmental pathway: Son of sevenless functions downstream of the sevenless and EGF receptor tyrosine kinases.** *Cell.* 1991; 64: 39-48.
191. Wang Y, Boguski M, Riggs M, Rodgers L, Wigler M: **Sar1, a gene from *Schizosaccharomyces pombe* encoding a protein that regulates ras1.** *Cell. Regul.* 1991; 2: 453-465.
192. Imai Y, Miyake S, Hughes DA, Yamamoto M: **Identification of a GTPase-activating protein homolog in *Schizosaccharomyces pombe*.** *Mol. Cell. Biol.* 1991; 11: 3088-3094.
193. Gaul U, Mardon G, Rubin GM: **A putative Ras GTPase activating protein acts as a negative regulator of signaling by the Sevenless receptor tyrosine kinase.** *Cell.* 1992; 68: 1007-1019.
194. Pusztai L, Lewis CE, Lorenzen J, McGee JO'D: **Growth factors: Regulation of normal and neoplastic growth.** *J. Pathol.* 1993; 169: 191-201.
195. Molloy CJ, Fleming TP, Bottaro DP, Cuadrado A, Aaronson SA: **Platelet-derived growth factor stimulation of GTPase-activating protein tyrosine phosphorylation in control and c-H-ras-expressing NIH 3T3 cells correlates with p21ras activation.** *Mol. Cell. Biol.* 1992; 12: 3903-3909.
196. Satoh T, Endo M, Nakafuku M, Akiyama T, Yamamoto T, Kaziro Y: **Accumulation of p21ras.GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity.** *Proc. Natl. Acad. Sci. U. S. A.* 1990; 87: 7926-7929.
197. Satoh T, Endo M, Nakafuku M, Nakamura S, Kaziro Y: **Platelet-derived growth factor stimulates formation of active p21ras.GTP complex in Swiss mouse 3T3 cells.** *Proc. Natl. Acad. Sci. U. S. A.* 1990; 87: 5993-5997.
198. Reedijk M, Liu XQ, Pawson T: **Interactions of phosphatidylinositol kinase, GTPase-activating protein (GAP), and GAP-associated proteins with the colony-stimulating factor 1 receptor.** *Mol. Cell. Biol.* 1990; 10: 5601-5608.
199. Molloy CJ, Bottaro DP, Fleming TP, Marshall MS, Gibbs JB, Aaronson SA: **PDGF induction of tyrosine phosphorylation of GTPase activating protein.** *Nature.* 1989; 342: 711-714.
200. Margolis B, Li N, Koch A, *et al*: **The tyrosine phosphorylated carboxyterminus of the EGF receptor is a binding site for GAP and PLC-gamma.** *Embo. J.* 1990; 9: 4375-4380.

201. Kaplan DR, Morrison DK, Wong G, McCormick F, Williams LT: **PDGF beta-receptor stimulates tyrosine phosphorylation of GAP and association of GAP with a signaling complex.** *Cell.* 1990; 61: 125-133.
202. Kazlauskas A, Ellis C, Pawson T, Cooper JA: **Binding of GAP to activated PDGF receptors.** *Science.* 1990; 247: 1578-1581.
203. Yarden Y, Ullrich A: **Growth factor receptor tyrosine kinases.** *Annu. Rev. Biochem.* 1988; 57: 443-478.
204. Morrison DK, Kaplan DR, Rhee SG, Williams LT: **Platelet-derived growth factor (PDGF)-dependent association of phospholipase C-gamma with the PDGF receptor signaling complex.** *Mol. Cell. Biol.* 1990; 10: 2359-2366.
205. Kazlauskas A, Kashishian A, Cooper JA, Valius M: **GTPase-activating protein and phosphatidylinositol 3-kinase bind to distinct regions of the platelet-derived growth factor receptor beta subunit.** *Mol. Cell. Biol.* 1992; 12: 2534-2544.
206. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J: **Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.** *Nature.* 1992; 356: 713-715.
207. Medema RH, de Vries-Smits AMM, van der Zon GCM, Maassen JA, Bos JL: **Ras activation by insulin and epidermal growth factor through enhanced exchange of guanine nucleotides on p21ras.** *Mol. Cell. Biol.* 1993; 13: 155-162.
208. Buday L, Downward J: **Epidermal growth factor regulates the exchange rate of guanine nucleotides on p21ras in fibroblasts.** *Mol. Cell. Biol.* 1993; 13: 1903-1910.
209. Ellis C, Moran M, McCormick F, Pawson T: **Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases.** *Nature.* 1990; 343: 377-381.
210. Wong G, Muller O, Clark R, *et al*: **Molecular cloning and nucleic acid binding properties of the GAP-associated tyrosine phosphoprotein p62.** *Cell.* 1992; 69: 551-558.
211. Settleman J, Narasimhan V, Foster LC, Weinberg RA: **Molecular cloning of cDNAs encoding the GAP-associated protein p190: implications for a signaling pathway from ras to the nucleus.** *Cell.* 1992; 69: 539-549.
212. Rossomando AJ, Payne DM, Weber MJ, Sturgill TW: **Evidence that pp42, a major tyrosine kinase target protein, is a mitogen-activated serine/threonine protein kinase.** *Proc. Natl. Acad. Sci. USA* 1989; 86: 6940-6943.
213. Crews CM, Alessandrini A, Erikson RL: **Erks: Their fifteen minutes has arrived.** *Cell Growth and Differentiation* 1992; 3: 135-142.
214. Davis RJ: **The mitogen-activated protein kinase signal transduction pathway.** *J. Biol. Chem.* 1993; 268: 14553-14556.
215. Alvarez A, Northwood IC, Gonzalez FA, *et al*: **Pro-Leu-Ser/Thr-Pro is a consensus primary sequence for substrate protein phosphorylation.** *J. Biol. Chem.* 1991; 266: 15277-15285.
216. Seth A, Alvarez E, Gupta S, Davis RJ: **A phosphorylation site located in the NH2-terminal domain of c-Myc increases transactivation of gene expression.** *J. Biol. Chem.* 1991; 266: 23521-23524.
217. Kyriakis JM, App H, Zhang X-f, *et al*: **Raf-1 activates MAP kinase-kinase.** *Nature.* 1992; 358: 417-420.
218. Howe LR, Leever SJ, Gomez N, Nakielnny S, Cohen P, Marshall CJ: **Activation of the MAP kinase pathway by the protein kinase raf.** *Cell.* 1992; 71: 335-342.
219. Vojtek AB, Hollenberg SM, Cooper JA: **Mammalian Ras interacts directly with the serine/threonine kinase Raf.** *Cell.* 1993; 74: 205-214.
220. Zhang X-f, Settleman J, Kyriakis JM, *et al*: **Normal and oncogenic p21 ras proteins bind to the amino-terminal domain of c-Raf-1.** *Nature.* 1993; 364: 308-313.

221. Warns PH, Viçlana PR, Downward J: **Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro.** *Nature.* 1993; 364: 352-355.
222. Moley JF, Brother MB, Wells SA, Spengler BA, Biedler JL, Brodeur GM: **Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers.** *Cancer. Res.* 1991; 51: 1596-1599.
223. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: **Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.** *Cell.* 1988; 53: 549-554.
224. Reddy EP, Reynolds RK, Santos E, Barbacid M: **A pointmutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene.** *Nature.* 1982; 300: 149-152.
225. Tabin CJ, Bradley SM, Bargmann CI, *et al*: **Mechanism of activation of a human oncogene.** *Nature.* 1982; 300: 143-149.
226. Bos JL, Toksoz D, Marshall CJ, *et al*: **Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia.** *Nature.* 1985; 315: 726-730.
227. Manne V, Bekesi E, Kung HF: **Ha-ras proteins exhibit GTPase activity: point mutations that activate Ha-ras gene products result in decreased GTPase activity.** *Proc. Natl. Acad. Sci. U. S. A.* 1985; 82: 376-380.
228. Buss JE, Solski PA, Schaeffer JP, MacDonald MJ, Der CJ: **Activation of the cellular proto-oncogene product p21Ras by addition of a myristylation signal.** *Science.* 1989; 243: 1600-1603.
229. Munder T, Furst P: **The *Saccharomyces cerevisiae* CDC25 gene product binds specifically to catalytically inactive ras proteins in vivo.** *Mol. Cell. Biol.* 1992; 12: 2091-2099.
230. Gross E, Goldberg D, Levitzki A: **Phosphorylation of the *S. cerevisiae* Cdc25 in response to glucose results in its dissociation from Ras.** *Nature.* 1992; 360: 762-765.
231. Medema RH, Wubbols R, Bos JL: **Two dominant inhibitory mutants of p21ras interfere with insulin-induced gene expression.** *Mol. Cell. Biol.* 1991; 11: 5963-5967.
232. Feig LA, Cooper GM: **Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP.** *Mol. Cell. Biol.* 1988; 8: 3235-3243.
233. Feig LA: **The many roads that lead to ras.** *Science.* 1993; 260: 767-768.
234. McCormick F: **How receptors turn Ras on.** *Nature.* 1993; 363: 15-16.
235. Perrimon N: **The torso receptor protein-tyrosine kinase signaling pathway: An endless story.** *Cell.* 1993; 74: 219-222.
236. Rozakis-Adcock M, McGlade J, Mbamalu G, *et al*: **Association of the Shc and Grb2/Sem-5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases.** *Nature.* 1992; 360: 689-692.
237. Egan SE, Giddings BW, Brooks MW, Buday L, Sizeland AM, Weinberg RA: **Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation.** *Nature.* 1993; 363: 45-51.
238. Chang EH, Furth ME, Scolnick EM, Lowy DR: **Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus.** *Nature.* 1982; 297: 479-483.
239. Feramisco JR, Gross M, Kamata T, Rosenberg M, Sweet RW: **Microinjection of the oncogene form of the human H-ras (T-24) protein results in rapid proliferation of quiescent cells.** *Cell.* 1984; 38: 109-117.
240. Stacey DW, Kung H-F: **Transformation of NIH 3T3 cells by microinjection of Ha-ras p21 protein.** *Nature.* 1984; 310: 508-511.

241. Egan SE, Wright JA, Jarolim L, Yanagihara K, Bassin RH, Greenberg AH: **Transformation by oncogenes encoding protein kinases induces the metastatic phenotype.** *Science.* 1987; 238: 202-205.
242. Egan SE, McClarty GA, Jarolim L, *et al*: **Expression of H-ras correlates with metastatic potential: evidence for direct regulation of the metastatic phenotype in 10T1/2 and NIH 3T3 cells.** *Mol. Cell. Biol.* 1987; 7: 830-837.
243. Chambers AF, Denhardt GH, Wilson SM: **ras-transformed NIH 3T3 cell lines, selected for metastatic ability in chick embryos, have increased proportions of p21-expressing cells and are metastatic in nude mice.** *Invasion. Metastasis.* 1990; 10: 225-240.
244. Egan SE, Broere JJ, Jarolim L, Wright JA, Greenberg AH: **Co-regulation of metastatic and transforming activity of normal and mutant ras genes.** *Int. J. Cancer.* 1989; 43: 443-448.
245. Bradley MO, Kraynak AR, Storer RD, Gibbs JB: **Experimental metastasis in nude mice of NIH 3T3 cells containing various ras genes.** *Proc. Natl. Acad. Sci. U. S. A.* 1986; 83: 5277-5281.
246. Muschel RJ, Williams JE, Lowy DR, Liotta LA: **Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell.** *Am. J. Pathol.* 1985; 121: 1-8.
247. Thorgeirsson UP, Turpeenniemi-Hujanen T, Williams JE, *et al*: **NIH/3T3 cells transfected with human tumor DNA containing activated ras oncogenes express the metastatic phenotype in nude mice.** *Mol. Cell. Biol.* 1985; 5: 259-262.
248. Sidhu MK, Russo MS, Zirvi KA, Scala L, Kumar S: **Tumorigenicity of EJ-ras oncogene transformed NIH 3T3 cells and expression of plasminogen activators.** *Cell. Biol. Int. Rep.* 1990; 14: 527-542.
249. Hill SA, Wilson S, Chambers AF: **Clonal heterogeneity, experimental metastatic ability, and p21 expression in H-ras-transformed NIH 3T3 cells.** *J. Natl. Cancer. Inst.* 1988; 80: 484-490.
250. Seiki M, Sato H, Liotta LA, Schiffmann E: **Comparison of autocrine mechanisms promoting motility in two metastatic cell lines: human melanoma and ras-transfected NIH3T3 cells.** *Int. J. Cancer.* 1991; 49: 717-720.
251. Bolscher JG, van-der-Bijl MM, Neefjes JJ, Hall A, Smets LA, Ploegh HL: **Ras (proto)oncogene induces N-linked carbohydrate modification: temporal relationship with induction of invasive potential.** *Embo. J.* 1988; 7: 3361-3368.
252. Springer TA: **Adhesion receptors of the immune system.** *Nature.* 1990; 346: 425-434.
253. Pozzatti R, Muschel R, Williams J, *et al*: **Primary rat embryo cells transformed by one or two oncogenes show different metastatic potentials.** *Science.* 1986; 232: 223-227.
254. Garbisa S, Pozzatti R, Muschel RJ, *et al*: **Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-E1a.** *Cancer. Res.* 1987; 47: 1523-1528.
255. Spandidos DA, Wilkie NM: **Malignant transformation of early passage rodent cells by a single mutated human oncogene.** *Nature.* 1984; 310: 469-475.
256. Muschel RJ, Nakahara K, Chu E, Pozzatti R, Liotta LA: **Karyotypic analysis of diploid or near diploid metastatic Harvey ras transformed rat embryo fibroblasts.** *Cancer. Res.* 1986; 46: 4104-4108.
257. McKenna WG, Nakahara K, Muschel RJ: **Site-specific integration of H-ras in transformed rat embryo cells.** *Science.* 1988; 241: 1325-1328.
258. Bardwell L: **The mutagenic and carcinogenic effects of gene transfer.** *Mutagenesis.* 1989; 4: 245-253.
259. Ricketts MH, Levinson AD: **High-level expression of c-H-ras1 fails to fully transform rat-1 cells.** *Mol. Cell. Biol.* 1988; 8: 1460-1468.

260. Hurlin PJ, Maher VM, McCormick JJ: **Malignant transformation of human fibroblasts caused by expression of a transfected T24 HRAS oncogene.** Proc. Natl. Acad. Sci. U. S. A. 1989; 86: 187-191.
261. Wilson DM, Yang DJ, Dillberger JE, Dietrich SE, Maher VM, McCormick JJ: **Malignant transformation of human fibroblasts by a transfected N-ras oncogene.** Cancer. Res. 1990; 50: 5587-5593.
262. Fry DG, Milam LD, Dillberger JE, Maher VM, McCormick JJ: **Malignant transformation of an infinite life span human fibroblast cell strain by transfection with v-Ki-ras.** Oncogene. 1990; 5: 1415-1418.
263. Jankun J, Maher VM, McCormick JJ: **Malignant transformation of human fibroblasts correlates with increased activity of receptor-bound plasminogen activator.** Cancer. Res. 1991; 51: 1221-1226.
264. Wilson DM, Fry DG, Maher VM, McCormick JJ: **Transformation of diploid human fibroblasts by transfection of N-ras-oncogenes.** Carcinogenesis. 1989; 10: 635-640.
265. Sager R, Tanaka K, Lau CC, Ebina Y, Anisowicz A: **Resistance of human cells to tumorigenesis induced by cloned transforming genes.** Proc. Natl. Acad. Sci. U. S. A. 1983; 80: 7601-7605.
266. Kinsella AR, Fiszer-Maliszewska L, Mitchell EL, Guo YP, Fox M, Scott D: **Introduction of the activated N-ras oncogene into human fibroblasts by retroviral vector induces morphological transformation and tumorigenicity.** Carcinogenesis. 1990; 11: 1803-1809.
267. Kerbel RS, Waghorne C, Man MS, Elliott B, Breitman ML: **Alteration of the tumorigenic and metastatic properties of neoplastic cells is associated with the process of calcium phosphate-mediated DNA transfection.** Proc. Natl. Acad. Sci. U. S. A. 1987; 84: 1263-1267.
268. Kyprianou N, Isaacs JT: **Relationship between metastatic ability and H-ras oncogene expression in rat mammary cancer cells transfected with the v-H-ras oncogene.** Cancer. Res. 1990; 50: 1449-1454.
269. Vousden KH, Eccles SA, Purvies H, Marshall CJ: **Enhanced spontaneous metastasis of mouse carcinoma cells transfected with an activated c-Ha-ras-1 gene.** Int. J. Cancer. 1986; 37: 425-433.
270. Treiger B, Isaacs J: **Expression of a transfected v-Harvey-ras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability.** J. Urol. 1988; 140: 1580-1586.
271. Partin AW, Isaacs JT, Treiger B, Coffey DS: **Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene.** Cancer. Res. 1988; 48: 6050-6053.
272. Cooke DB, Quarmby VE, Petrusz P, *et al*: **Expression of ras proto-oncogenes in the Dunning R3327 rat prostatic adenocarcinoma system.** Prostate. 1988; 13: 273-287.
273. Ichikawa T, Schalken JA, Ichikawa Y, Steinberg GD, Isaacs JT: **H-ras expression, genetic instability, and acquisition of metastatic ability by rat prostatic cancer cells following v-H-ras oncogene transfection.** Prostate. 1991; 18: 163-172.
274. Ichikawa T, Kyprianou N, Isaacs JT: **Genetic instability and the acquisition of metastatic ability by rat mammary cancer cells following v-H-ras oncogene transfection.** Cancer. Res. 1990; 50: 6349-6357.
275. Ciardiello F, McGeedy ML, Kim N, *et al*: **Transforming growth factor- α expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor- α complementary DNA leads to transformation.** Cell. Growth. Differ. 1990; 1: 407-420.

276. Lebeau J, Le-Chalony C, Prosperi MT, Goubin G: **Constitutive overexpression of a 89 kDa heat shock protein gene in the HBL100 human mammary cell line converted to a tumorigenic phenotype by the EJ/T24 Harvey-ras oncogene.** *Oncogene.* 1991; 6: 1125-1132.
277. Theodorescu D, Cornil I, Fernandez BJ, Kerbel RS: **Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma.** *Proc. Natl. Acad. Sci. U. S. A.* 1990; 87: 9047-9051.
278. Pratt CI, Kao CH, Wu SQ, Gilchrist KW, Oyasu R, Reznikoff CA: **Neoplastic progression by EJ/ras at different steps of transformation in vitro of human uroepithelial cells.** *Cancer. Res.* 1992; 52: 688-695.
279. Theodorescu D, Cornil I, Sheehan C, Man MS, Kerbel RS: **Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells.** *Cancer. Res.* 1991; 51: 4486-4491.
280. Dotto GP, Weinberg RA, Ariza A: **Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells.** *Proc. Natl. Acad. Sci. U. S. A.* 1988; 85: 6389-6393.
281. Boukamp P, Stanbridge EJ, Foo DY, Cerutti PA, Fusenig NE: **c-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy.** *Cancer. Res.* 1990; 50: 2840-2847.
282. Fang XJ, Flowers M, Keating A, Cameron R, Sherman M: **ras transformation of simian virus 40-immortalized rat hepatocytes: an in vitro model of hepatocarcinogenesis.** *Cancer. Res.* 1992; 52: 173-180.
283. Isom HC, Woodworth CD, Meng Y, Kreider J, Miller T, Mengel L: **Introduction of the ras oncogene transforms a simian virus 40-immortalized hepatocyte cell line without loss of expression of albumin and other liver-specific genes.** *Cancer. Res.* 1992; 52: 940-948.
284. Stevenson M, Volsky DJ: **Activated v-myc and v-ras oncogenes do not transform normal human lymphocytes.** *Mol. Cell. Biol.* 1986; 6: 3410-3417.
285. Collard JG, Schijven JF, Roos E: **Invasive and metastatic potential induced by ras-transfection into mouse BW5147 T-lymphoma cells.** *Cancer. Res.* 1987; 47: 754-759.
286. Nasi S, Sirinian MJ, Panetta G, Marchetti A, Jucker R: **Induction of the neoplastic phenotype of EBV-established B lymphocytes by the human Ha-ras oncogene.** *Oncogene.* 1990; 5: 117-122.
287. Seremetis S, Inghirami G, Ferrero D, *et al*: **Transformation and plasmacytoid differentiation of EBV-infected human B lymphoblasts by ras oncogenes.** *Science.* 1989; 243: 660-663.
288. Nakagawa T, Mabry M, de-Bustros A, Ihle JN, Nelkin BD, Baylin SB: **Introduction of v-Ha-ras oncogene induces differentiation of cultured human medullary thyroid carcinoma cells.** *Proc. Natl. Acad. Sci. U. S. A.* 1987; 84: 5923-5927.
289. Noda M, Ko M, Ogura A, *et al*: **Sarcoma viruses carrying ras oncogenes induce differentiation-associated properties in a neuronal cell line.** *Nature.* 1985; 318: 73-75.
290. Mabry M, Nakagawa T, Baylin S, Pettengill O, Sorenson G, Nelkin B: **Insertion of the c-Ha-ras oncogene induces differentiation of calcitonin-producing human small cell lung cancer.** *J. Clin. Invest.* 1989; 84: 194-199.
291. Benito M, Porras A, Nebreda AR, Santos E: **Differentiation of 3T3-L1 fibroblasts to adipocytes induced by transfection of ras oncogenes.** *Science.* 1991; 253: 565-568.
292. Baisch H, Collard J, Zywiets F, Jung H: **No acquisition of metastatic capacity of R1H rhabdomyosarcoma upon transfection with c-Ha-ras oncogene.** *Invasion. Metastasis.* 1990; 10: 193-207.

293. Price JE, Aukerman SL, Ananthaswamy HN, *et al*: **Metastatic potential of cloned murine melanoma cells transfected with activated c-Ha-ras.** *Cancer. Res.* 1989; 49: 4274-4281.
294. Tuck AB, Wilson SM, Chambers AF: **ras transfection and expression does not induce progression from tumorigenicity to metastatic ability in mouse LTA cells.** *Clin. Exp. Metastasis.* 1990; 8: 417-431.
295. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M: **Detection of high incidence of K-ras oncogenes during human colon tumorigenesis.** *Nature.* 1987; 327: 298-303.
296. Farr CJ, Marshall CJ, Easty DJ, Wright NA, Powell SC, Paraskeva SC: **A study of ras gene mutations in colonic adenomas from familial polyposis coli patients.** *Oncogene.* 1988; 3: 673-678.
297. Vogelstein B, Fearon ER, Hamilton SR, *et al*: **Genetic alterations during colorectal-tumor development.** *N. Engl. J. Med.* 1988; 319: 525-532.
298. Bos JL, Fearon ER, Hamilton SR, *et al*: **Prevalence of ras gene mutations in human colorectal cancers.** *Nature.* 1987; 327: 293-297.
299. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL: **KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.** *Nucleic. Acids. Res.* 1988; 16: 7773-7782.
300. Losi L, Benhattar J, Costa J: **Stability of K-ras mutations throughout the natural history of human colorectal cancer.** *Eur. J. Cancer.* 1992; 28A: 1115-1120.
301. Suchy B, Zietz C, Rabes HM: **K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis.** *Int. J. Cancer.* 1992; 52: 30-33.
302. Daar I, Nebreda AR, Yew N, *et al*: **The ras oncoprotein and M-phase activity.** *Science.* 1991; 253: 74-76.
303. Nebreda AR, Porras A, Santos E: **p21Ras-induced meiotic maturation of Xenopus oocytes in the absence of protein synthesis: MPF activation is preceded by activation of MAP and S6 kinases.** *Oncogene.* 1993; 8: 467-477.
304. Gallick GE, Kurzrock R, Kloetzer WS, Arlinghaus RB, Gutterman JU: **Expression of p21ras in fresh primary and metastatic human colorectal tumors.** *Proc. Natl. Acad. Sci. U. S. A.* 1985; 82: 1795-1799.
305. De-Biasi F, Del-Sal G, Hand PH: **Evidence of enhancement of the ras oncogene protein product (p21) in a spectrum of human tumors.** *Int. J. Cancer.* 1989; 43: 431-435.
306. Jansson DS, Radosevich JA, Carney WP, *et al*: **An immunohistochemical analysis of ras oncogene expression in epithelial neoplasms of the colon.** *Cancer.* 1990; 65: 1329-1337.

CHAPTER 2

BEHAVIOR OF ORTHOTOPIC HUMAN COLORECTAL CARCINOMA XENOGRAPHS IN RELATION TO IN VITRO INVASION

J.E. de Vries, W.N.M. Dinjens, H.W. Verspaget, E.P.M. van der Linden, A.P. de Bruijne,
M.M. Mareel, F.T. Bosman, and J. ten Kate.

Manuscript submitted for publication.

2.1 INTRODUCTION

The mechanisms underlying tumor metastasis formation have been intensively studied in the past decade (1-4). Metastasis appears to be a multistep process but it is not yet clear which steps in the cascade of events ultimately determine whether or not a metastasis will occur. In any case invasion, defined as the ability of carcinoma cells to traverse the basement membrane (BM), detach from the primary tumor, and migrate into the extracellular matrix (ECM), is an important step. Various in vitro models have been developed to study invasion (5), including invasion of tumor cells into embryonic chick heart fragments (6).

In vivo models more closely resemble the human situation than in vitro models and allow the study not only of invasion, but also of the further steps involved in metastasis formation. In general terms, two different approaches have been used in in vivo studies. The most frequent one is intravascular injection of cancer cells, which then lodge in and potentially grow out into a capillary bed along the circulation. In this approach only the final steps in metastasis formation can be studied. The more tedious and time consuming approach is the establishment of a primary xenograft, from which then spontaneous metastases might occur. In such a model, all steps of the metastatic cascade might be studied.

For reasons of convenience, subcutaneous inoculation has been most frequently used for xenografting. Subcutaneous xenografts, however, rarely metastasize. Following the ideas put forward by Fidler and Hart (7-9) concerning the influence of the microenvironment of a tumor xenograft on its tendency to metastasize, orthotopic xenografting has been adopted. From orthotopic sites spontaneous metastases more readily develop. We and others designed a model in which human colon cancer cell lines are xenografted orthotopically in the wall of the cecum of nude mice (10, 11). In this model, the obtained primary xenografts spontaneously give rise to lymph node, liver and lung metastases. This observation suggests that local tissue factors might play a role in the activation or inactivation of genes, of which the products are necessary for the development of metastases.

Of the proteins, potentially involved in invasion and metastasis, two categories have been extensively investigated. Proteases, responsible for dissolution of the basement membrane and the surrounding interstitial stroma, deserve to be mentioned. It has been shown that, depending on the experimental conditions and on the cell type under investigation, the expression of proteases such as urokinase plasminogen activator (u-PA) and type IV collagenase, is upregulated in invading and metastasizing cells (12-16). Cell-adhesion molecules have been studied, following the concept that as long as tumor cells remain integrated in a tissue structure, they will not dislodge and therefore not invade surrounding tissue and metastasize. Compelling experimental evidence in favor of such a role for E-cadherin has been provided by Behrens et al. (17) and Vleminckx et al. (18). Integrins, a fairly recently discovered family of cell-cell and cell-matrix adhesion molecules, might be expected to play a similar role in invasion and metastasis,

particularly in the migration of invasive cells through the extracellular matrix and the lodging of tumor cells at distant sites in the microcirculation (reviewed in 19).

For the study of invasion and metastasis in colorectal cancer, orthotopic xenograft models have been developed, but a limited number of cell lines has been studied (10, 11, 20-22). We xenografted a series of 9 colorectal carcinoma cell lines in the subcutis and in the cecum of nude mice in order to establish which of these cell lines would show tumorigenicity, local invasion and metastasis formation from either site. In a selected subset of cell lines we furthermore studied invasion in vitro (into chick heart embryonic heart fragments), in vitro production of the proteases u-PA and t-PA, E-cadherin expression in vitro and in vivo, and in vitro expression of $\alpha_2\beta_1$, $\alpha_3\beta_1$, and $\alpha_6\beta_1$ integrin receptors. Our results fit the hypothesis that the capacity of neoplastic cells to invade and metastasize is not only determined by the inherent characteristics of the cancer cells but is also modulated by the local microenvironment.

2.2 MATERIALS AND METHODS

2.2.1 Cell culture

The following human colorectal cancer cell lines were used: CaCo 2 (23), SW1116, SW480, SW620 (24), NCI-H716 (25), LS174T (26), 5583E, 5583S (27), HT29 (28). The cells were maintained in Dulbecco's Modified Eagle's Medium supplemented with 10% Fetal Calf Serum.

2.2.2 Xenografting

Athymic CD-1 male nude mice, 3-4 weeks old, were obtained from Charles River Wiga (Freiburg, Germany) and maintained in a laminar air flow cabinet under specific pathogen free conditions.

Tumor cells were harvested with 0.1 g trypsin, 0.02 g EDTA per 100 ml PBS, washed and diluted in sterile PBS to a density of 1×10^7 /ml. Nude mice under ether anesthesia were injected with 1×10^6 tumor cells in the subcutis, the spleen or the cecal wall, which was approached through a small median abdominal incision. Then, the tumor cells were injected along the mesocolon using a 30 G needle. The abdomen was subsequently closed in two layers (11). Liver colonizing ability was determined by inoculation of tumor cells into the spleen (20). The spleen was exposed through a small incision in the skin and peritoneum, and tumor cells were injected subcapsularly. The spleen was repositioned and the incision was sutured. The mice were sacrificed after 7 weeks. Of all mice, at autopsy the tumor at the site of injection as well as the liver, lungs and lymph nodes were collected, in order to detect the presence of metastases macroscopically as well as microscopically. Tissues were fixed in 4% formalin, embedded in paraplast for histology and for immunohistochemical staining. At least three non-consecutive sections were examined when there was no macroscopic evidence of metastasis.

2.2.3 Invasion into embryonic chick heart fragments

Briefly, cells growing in suspension were harvested by centrifugation and cells growing in a monolayer by scraping with a rubber policeman. The cells were brought into contact with precultured 9-day-old embryonic chick heart fragments on top of a semisolid agar medium. After incubation overnight (37°C), individual confronting pairs were put into 5 ml. Erlenmeyer flasks with 1.5 ml. of liquid culture medium on a gyrotory shaker and further incubated (120 rpm, 37°C). The confronting pairs were fixed, embedded in paraffin and sectioned for microscopy after 4 and 7 days. Invasiveness was determined and scored as described previously (5).

2.2.4 Quantitation of u-PA and t-PA

When the cells in stock culture had almost reached confluency, the medium was changed and after 24 h, the supernatant harvested, centrifuged and directly stored at -70°C until further analysis.

Cells growing in suspension were harvested by centrifugation and washed twice. Cells growing in a monolayer were rinsed twice with PBS and harvested by scraping with a rubber policeman. Cell pellets were lysed in 1 ml PBS/0.5% Triton X-100 and stored at -70°C until further analysis. u-PA and t-PA were measured by sandwich ELISA as described previously (29, 30). Protein content of the cell extracts was determined according to Lowry et al. (31). The intra- and intersample variation did not exceed 3% and 10% respectively.

2.2.5 Immunohistochemistry

E-cadherin

After trypsinization of a monolayer culture, the solitary cells were seeded on glass coverslips in a 24 well plate. Two to 3 days after incubation the coverslips containing the cells were washed briefly in PBS containing Ca^{2+} and Mg^{2+} and fixed in methanol at -25°C for 15 min, air dried and stored at -25°C until use.

Fixed cell cultures were taken from frozen stock and brought to room temperature. They were rehydrated in Tris buffered saline pH = 7.6 (TBS) and incubated in 5% BSA in TBS for 30 min. Then a mixture of primary antibodies composed of a monoclonal mouse antibody against human E-cadherin (HECD-1 (British Biotechnology Products LTd, Abingdon, UK), diluted 1:100 in TBS) and a polyclonal rabbit antibody against keratin (PKE (Euro-Diagnostica, Apeldoorn, The Netherlands), diluted 1:50) was added for 1 h. After 3 subsequent washings, a mixture of secondary antibodies composed of ShAM conjugated with biotin (Amersham, UK), diluted 1:50 in TBS, and GAR conjugated to FITC (Nordic, Tilburg, The Netherlands), diluted 1:20, was added for 1 h. A final incubation was done in Streptavidin linked to Texas red (Amersham, UK), diluted 1:50 in TBS, and DAPI (4',6'-diamidino-2-phenyl-indole (Sigma, St. Louis, MO, USA), 0.4 µg/ml in TBS, for 15 min. After thorough rinsing the coverslips were mounted in Glycergel (DAKO, Glostrup, Denmark). Photographs were taken with a Leitz-Dialux 20 photomicroscope equipped for epifluorescence.

Xenografted tumor tissue specimens were formalin fixed (3 h, RT) and paraffin embedded. Sections were mounted on glass slides and dehydrated. Endogenous peroxidase was blocked by incubation in PBS/0.3% with H_2O_2 (20 min, RT). The slides were incubated with the primary antibody and, after washing with PBS, incubated with rabbit anti-mouse horseradish peroxidase conjugate (DAKO, P260, Glostrup, Denmark). Peroxidase activity was visualized with diaminobenzidine and the slides were counterstained with hematoxylin.

Integrins

Cells were harvested by gentle scraping with a rubber policeman, washed twice with PBS, diluted in PBS/1% BSA and centrifuged on a glass slide. Methanol (1 min, $-20^{\circ}C$) followed by acetone (3x1 sec, $-20^{\circ}C$) was used for fixation of the cells. Monoclonal antibodies 10G11, specific for the $\alpha_2\beta_1$ integrin (32) and GoH3, specific for the α_6 chain (33) were generous gifts from Dr. A. Sonnenberg, the monoclonal antibody J143 directed against the α_3 chain was a kind gift from Dr. A. P. Albino (34). Integrin chains were detected as described for E-cadherin in xenografts.

As negative controls, specific antibodies were omitted and normal human colon mucosa was used as a positive control. Immunohistochemical results were scored independently by two observers (JdV, EvdL), providing largely concordant results.

2.3 RESULTS

In vivo behavior of human colorectal carcinoma cell lines

The take rate of human colorectal carcinoma cell lines xenografted in the subcutis of nude mice was 100%, except for CaCo2 cells, which under standard xenografting conditions did not produce tumors (Table 1). All cell lines grew expansively in the subcutis, with a rim of fibrous tissue surrounding the tumor in SW1116, SW480, SW620, LS174T and 5583E xenografts. Invasion into surrounding tissue was observed for NCI-H716, 5583S, and HT29. After grafting in the subcutis, none of the tumor cell lines gave rise to metastatic lesions.

Orthotopic xenografting of the colorectal carcinoma cell lines in the wall of the cecum yielded in general lower take rates varying between 25% (NCI-H716 and SW1116) and 100% (LS174T and 5583E) with the exception of CaCo 2 cells, which did not produce tumors. SW1116, SW480 and SW620 showed tumor growth in solid nodules in the subserosa without invasion of the bowel wall (Fig. 1) or the development of metastases. NCI-H716 and LS174T cells developed primary tumors with irregular nests and strands of cells, invading the muscularis propria and mucosa. Metastases, however, were not observed (Table 1). HT29, 5583E and 5583S xenografts showed an invasive growth pattern but also gave rise to lymph node metastases and microscopic metastases in the lungs and in the liver. The metastases extended from small arteries in the lungs or venules in the portal triads in the liver (Fig. 1).

Table 1. In vivo behavior of human colorectal cancer cell lines.

Cell line	Subcutis	Cecum ¹ primary	invasive ²	metastasis	Spleen
CaCo 2	0/5	0/5	0/5	0/5	NT ³
SW1116	5/5	1/4	0/1	0/1	1/4
SW480	10/11	3/5	0/3	0/3	3/4
SW620	7/8	8/9	0/8	0/8	NT
NCI-H716	24/26	1/4	1/1	0/1	NT
LS174T	4/4	7/7	7/7	0/7	3/3
5583E	5/5	5/5	1/5	1/1 (lung)	2/3
5583S	5/5	6/10	3/6	1/3 (liver)	3/8
HT29	5/5	4/5	4/4	3/4 (lung)	NT

1. Number of primary tumors per number of inoculations of tumor cells into the wall of the cecum.

2. Invasive if tumor cells were observed in the muscularis mucosa or adjacent to colon crypt cells.

3. NT = not tested.

Table 2. Parameters of human colorectal cancer cell lines.

Cell line	ECHF	u-PA ² medium ³	cell ⁴	t-PA ² cell ⁴	E-Cadherin		Integrins		
					in vitro	in vivo	$\alpha_2\beta_1$	$\alpha_3\beta_1$	$\alpha_6\beta_1$
CaCo 2	- ¹	1332	37	579	Hmg ⁵	NT	$\pm^6$	-	++
SW620	+	22850	161	498	Htr	-	$\pm$	-	+++
LS174T	-	540	17	388	Hmg	-	++	-	+++
HT29	-	1308	240	269	Hmg	Htr	+++	++	+++

1. Invasion into embryonic chick heart fragments: - = not invasive, + = invasive.

2. Mean values obtained in two independent experiments; 3. Pg/ml medium; 4. Pg per mg protein.

5. Hmg = homogenous expression; Htr = heterogenous expression; NT = not tested for lack of tissue.

6. Percentage positive cells: - = 0%; $\pm \leq 1\%$; + = 1% - 10%; ++ = 10% - 75%; +++ = > 75% positive cells.

Intrasplenic injection of colorectal carcinoma cell lines, either non-metastatic or metastatic after grafting in the cecum, demonstrated that both categories of tumor cells were able to colonize the liver (Table 1). The take rate varied, being 25% for SW1116 and 100% for LS174T, and ranged between these values in SW480 and 5583 (E and S). For further characterization we selected CaCo2 (poorly tumorigenic), SW620 (tumorigenic, non-invasive in the cecum), LS174T (tumorigenic, invasive in the cecum, non-metastatic), and HT29 cells (tumorigenic, invasive in the cecum and metastatic).

Figure 1. Growth behavior of colorectal cancer cell lines in vivo.

A. Behavior of SW620 cells in the cecum, the muscularis mucosa is not invaded by tumor cells. **B.** Behavior of HT29 cells in the cecum, tumor cells have migrated through the muscularis mucosa, adjacent to crypt cells of the colon. **C.** Metastatic lesion of 5583S in the liver. **D.** Metastatic lesion of HT29 in the lung. Bar is 20 μm (A, B) and 10 μm (C, D).

T = tumor cells; M = muscularis mucosa; C = crypt cells of the colon; L = liver (C) or lung (D).

Figure 2. In vitro invasion.

The colorectal cell line CaCo 2 does not invade embryonic chick heart fragments after 7 days of coculture. Bar is 40 μm .

T = tumor cells; H = Heart tissue.

Invasion of embryonic chick heart fragments

CaCo2 and LS174T cells did not demonstrate invasive behavior in this assay, whereas SW620 cells invaded into the myocardial tissue (Fig. 2, Table 2). HT29 cells could only

be successfully confronted with embryonic chick heart fragments on top of a semi-solid agar medium containing DMEM. In this approach HT29 cells did not invade into the myocardial tissue.

Figure 3. E-cadherin expression in vitro.
Immunofluorescence staining of E-cadherin (A,C,E,G) and keratin (B,D,F,H) of LS174T (A,B), SW620 (C,D), HT29 (E,F), and CaCo 2 cells (G,H). Scale bar = 50 μ m.

Production of u-PA and t-PA in vitro

The results of the u-PA and t-PA assays are listed in Table 2. By far the highest amount of u-PA in the culture medium was found in SW620 cells. This was also the only cell line invasive in the embryonic chick heart assay. CaCo2 and HT29 cells produced roughly equal amounts of u-PA while the lowest amount was secreted by LS174T cells. The release of u-PA into the medium did not correlate with any of the features of in vivo growth. The amount of u-PA recovered from cell extracts was considerably lower than the amount of u-PA recovered from the medium. Hardly any t-PA was found in the culture medium (data not shown). In cell extracts, all cell lines showed roughly equal amounts of t-PA (Table 2).

Expression of E-cadherin

The presence of cytokeratin filaments in all cell lines confirmed the epithelial origin of these cell lines, with the most highly structured filamentous pattern observed in CaCo 2 cells. The cell lines CaCo2, LS174T, and HT29 demonstrated in vitro homogenous staining for E-cadherin, which was membrane-associated. In contrast, SW620 cells showed heterogenous staining: Membrane-associated immunoreactivity was observed only in multilayered cell clusters, whereas cells in a monolayer were negative (Fig. 3, Table 2).

In vivo, E-cadherin expression could not be studied on CaCo2 cells. In cecal grafts of SW620 and LS174T cells E-cadherin expression was not detected (Fig. 4, Table 2). Heterogenous expression was observed in cecal grafts of the HT29 cell line. Membranous E-cadherin immunoreactivity was detected only focally in clusters of HT29 tumor cells with a more highly differentiated growth pattern (Fig. 4, Table 2).

Figure 4. E-cadherin expression in vivo.

A. Cecal xenograft of SW620 cells. Note the lack of E-cadherin expression. **B.** Cecal xenograft of HT29 cells. Note E-cadherin staining at the membrane of tumor cells, indicated by arrows. Magnification 200x. T = tumor cells; M = muscularis mucosa; C = crypt cells of the colon.

Expression of integrin receptors in vitro

As integrin receptors are only functional on the cell surface, only membrane staining was taken into account. High expression of $\alpha_2\beta_1$ and $\alpha_3\beta_1$ was restricted to HT29 cells, LS174T cells only showing occasional weakly stained cells for $\alpha_2\beta_1$, whereas $\alpha_3\beta_1$ was not detected in the other cell lines at all. Expression of $\alpha_6\beta_1$ was detected on all cells (Fig. 5, Table 2). As integrins can be only stained on unfixed tissue, integrin expression was not assayed in the in vivo situation.

Figure 5. Integrin receptor expression in vitro.

A. HT29 cells stained with an antibody specific for $\alpha_2\beta_1$. **B.** HT29 cells stained with an antibody specific for $\alpha_3\beta_1$. **C.** SW620 cells stained with an antibody specific for $\alpha_6\beta_1$. Arrows indicate cells with immunoreactivity for the antigen detected by the monoclonal antibody used. Note the heterogeneity in the intensity of expression in positive cells. Bar is 5 μm .

2.4 DISCUSSION

In order to study the mechanisms involved in the development of metastases, orthotopic nude mouse xenograft models have evolved in which the primary graft will spontaneously give rise to metastases. Earlier models, such as injection of tumor cells in the subcutis or intravenous injection of tumor cells, either do not give rise to metastases or only allow evaluation of late steps in the metastatic cascade. Following earlier reports (9-11) we have employed an in vivo model in which human colorectal carcinoma cells are xenografted orthotopically into the wall of the cecum of nu/nu mice. The major advantage of this model is that the entire metastatic cascade can be studied.

We initially studied the behavior of the cancer cells after subcutaneous inoculation in comparison with injection in the wall of the cecum. All cell lines, with the exception of CaCo2 cells which were non-tumorigenic, showed in the subcutis either non-invasive encapsulated growth or invasion into surrounding tissue, but metastases did not occur. In the cecum, the cell lines were either non-tumorigenic, tumorigenic but non-invasive, tumorigenic and invasive but non-metastatic or tumorigenic, invasive and metastatic. Also LS174T and 5583E cells, which were non-invasive in the subcutis, displayed

invasive behavior in the wall of the cecum. Hematogenous metastases occurred in the liver as well as in the lungs.

The occurrence of lung metastases contrasts with the findings of Morikawa et al. (22) and of Bresalier et al. (10) who did not observe lung metastases in similar studies. It is possible that in our but not in their experiments the cells entered the lymphatic circulation from the peritoneal cavity and then spread hematogenously to the lungs. Another possibility is that the tumor cells bypassed the liver via portocaval shunts.

The observation that all metastatic cell lines showed invasive primary tumors underlines that invasive ability is an essential prerequisite for the development of metastatic lesions. Lack of metastatic capacity after orthotopic xenografting was not due to the inability of tumor cells to grow at ectopic sites, because all cell lines, with the exception of CaCo2 cells, yielded primary tumors in the subcutis. Moreover, non-metastatic SW1116, SW480 and LS174T cell lines were able to colonize the liver after intrasplenic injection. These observations indicate firstly that invasive capacity does not necessarily also implies metastatic capacity and secondly that cancer cells differ in the ability to invade and metastasize. A third conclusion is that the expression of the invasive and/or metastatic phenotype apparently can be modulated by local tissue factors.

We furthermore investigated in CaCo2, SW620, LS174T and HT29 cells whether or not in vivo behavior of the tumor cells correlated with specific in vitro characteristics. The capacity of colorectal carcinoma cells to invade embryonic chick heart fragments was not predictive for invasion in vivo. Although the non-tumorigenic CaCo2 cells were not invasive in this assay, LS174T and HT29 cells were invasive in vivo but not in vitro, whereas SW620 cells were invasive in vitro but not in vivo. This discrepancy may again be explained in terms of the modulating effects of cancer cell micro-environments on cancer cell behavior. Apparently tissue specific factors in the host may either induce or inhibit the invasive phenotype (35).

A role for u-PA or t-PA in invasion has been postulated because of their involvement in the breakdown of the extracellular matrix, which is essential for carcinoma cells to invade surrounding stroma (3, 36-40). Indeed, a high level of u-PA production by SW620 cells in stock-culture was found together with invasion into embryonic chick heart fragments. However, neither the cellular content nor the release of u-PA and t-PA into the medium of stock cultured cells correlated with in vivo invasive behavior. This was reported also for a panel of breast carcinoma cell lines (41). These observations do certainly not exclude a role for u-PA or t-PA in invasion, because the enzymatic activity of these plasminogen activators is not only determined by the amount of enzyme available but is also subject to several regulating mechanisms, which include specific activators, inhibitors and receptors (42-45).

In our experiments E-cadherin expression was observed in vitro in all cell lines. However, the CaCo 2, LS174T, and HT29 cell lines demonstrated in vitro homogenous expression of E-cadherin, whereas it was heterogenous in SW620. Only the latter showed invasive behavior in the embryonic chick heart fragment assay. E-cadherin

immunoreactivity in vivo was not observed in xenografts of SW620 and LS174T, and was heterogenous in xenografts of HT29. This suggests downmodulation of E-cadherin expression in vivo (46) and demonstrates that the microenvironment in which the cells reside (medium vs. tissue) modulates E-cadherin expression. Furthermore, invasive behavior in vitro thus appears to be correlated with heterogenous expression of E-cadherin in vitro. The fact that in vivo SW620 cells are not invasive, while negative for E-cadherin, suggests that additional factors must be involved to acquire invasive capacity, as has been mentioned before by Mareel et al. (47). Therefore, the relationship between E-cadherin expression and invasion in vivo is complex. This is demonstrated by immunohistochemical studies of primary human colon carcinomas, where E-cadherin expression correlates strongly with the differentiation grade of the tumor but less obviously with invasive and metastatic potential (48, 49).

The expression of $\alpha_2\beta_1$ and $\alpha_3\beta_1$ integrin, which bind a.o. laminin and type IV collagen (50), was high in the in vivo metastatic HT29 cells, in agreement with Schreiner et al. (51). It has been reported previously that the metastatic potential of rhabdomyosarcoma cells increased after transfection with cDNA coding for the α_2 integrin subunit (52). This finding may be explained in terms of a mediating role for integrin receptors in the migration of the cancer cell through the extracellular matrix and in the adhesion of circulating cancer cells to a potential metastatic site.

We conclude that; 1. Homogenous expression of E-cadherin in vitro and low production of u-PA in vitro correlate with non-invasive behavior in vitro, whereas cell lines invasive in vivo show heterogenous or absence of E-cadherin expression; 2. Invasive behavior in vitro does not necessarily go along with invasion and metastasis in vivo; 3. Invasion in vivo is not associated with u-Pa and t-PA production in vitro, E-cadherin expression in vitro as well as in vivo, and expression of the $\alpha_3\beta_1$ and $\alpha_6\beta_1$ integrin receptors, but seems to associated with $\alpha_2\beta_1$ integrin receptors; 4. Local tissue factors may play a role in the induction of the expression of the genes responsible for invasion and metastasis, which is exemplified by the different expression of E-cadherin in vitro compared with the expression of E-cadherin in vivo. These results suggest that the microenvironment in which cancer cells grow is one of the factors involved in the regulation of invasive and metastatic behavior.

2.5 REFERENCES

1. Poste G, Fidler IJ: **The pathogenesis of cancer metastasis.** *Nature.* 1980; 283: 139-146.
2. Liotta LA: **Tumor invasion and metastases: role of the basement membrane. Warner-Lambert Parke-Davis Award lecture.** *Am. J. Pathol.* 1984; 117: 339-348.
3. Liotta LA, Steeg PS, Stetler-Stevenson WG: **Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.** *Cell.* 1991; 64: 327-336.
4. van Roy F, Mareel M: **Tumour invasion: effects of cell adhesion and motility.** *Trends in Cell Biology* 1992; 2: 163-169.
5. Mareel MM, Van-Roy FM, Messiaen LM, Boghaert ER, Bruyneel EA: **Qualitative and quantitative analysis of tumour invasion in vivo and in vitro.** *J. Cell. Sci. Suppl.* 1987; 8: 141-163.
6. Mareel M, Kint J, Meyvisch C: **Methods of study of the invasion of malignant C3H-mouse fibroblasts into embryonic chick heart in vitro.** *Virchows Arch. B Cell Path.* 1979; 30: 95-111.
7. Hart IR: **'Seed and soil' revisited: Mechanisms of site-specific metastasis.** *Cancer. Metastasis. Rev.* 1982; 1: 5-17.
8. Fidler IJ: **Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis.** *Cancer. Metastasis. Rev.* 1986; 5: 29-49.
9. Fidler IJ, Naito S, Pathak S: **Orthotopic implantation is essential for the selection, growth and metastasis of human renal cell cancer in nude mice.** *Cancer. Metastasis. Rev.* 1990; 9: 149-165.
10. Bresalier RS, Raper SE, Hujanen ES, Kim YS: **A new animal model for human colon cancer metastasis.** *Int. J. Cancer.* 1987; 39: 625-630.
11. Sekikawa K, Arends JW, Verstijnen CP, *et al*: **Influence of implantation site on growth, antigen expression and metastatic potential of human colonic cancer HT29 and 5583 xenografts in nude mice.** *Invasion. Metastasis.* 1988; 8: 238-252.
12. Cajot JF, Sordat B, Bachmann F: **Human primary colon carcinomas xenografted into nude mice. II. Modulation of tumor plasminogen activator activity by the host tissue environment.** *J. Natl. Cancer. Inst.* 1986; 77: 1099-1107.
13. Turpeenniemi-Hujanen T, Thorgeirsson UP, Hart IR, Grant SS, Liotta LA: **Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential.** *J. Natl. Cancer. Inst.* 1985; 75: 99-103.
14. Greig RG, Koestler TP, Trainer DL, *et al*: **Tumorigenic and metastatic properties of "normal" and ras-transfected NIH/3T3 cells.** *Proc. Natl. Acad. Sci. U. S. A.* 1985; 82: 3698-3701.
15. Ura H, Bonfil RD, Reich R, *et al*: **Expression of type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive, and metastatic abilities of oncogene-transformed human bronchial epithelial cells.** *Cancer. Res.* 1989; 49: 4615-4621.
16. Quax PHA, van Muijen GNP, Weening-Verhoeff EJD, *et al*: **Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase mediated matrix degradation.** *J. Cell. Biol.* 1991; 115: 191-199.
17. Behrens J, Mareel MM, Van-Roy FM, Birchmeier W: **Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion.** *J. Cell. Biol.* 1989; 108: 2435-2447.

18. Vlemminckx K, Vakaet L Jr, Mareel M, Fiers W, van-Roy F: **Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role.** *Cell.* 1991; 66: 107-119.
19. Albelda SM: **Role of integrins and other cell adhesion molecules in tumor progression and metastasis.** *Lab. Invest.* 1993; 68: 4-17.
20. Giavazzi R, Jessup JM, Campbell DE, Walker SM, Fidler IJ: **Experimental nude mouse model of human colorectal cancer liver metastasis.** *J. Natl. Cancer. Inst.* 1986; 77: 1303-1308.
21. Morikawa K, Walker SM, Jessup JM, Fidler IJ: **In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice.** *Cancer. Res.* 1988; 48: 1943-1948.
22. Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ: **Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice.** *Cancer. Res.* 1988; 48: 6863-6871.
23. Fogh J, Fogh JM, Orfeo T: **One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.** *J. Natl. Cancer. Inst.* 1977; 59: 221-225.
24. Leibovitz A, Stinson JC, McCombs WB, *et al*: **Classification of human colorectal adenocarcinoma cell lines.** *Cancer Research* 1976; 36: 4562-4569.
25. Park J-G, Oie HK, Sugarbaker PH, *et al*: **Characteristics of cell lines established from human colorectal carcinoma.** *Cancer. Res.* 1987; 47: 6710-6718.
26. Tom BH, Rutzky LP, Jakstyn MM, Oyaser R, Kaye CE, Kahan BD: **I. Establishment and description of a new line.** *In Vitro* 1976; 12: 180-191.
27. Verstijnen CPHJ, Arends JW, Moerkerk PTM, Geraedts JPM, Uitendaal MP, Bosman FT: **Two new colonic carcinoma cell lines derived from one human colonic adenocarcinoma: establishment and characterization.** *Virchows Arch. B Cell Path.* 1987; 53: 191-197.
28. Fogh J, Trempe G: **New human tumor cell lines.** New York: Plenum Publishing Corp., 1975
29. Binnema DJ, van Iersel JJJ, Dooijewaard G: **Quantitation of urokinase antigen in plasma and culture media by use of an ELISA.** *Thromb. Res.* 1986; 43: 569-577.
30. Rijken DC, van Hinsbergh VWM, Sens EHC: **Quantitation of tissue-type plasminogen activator in human endothelial cell cultures by use of an enzyme immunoassay.** *Thromb. Res.* 1984; 33: 145-153.
31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: **Protein measurement with the Folin phenol reagent.** *J. Biol. Chem.* 1951; 193: 265-275.
32. Giltay JC, Brinkman HJ, Modderman PW, von-dem-Borne AE, van-Mourik JA: **Human vascular endothelial cells express a membrane protein complex immunochemically indistinguishable from the platelet VLA-2 (glycoprotein Ia-IIa) complex.** *Blood.* 1989; 73: 1235-1241.
33. Sonnenberg A, Hogervorst F, Osterop A, Veltman FE: **Identification and characterization of a novel antigen complex on mouse mammary tumor cells using a monoclonal antibody against platelet glycoprotein Ic.** *J. Biol. Chem.* 1988; 263: 14030-14038.
34. Fradet Y, Cordon-Cardo C, Thomson T, *et al*: **Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies.** *Proc. Natl. Acad. Sci. U. S. A.* 1984; 81: 224-228.
35. Mareel MM, Van-Roy FM, De-Baetselier P: **The invasive phenotypes.** *Cancer. Metastasis. Rev.* 1990; 9: 45-62.
36. Reich R, Thompson EW, Iwamoto Y, *et al*: **Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells.** *Cancer. Res.* 1988; 48: 3307-3312.

37. Havenith MG, Arends JW, Simon R, Volovics A, Wiggers T, Bosman FT: **Type IV collagen immunoreactivity in colorectal cancer. Prognostic value of basement membrane deposition.** *Cancer.* 1988; 62: 2207-2211.
38. Hendrix MJ, Wood WR, Seftor EA, *et al*: **Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor.** *Cancer. Res.* 1990; 50: 4121-4130.
39. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: **Plasminogen activators, tissue degradation, and cancer.** *Adv. Cancer. Res.* 1985; 44: 139-266.
40. Bosman FT, Havenith MG, Visser R, Cleutjens JPM: **Basement membranes in neoplasia.** *Progr. Histochem. Cytochem.* 1992; 24: 1-92.
41. Madsen MW, Briand P: **Relationship between tumorigenicity, in vitro invasiveness, and plasminogen activator production of human breast cell lines.** *Eur. J. Cancer.* 1990; 26: 793-797.
42. de Bruin PAF, Griffioen G, Verspaget HW, Verheijen JH, Lamers CBHW: **Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.** *Cancer. Res.* 1987; 47: 4654-4657.
43. Pyke C, Kristensen P, Ralfkiaer E, *et al*: **Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.** *Am. J. Pathol.* 1991; 138: 1059-1067.
44. Hollas W, Blasi F, Boyd D: **Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.** *Cancer. Res.* 1991; 51: 3690-3695.
45. Sier CFM, Verspaget HW, Griffioen G, *et al*: **Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia.** *Gastroenterology* 1991; 101: 1522-1528.
46. Mareel MM, Behrens J, Birchmeier W, *et al*: **Down-regulation of E-cadherin expression in Madin Darby canine kidney (MDCK) cells inside tumors of nude mice.** *Int. J. Cancer.* 1991; 47: 922-928.
47. Mareel M, Vleminckx K, Vermeulen S, *et al*: **Homotypic cell-cell adhesion molecules and tumor invasion.** In: Graumann W, Drukker J, eds. *Progress in Histo- and Cytochemistry*, 26: *Histochemistry of receptors.* Stuttgart-Jena-New York: Fischer-Verlag, 1992:95-106.
48. Dorudi S, Sheffield JP, Poulson R, Northover JMA, Hart IR: **E-cadherin expression in colorectal cancer; An immunohistochemical and in situ hybridization study.** *Am. J. Pathol.* 1993; 142: 981-986.
49. van der Wurff AA, ten Kate J, van der Linden EPM, Dinjens WNM, Arends J-W, Bosman FT: **L-CAM expression in normal, premalignant, and malignant colon mucosa.** *J. Pathol.* 1992; 168: 287-291.
50. Springer TA: **Adhesion receptors of the immune system.** *Nature.* 1990; 346: 425-434.
51. Schreiner C, Bauer J, Margolis M, Juliano RL: **Expression and role of integrins in adhesion of human colonic carcinoma cells to extracellular matrix components.** *Clin. Exp. Metastasis.* 1991; 9: 163-178.
52. Chan BMC, Matsuura N, Takada Y, Zetter BR, Hemler ME: **In vitro and in vivo consequences of VLA-2 expression on rhabdomyosarcoma cells.** *Science.* 1991; 251: 1600-1602.

CHAPTER 3

CHROMOSOMAL LOCALIZATION OF TRANSFECTED GENES BY A COMBINATION OF HOT BANDING AND FLUORESCENCE IN SITU HYBRIDIZATION

J.E. de Vries, F.H.A.C. Kornips, J. Wiegant, P.M. Moerkerk, N. Senden, B. Schutte, J.P.M. Geraedts, F.T. Bosman, and J. ten Kate.

J. Histochem. Cytochem. 1992; 40: 1053-1058.

(Copyright 1992 by The Histochemical Society)

3.1 INTRODUCTION

A variety of techniques can be applied to introduce foreign DNA into mammalian cells. One of the most widely used transfection techniques consists of the coprecipitation of DNA with calcium phosphate (1,2). It is assumed that, with this technique, integration of introduced DNA into chromosomes occurs at a random site (3,4,5). In contrast, McKenna et al. (6) found in rat embryo fibroblasts, which were morphologically transformed after transfection with the c-Ha-ras gene that integration frequently occurred in chromosome 3. These authors postulated as an explanation the existence of a specific receptive integration site on this chromosome. This finding raises the question, whether cellular alterations observed after gene transfection are determined only by the characteristics of the introduced gene or could also be modulated according to the site of integration.

To answer the question whether or not the integration site influences the expression of the transfected gene, and as such might modulate the ensuing alterations in cellular behaviour, it is necessary to visualize and localize the site of integration. By fluorescence in situ hybridization techniques (7,8,9), it is possible to visualize integrated DNA with more speed and with higher spatial resolution than with radioactive in situ hybridization techniques (10). In this study probes labeled by nick translation were compared with random primed labeled probes to develop an optimal procedure for fluorescence in situ hybridization.

To identify the integration sites on specific chromosomes it is necessary to generate a chromosome banding pattern combined with in situ hybridization. However, chromosomes treated with the routine banding techniques are not suited for in situ hybridization (11). One banding technique compatible with in situ hybridization, requires the incorporation of BrdU in the late S-phase of synchronized cells leading to R-banding after Giemsa staining (12-14). However, the synchronization of cells is a time consuming and laborious process. Furthermore a banding method is described when a low trypsin concentration is used in order to obtain banding, with improvement of the cytogenetic analysis by subsequent fluorescence in situ hybridization with chromosome specific centromere probes (15). We chose to use a simple and rapid technique, the so called hot banding (16), as an alternative procedure. It is based on the principle first described by Sumner et al. (16), they induced a banding pattern by incubating chromosome spreads in a hot saline-citrate solution. As test substrate was used the cell line SW480, derived from a human colon carcinoma (17), which was transfected in our laboratory with pSV₂neoEJ, containing the pointmutated c-Ha-ras oncogene (18) within the Bam HI site of the pSV₂neo plasmid.

In this report we describe the combination of hot banding and fluorescence in situ hybridization with nick translated probes to localize the integration site of a plasmid after transfection.

3.2 MATERIAL AND METHODS

3.2.1 Cell-culture

SW480 EJ2 was routinely cultured in DMEM supplemented with 5% fetal calf serum at 37°C in a humidified atmosphere with 5% CO₂. Gentamycine (GIBCO,G418) was added to the culture medium (800 µg/ml). The parent cell line SW480 is a human colon tumor derived cell line (17).

3.2.2 Transfection

The plasmid pSV2neoEJ, containing a 6.6 kb genomic Bam HI fragment of the c Ha-ras gene with a G to T transversion in the twelfth codon was a kind gift of Prof. Dr. P. Cerruti. The plasmid pSV2neoEJ was used in transfection experiments with SW480. For transfection the protocol of Graham and van der Eb (1) was followed with modifications as described by Chen and Okayama (2).

3.2.3 Southern blotting

Southern blotting was performed following routine procedures (19).

3.2.4 Chromosome preparation and banding

Exponentially growing cells were trypsinized and incubated with vinblastin (0.1 µg/ml) for 1 h at 37°C. The cells were treated with a hypotonic solution (1% sodium citrate; 30' at 37°C) and fixed three times with methanol:glacial acetic acid 2:1 (v/v). Chromosome spreads were made on clean glass slides and air dried. Metaphase slides were used for hot banding (16) either two weeks after preparation or after overnight heating at 40°C.

In our hands we found optimal banding at 86°C in 2xSSC. At 86°C an incubation time of 0.5 minute is minimally required to induce banding. The quality of the banding diminished if incubation times were longer than 4 minutes. The optimal incubation period varied for each batch of chromosome suspension prepared within the incubation periods mentioned. The hot banded metaphase spreads were Giemsa stained. Metaphases were located and photographed. Before in situ hybridization slides were destained in methanol and air dried after dehydration with a graded ethanol series.

3.2.5 Probe labeling

The pSV2neo plasmid, 5.6 kb, was labeled with biotin (ENZO) or digoxigenin (Boehringer) by random primed labeling (Boehringer) or nick translation (ENZO) according to manufacturers instruction. Labeled probes were purified by gelfiltration on Sephadex G-50 columns equilibrated with 10 mM Tris.HCl, 1 mM EDTA, pH 7.8. Samples of the labeled probes were serially diluted and spotted on nylon filter (Hybond) for spot blot analysis.

The remaining probe was ethanol precipitated in the presence of 50 times excess sonicated salmon sperm DNA and dissolved in 50% deionized formamide, 2xSSC, 50 mM phosphate, pH 7 at a concentration of 10 ng/ μ l.

Spot blot analysis of digoxigenin labeled probe was carried out with alkaline phosphatase conjugated sheep-anti-digoxigenin (Fab fragments; Boehringer) followed by NBT/BCIP reaction (Boehringer); spot blot analysis of biotin labeled probes was done with peroxidase conjugated avidin (Sanbio) followed by DAB reaction.

3.2.6 In situ hybridization

This was performed according to Wiegant et. al. (9). Briefly, slides were pretreated with RNA'se A (100 μ g/ 2 ml 2xSSC) for one hr at 37°C, followed by treatment with proteinase K. (Merck; 0.1 μ g Proteinase K/100 ml 20 mM Tris HCl, 2 mM CaCl₂, pH 7.4) for 8 min. at 37°C. Finally, the slides were dehydrated through an ethanol series and air dried.

The hybridization mixture contained per μ l 50% deionized formamide, 2xSSC, 10% dextran sulphate, 50 mM sodium phosphate pH 7: 2 ng labeled probe and 100 ng sonicated salmon sperm DNA as carrier DNA. Ten μ l of hybridization mixture was put on a slide, covered with an 18x18 mm coverslip and sealed with rubber cement. Simultaneous denaturation of both probe and target DNA was done by placing the slide on a 80°C metal plate for 5 min. After this the slide was transferred to a moist chamber at 37°C and the hybridization was proceeded overnight.

3.2.7 Post hybridization washings and detection

Slides were immersed in 50% formamide, 2xSSC, 50 mM phosphate pH 7 at 45°C for 5 min. to loosen the coverslips. After that the slides were washed 3x5 min. with 50% formamide, 2xSSC, 50 mM phosphate pH 7 at 45°C. Then they were washed for 5 min. with 2xSSC, 0.05% Tween-20 at room temperature.

Prior to the immunocytochemical incubations, the slides were blocked with 4xSSC, 0.5% Blocking Reagent (Boehringer) for 10 min. at room temperature. Slides to which biotinated probes were hybridized, were incubated for 30 min. at 37°C with 5 μ g/ml of Avidin.D-FITC (Vector Laboratories, USA) diluted in 2xSSC, 0.5% Blocking Reagent. Slides to which digoxigeninated probes were hybridized, were incubated for 30 min. at 37°C with sheep-anti-digoxigenin-FITC (Boehringer) diluted in 2xSSC, 0.5% Blocking Reagent. After 3 washes of 5 min. with 2xSSC, 0.05% Tween-20 and a 1x5 min. wash with PBS, the slides were dehydrated through a graded ethanol series and airdried. Finally, the slides were embedded in antifade medium consisting of 2% 1,4-diazabicyclo-(2,2,2)-octane (DABCO; Sigma, USA) in 9 parts glycerol and 1 part 0.2 M TrisHCl pH 7.5 containing 0.5 μ g/ml 4', 6-diamidino-2-phenylindole (DAPI) as a general DNA counterstain for photomicrographs and image analysis. Photomicrographs of fluorescence images were taken on a Zeiss Axiophot microscope equipped for epi illumination using Kodak 400 asa black and white film for fotoprints.

3.2.8 Image analysis

Interphase nuclei were analyzed with a BioRad MRC 600 Confocal Scanning Laser Microscope, equipped with a mixed Argon/Krypton gas laser. FITC fluorescence was excited with the 488 nm laser line and recorded using a 515 lp band pass filter. Settings were adjusted to prevent saturation of the image of the confocal plane with maximum fluorescence intensity. From a projection of a stack of confocal images the average dot intensity per cell was measured and presented in arbitrary units. These were corrected for background levels as follows. A threshold grey level for the mean nuclear background was set arbitrarily, in such a way that in all nuclei the positive dots were visible. Grey levels above this threshold were integrated per cell and recorded as dot intensity.

3.3 RESULTS

SW480 cells, transfected with pSV2neoEJ were analysed by southern blotting to detect integration of the plasmid DNA into recipient DNA. Figure 1 shows distinct bands in DNA of transfected cells after hybridization with a 3.8 kb PvuII fragment of pSV2neo. No bands were observed in control DNA from SW480 cells. This proves integration of pSV2neoEJ into SW480 after transfection. The cell line, designated SW480 EJ2, was used in further experiments.

Probes, labeled by nick translation and random priming, were analysed in a spot blot test on a nylon filter. The results are illustrated in Figure 2. The lowest detectable amount of probe was similar for both labeling methods: at least 0.5 pg for digoxigeninated DNA and 2 pg for biotinylated DNA without using an amplification step.

Figure 3 illustrates the results of in situ hybridization on interphase nuclei and chromosome spreads. Nick translated probes gave stronger hybridization signals than random primed labeled probes, regardless of the choice of label. By visual estimation probes labeled with digoxigenin gave somewhat better results than probes labeled with biotin (Fig. 3). The random primed biotin labeled probe did not yield a detectable signal (Fig. 3D). A striking phenomenon was the occurrence of hybridization signals predominantly in the periphery of the interphase nuclei (Fig. 3).

To quantify the two different labeling methods after in situ hybridization, the intensities of the specific signals in interphase nuclei were measured with confocal scanning laser microscopy. The results are summarized in table 1. The signal intensity between individual nuclei showed a wide variation (Tables 1 and 2). On the average the nick translated digoxigenin labeled probes yielded a threefold higher signal intensity than random primed digoxigenin labeled probes. This difference was statistically significant (Table 1). Similarly, nick translated biotin labeled probes yielded a higher signal than random primed biotin labeled probes, the latter remaining undetectable above background level. Finally, the digoxigenin signal appeared to be twofold higher than

Figure 1. Integration of plasmid DNA in transfected SW480 cell lines.

A. Ethidium bromide stained 0.8% agarose gel loaded with 10 μ g BamHI digested chromosomal DNA. Lane 1: SW480; 2: SW480 EJ1; 3: SW480 EJ2. **B.** Southern blot of the gel shown in A. The 3.8 kb PvuII fragment of pSV₂neo was used as probe.

Figure 2. Visualization of pSV₂neo labeled with digoxigenin by spot-blotting.

A. pSV₂neo labeled by nick translation; **B.** pSV₂neo labeled by random priming.

Table 1. Nick translation compared with random primed labeling.

Labeling	Mean ^a	SEM ^b	Range	n
Nick translation	1935*	353	876-3403	7
Random priming	659*	136	319-1312	7

a. Pixel intensity (arbitrary units) measured by confocal scan laser microscopy of SW480 EJ2 interphase nuclei, hybridized with a digoxigenin labeled pSV₂neo probe.

b. Standard error of the mean.

*. $p < 0.01$, as analysed with Student's *t*-test.

biotin for nick translation labeled probes, which was statistically significant also (Table 2).

Figure 3. Intensity of fluorescence in situ hybridization signals.

Microphotographs were obtained by fluorescence microscopy of interphase nuclei and metaphase spreads of SW480 EJ2 after hybridization with: **A.** Nick translated digoxigenin labeled pSV₂neo; **B.** Nick translated biotin labeled pSV₂neo; **C.** Random primed digoxigenin labeled pSV₂neo; **D.** Random primed biotin labeled pSV₂neo. The chromosomes and interphase nuclei were counterstained with DAPI. Arrows indicate the hybridization signals. **Insets** (same magnification) show interphase nuclei with hybridization signals. Bar = 10 μ m.

Table 2. Comparison of probes labeled with digoxigenin or biotin.

Label	Mean ^a	SEM ^b	Range	n
Digoxigenin	2649*	246	270-7612	45
Biotin	1236*	160	123-4500	49

a. Pixel intensity (arbitrary units) measured by confocal scan laser microscopy of SW480 EJ2 interphase nuclei, hybridized with a nick translated pSV₂neo probe.

b. Standard error of the mean.

* $p < 0.00001$, as analysed with Student's *t*-test.

To localize the integration site of the plasmid in the SW480 EJ2 cell line, metaphase spreads were hot banded, followed by fluorescence in situ hybridization. After hot banding, 100% of the metaphase spreads and interphase nuclei showed positivity in the fluorescence in situ hybridization, albeit that the intensity of the signals varied widely and was less intense compared with not hot banded prepartes by visual observation.

Figure 4A shows a hot banded metaphase spread and figure 4B shows the same metaphase spread after fluorescence in situ hybridization. The hybridization signal is seen as two bright spots. The chromosome was karyotyped as the X-chromosome, with a translocation possibly involving the 5q arm. The integration of pSV2neoEJ is localized at the translocation site. This marker chromosome was not found in the parent SW480 cell line.

Figure 4. Detection of a chromosomal integration site in SW480 EJ2 by hot banding and FISH. A. Metaphase spread after hot banding; B. The hot banded metaphase spread of A after fluorescence in situ hybridization. Arrow indicates the hybridization signal on marker chromosome Xp⁺. Bar = 10 μ m.

3.4 DISCUSSION

With a variety of transfection techniques it is possible to achieve stable integration of DNA sequences into an eukaryotic genome (1,2). The site of integration in the recipient genome can be relatively easily located by fluorescence in situ hybridization (7-9). Stable labels, like AAF (20), BrdU (21) and recently digoxigenin (Boehringer), can be used as haptens, which can be visualized with antibodies conjugated with fluorochromes or the biotin-avidin system can be exploited (22). Probes can be labeled by nick translation or by random priming labeling methods.

In theory, random primed labeling should be superior, since a more efficient incorporation of labeled nucleotides into the probe is obtained as compared to nick translation. To determine optimal conditions for our experiments we compared both methods and found that nick translated probes gave better signals than random primed labeled probes, regardless of the label used (Figure 3, table 1). Nick translated probes yielded detection levels similar to those of random primed labeled probes as analysed by spot blots (Figure 2).

The cause of the difference in sensitivity in fluorescence in situ hybridization is not clear. The difference in signal intensities may be due to the labeling procedures which were carried out as described in the manufacturers protocols. In our hands nick translation was optimal, although we do not exclude that the procedure of random primed labeling could be optimized, so that the signal to background ratio may increase and match the nick translation results.

We measured, by confocal scanning laser microscopy, that the hybridization signal of digoxigenin labeled probes is on the average twice as high than that of biotin labeled probes (Tables 1 and 2) and that for our purposes the method of choice is a nick translated digoxigenin labeled probe, although in principle both labeling methods are applicable.

With fluorescence in situ hybridization the integration site in interphase nuclei was visualized. A recent study suggested that integration of plasmid DNA, introduced by calcium phosphate precipitation, might occur through non-homologous recombination (23), thus favoring random integration. The integration sites of our plasmid, however, appeared not to be randomly distributed, but in most of the interphase nuclei were located at the periphery of the nucleus. Several explanations should be considered for this observation. Firstly, plasmid DNA might integrate randomly into genomic DNA as soon as it is encountered at the periphery of the nucleus. Secondly, plasmid DNA might integrate randomly into genomic DNA throughout the nucleus. Once integrated it has to be actively transcribed for the transfectant to survive in selective medium. Actively transcribed genes are mostly located in the nuclear periphery (24). Finally, active DNA sequences might be more accessible to integration than inactive DNA sequences, which are highly condensed and shielded with histon proteins (25, 26). This would imply that transcriptionally active genes would be the most frequent target for integration of a transfected gene. The observation of Gruenert (27), who noted highest transfection

efficiency in exponentially growing cells which have a very high transcriptional activity, supports this notion. Indirect support for the involvement of active DNA sequences in integration, comes from viral integration studies where integration is associated with DNA'se I hypersensitive sites, a characteristic of genes actively transcribed (28).

We conclude that random integration in transcriptionally active DNA can explain the location of the integrated plasmid at the periphery of the interphase nuclei.

To study the relationship between the site of integration and the expression of the transfected gene, and secondly between the site of integration and the subsequent changes in cellular behaviour, the fluorescence in situ hybridization was combined with hot banding. To our knowledge this combination has not been described before. The site of the integration, specific or random, can then be assessed on a chromosomal level. Because hot banding is a simple and rapid technique, it can be employed to analyse large numbers of transfectants.

The integration site of plasmid pSV2neoEJ in the cell line SW480 EJ2 was localized on a marker chromosome, Xp+, at the site of the translocation (Figure 4). Analysis of more transfectants will give us the knowledge whether integration is specific or random on a chromosomal level. With hot banding and fluorescence in situ hybridization this can be done fast and efficient.

In conclusion: 1. Nick translated, digoxigenin labeled probes yield in our fluorescence in situ hybridization procedure the most optimal results. 2. The integration site is localized in most interphase nuclei at the periphery, which could be explained by random integration in transcriptionally active DNA. 3. The combination of hot banding and fluorescence in situ hybridization can be used to localize plasmid integration sites on chromosomes.

3.5 REFERENCES

1. Graham FL, van der Eb AJ: **A new technique for the assay of infectivity of human adenovirus 5 DNA.** Virology 1973; 52: 456-467.
2. Chen C, Okayama H: **High-efficiency transformation of mammalian cells by plasmid DNA.** Mol. Cell. Biol. 1987; 7: 2745-2752.
3. Pellicer A, Robins D, Wold B, *et al*: **Altering genotype and phenotype by DNA-mediated gene transfer.** Science. 1980; 209: 1414-1422.
4. Hsiung N, Warrick H, DeRiel JK, *et al*: **Cotransfer of circular and linear prokaryotic and eukaryotic DNA sequences into mouse cells.** Proc. Natl. Acad. Sci. USA 1980; 77: 4852-4856.
5. Robins DM, Ripley S, Henderson AS, Axel R: **Transforming DNA integrates into the host genome.** Cell. 1981; 23: 29-39.
6. McKenna WG, Nakahara K, Muschel RJ: **Site-specific integration of H-ras in transformed rat embryo cells.** Science. 1988; 241: 1325-1328.
7. Boyd E, Theriault A, Goddard JP, Kalaitzidaki M, Spathas DH, Connor JM: **Chromosomal assignment of a glutamic acid transfer RNA (tRNA^{Glu}) gene to 1p36.** Hum. Genet. 1989; 81: 153-156.
8. Vernole P: **Digoxigenin-labeled probes can detect single-copy genes in human metaphase chromosomes.** Biotechniques. 1990; 9: 200-204.
9. Wiegant J, Galjart NJ, Raap AK, d'Azzo A: **The gene encoding human protective protein (PPGB) is on chromosome 20.** Genomics. 1991; 10: 345-349.
10. Pallavicini MG, DeTeresa PS, Wurm FM: **Use of fluorescence in situ hybridization to detect and monitor transfected and amplified sequences in recombinant CHO cells.** Dev. Biol. Stand. 1989; 70: 165-172.
11. Malcolm S, Cowell JK, Young BD: **Specialist techniques in research and diagnostic clinical cytogenetics.** In: Rooney DE, Czepulkovski BH, eds. Human Genetics: A practical approach. Oxford, Washington: IRL Press, 1986:197-.
12. Viegas-Pequignot E, Li ZL, Dutrillaux B, Apiou F, Paulin D: **Assignment of human desmin gene to band 2q35 by nonradioactive in situ hybridization.** Hum. Genet. 1989; 83: 33-36.
13. Cherif D, Julier C, Delattre O, Derre J, Lathrop GM, Berger R: **Simultaneous localization of cosmids and chromosome R-banding by fluorescence microscopy: application to regional mapping of human chromosome 11.** Proc. Natl. Acad. Sci. U. S. A. 1990; 87: 6639-6643.
14. Ronne M, Kirpekar F, Shibasaki Y, Poulsen BS, Kristiansen K: **R-banding and in situ hybridization localization of single copy genes on high resolution banded chromosomes.** Anticancer. Res. 1990; 10: 375-377.
15. Smit VT, Wessels JW, Mollevanger P, *et al*: **Combined GTG-banding and nonradioactive in situ hybridization improves characterization of complex karyotypes.** Cytogenet. Cell. Genet. 1990; 54: 20-23.
16. Sumner AT, Evans HJ, Buckland RA: **New technique for distinguishing between human chromosomes.** Nature. 1971; 232: 31-32.
17. Leibovitz A, Stinson JC, McCombs WB, *et al*: **Classification of human colorectal adenocarcinoma cell lines.** Cancer Research 1976; 36: 4562-4569.
18. Capon DJ, Chen EY, Levinson AD, Seeburg PH, Goeddel DV: **Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue.** Nature. 1983; 302: 33-37.
19. Sambrook J, Fritsch EF, Maniatis T: **Molecular cloning.** second ed. New York: Cold Spring Harbor Laboratory Press, 1989

20. Landegent JE, Jasen-in-de-Wal N, Baan RA, Hoeijmakers JH, Van-der-Ploeg M: **2-Acetylaminofluorene-modified probes for the indirect hybridocytochemical detection of specific nucleic acid sequences.** *Exp. Cell. Res.* 1984; 153: 61-72.
21. Frommer M, Paul C, Vincent PC: **Localisation of satellite DNA sequences on human metaphase chromosomes using bromodeoxyuridine-labelled probes.** *Chromosoma.* 1988; 97: 11-18.
22. Pinkel D, Straume T, Gray JW: **Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization.** *Proc. Natl. Acad. Sci. U. S. A.* 1986; 83: 2934-2938.
23. Murnane JP, Yezzi MJ, Young BR: **Recombination events during integration of transfected DNA into normal human cells.** *Nucleic. Acids. Res.* 1990; 18: 2733-2738.
24. Krystosek A, Puck TT: **The spatial distribution of exposed nuclear DNA in normal, cancer, and reverse-transformed cells.** *Proc. Natl. Acad. Sci. U. S. A.* 1990; 87: 6560-6564.
25. Kaplan JG, Brown DL, Chaly N, *et al*: **Structural and evolutionary implications of the packaging of DNA for differentiation and proliferation in the lymphocyte.** *J. Mol. Evol.* 1987; 26: 173-179.
26. Weintraub H: **Assembly and propagation of repressed and depressed chromosomal states.** *Cell.* 1985; 42: 705-711.
27. Gruenert DC: **Differentiated properties of human epithelial cells transformed in vitro.** *Biotechniques.* 1987; 5: 740-749.
28. Schubach W, Groudine M: **Alteration of c-myc chromatin structure by avian leukosis virus integration.** *Nature.* 1984; 307: 702-708.

CHAPTER 4

TRANSFECTED C-HA-RAS ONCOGENE ENHANCES KARYOTYPIC INSTABILITY AND INTEGRATES PREDOMINANTLY IN ABERRANT CHROMOSOMES

J.E. de Vries, F.H.A.C. Kornips, P. Marx, J.P.M. Geraedts, F.T. Bosman, and J. ten Kate.
Cancer Genet. Cytogenet. 1993; 65: 35-43.

(Copyright 1993 by Elsevier Science Publishing Company, Inc)

4.1 INTRODUCTION

In studies with genes involved in initiation and progression of cancer, gene transfection has been used to investigate the role of particular (normal or abnormal) genes in disturbed cell function. Thus, transfection of the c-Ha-ras oncogene was shown to convey metastatic potential to NIH 3T3 cells. This change in cell behavior might be caused by expression of the c-Ha-ras oncogene or by overexpression of the wild type c-Ha-ras gene (1-3). Both have been shown to induce upregulation in the activity of collagenase, gelatinase, and urokinase plasminogen activator (4-9), suggesting a role for the c-Ha-ras oncogene in induction of tumor cell invasion. In addition, increased expression of the epidermal growth factor receptor (EGFR) has been demonstrated (10), which may sensitize cells to a mitogenic stimulus of EGF. The observed effects of the c-Ha-ras oncogene may depend on the genotypic and phenotypic characteristics of the recipient cell (11, 12).

The progression of cancer *in vivo* is associated with increase of chromosome aberrations and aneuploidy (13). Some oncogene transfection studies have included cytogenetic analysis before and after transfection (12, 14-16). These studies report interesting though conflicting data. Rat mammary and rat prostatic cancer cells showed a significant increase in structural and numerical chromosome changes after c-Ha-ras oncogene transfection (14, 15). Induction of metastatic potential in rat mammary cancer cells was associated with gain of chromosome 4 (14). A human urothelial cell line transfected with the c-Ha-ras oncogene showed loss of chromosome arms 3p, 10p, 11p and 18, all of which might contain tumor suppressor genes (12). In contrast, MSU 1.1, a human fibroblast cell line, which displayed invasive capacity after c-Ha-ras oncogene transfection, showed no change in karyotype (16). The limited number of human cell lines analyzed cytogenetically after c-Ha-ras oncogene transfection and the lack of studies reporting transfection with the wild-type c-Ha-ras gene, make it difficult to ascribe induction of cytogenetic changes to specific expression of the c-Ha-ras oncogene.

Although the genotypic and phenotypic background of the recipient cell may contribute to the effects of the introduced c-Ha-ras oncogene, the site of integration might also be important. Viral integration can activate oncogenes by insertional mutagenesis, thus contributing to virus induced carcinogenesis (17). Recently, this was illustrated for hepatocellular carcinoma by integration of the hepatitis B virus in a cyclin A gene (18), a gene important in control of cell division (19). Integration of the c-Ha-ras oncogene at a specific chromosome site in rat embryo fibroblasts has suggested that the effect of transfection with the c-Ha-ras oncogene might depend on the site of integration (20), indicating that important information can be obtained by identifying integration sites of exogenous DNA.

To gain more insight into the way in which cellular changes are caused by the c-Ha-ras oncogene, we transfected SW480, a human colon carcinoma cell line (21), with the c-

Ha-ras oncogene and performed a detailed cytogenetic analysis in combination with localization of the chromosome integration sites.

4.2 MATERIAL AND METHODS

4.2.1 Cell culture and transfection

The SW480 cells (21) were cultured in Dulbecco's modified Eagle's medium (DMEM), with 5% fetal calf serum (Boehringer, Mannheim, Germany) at 37°C in a humidified atmosphere containing 5% CO₂.

The plasmid pSV₂neo (22) contains the neomycin gene, which provides resistance against the antibiotic gentamycin. The plasmid pSV₂neoEJ contains a 6.6 kilobase (kb) genomic BamHI fragment of the c-Ha-Ras oncogene with a G to T transversion in codon 12 (23). The plasmid pSV₂neoCO contains the 6.6-kb genomic BamHI fragment of the wild type c-Ha-Ras gene (24). pSV₂neoEJ and pSV₂neoCO were gifts from Dr. P.A. Cerutti (Swiss Institute for Experimental Cancer Research, CH-1066 Epalinges, Switzerland). The alkaline lysis method (25) was used for isolation of the plasmids, further purified by precipitation with NH₄Ac (7.5 M).

For transfection the protocol of Graham and van der Eb (26) was used with the modifications described by Chen and Okayama (27). The plasmid/CaCl₂ mixture was added to *N,N*-bis(2-hydroxyethyl)-2-aminoethane-sulfonic acid (BES)-buffered saline in continuous airflow (N. Stam, personal communication, NKI, Amsterdam, The Netherlands).

Cell lines were established using two procedures. Two days after transfection, SW480 cells were plated in 96 well plates, where selection was started by addition of G418 (800 µg/ml, GIBCO, Gaithersburg, USA) to the culture medium. After 3 weeks, selection was completed and colonies began to grow in 96 well plates. Only wells containing one colony were used for further experiments, yielding the cell lines SW480 EJ1, 2, and 4. Alternatively, 2 days after transfection SW480 cells were transferred into 75-cm² culture flasks and selection was started (G418, 800 µg/ml). Untransfected cells were no longer viable after 3 weeks, and colonies of transfected cells began to grow. These were trypsinized and plated in 96 well plates by limiting dilution. Only wells with one colony were used for further experiments, yielding the cell lines SW480 EJ6, CO5, and NEO12.

4.2.2 Northern blotting

Cytoplasmic mRNA was isolated after lysis of cells with NP40 in the presence of vanadyl ribonucleoside complex. Cell nuclei were pelleted and discarded. The supernatant was extracted with phenol/chloroform mixture and precipitated with ethanol (25). After gel electrophoresis and blotting on nylon filter, mRNA was hybridized with a 3.0-kb SacI fragment of the wild-type c-Ha-ras gene, random-primed-labeled with (³²P)dCTP. The amount of mRNA loaded was demonstrated by hybridization with a

probe specific for actin. The hybridization signals were scanned with a densitometer (LKB Ultrascan XL, Uppsala). The relative expression of exogenous c-Ha-ras mRNA was determined by normalizing the units obtained for endogenous c-Ha-ras mRNA expression in SW480. The hybridization signals of actin were used to correct for differences caused by unequal loading of mRNA.

4.2.3 Karyotyping

Exponentially growing cells were trypsinized and incubated with vinblastine (0.1 $\mu\text{g}/\text{ml}$, 45 minutes, 37°C). The cells were treated with a hypotonic solution (1% sodium citrate, 45 minutes, 37°C) and fixed in three changes of methanol:glacial acetic acid 2:1 (vol/vol). Chromosome spreads were made on clean glass slides and air dried.

Routine trypsin treatment was performed on metaphase chromosomes used for karyotyping, according to the International System for Human Cytogenetic Nomenclature (ISCN, 1991) (28). Loss of a specific chromosome in one cell was considered a technical artifact. Karyotypic instability of a cell line was determined by adding the number of clonal chromosome abnormalities not observed in all cells to the number of non clonal chromosome abnormalities; this number was divided by the number of cells analyzed.

Either a short trypsin treatment (29) or hot banding (30) was performed on metaphase chromosomes before performance of fluorescence in situ hybridization (FISH). The metaphases were located, photographed, and immediately rinsed in xylol, air dried and destained in methanol and air dried (31).

4.2.4 FISH

FISH was performed according to the method of Wiegant et al. (32) with a digoxigenin dUTP-labeled (Boehringer Mannheim) pSV₂neo as probe. Digoxigenin was incorporated by nick-translation (Promega kit). After overnight hybridization and washing (32), slides were blocked in 2 x SSC, 0.5% blocking reagent (Boehringer) (10 minutes, RT) and incubated with sheep-antidigoxigenin-FITC (Boehringer) (30 minutes, 37°C), diluted in 2 x SSC, 0.05% Tween-20. The slides were washed with 2 x SSC, 0.05% Tween-20 three times for 5 minutes each time (RT), dehydrated through a graded ethanol series, air dried, and embedded in 2% 1,4-diaza-bicyclo-(2,2,2)-octane (DABCO, Sigma, St. Louis, MO) in glycerol/0.2 M Tris.HCl pH 7.5 (9:1;vol/vol) containing 0.5 $\mu\text{g}/\text{ml}$ 4-, 6-diamidino-2-phenylindole (DAPI) to counterstain DNA for photomicrography.

FITC fluorescence was excited with the 488 nm laser line and recorded using a 515 lp bandpass filter. Photomicrographs were taken on a Zeiss Axiophot microscope equipped for epi-illumination, using Kodak 400 ASA black and white film for photoprints.

4.3 RESULTS

Expression of c-Ha-ras mRNA

Transfection yielded 23 stable clones with the c-Ha-ras oncogene and five stable clones with the wild-type c-Ha-ras gene, but of these 28 cell lines only three showed enhanced expression of c-Ha-ras mRNA (Table 1). Two cell lines (SW480 EJ1 and SW480 EJ2) showed a moderate increase in expression in c-Ha-ras mRNA after transfection with the c-Ha-ras oncogene. One cell line, SW480 CO5, demonstrated a significant increase in c-Ha-ras mRNA expression after transfection with the wild-type c-Ha-ras gene. Of 11 control cell lines isolated after transfection with pSV₂neo, none displayed increased levels of c-Ha-ras mRNA.

Table 1. Expression of c-Ha-ras mRNA, modal chromosome number, ploidy level and karyotypic instability of SW480 and transfected cell lines.

Cell line	c-Ha-Ras mRNA	Modal chromosome No. (Range) (n = 10)	Diploid: tetraploid (n = 100)	Karyotypic instability $\pm S_{DEV}$ (n)
SW480	1	54 (50-106)	68:32	1.4 $\pm$ 1.5 (10)
SW480 EJ1	5	100 (49-104)	32:68	3.9 $\pm$ 1.8 (11)*
SW480 EJ2	4	53 (50-105)	70:30	2.4 $\pm$ 1.9 (14)
SW480 EJ4	1	53 (48-107)	70:30	1.5 $\pm$ 0.5 (10)
SW480 EJ6	1	53 (51- 98)	65:35	0.4 $\pm$ 0.5 (7)
SW480 CO5	30	49 (48- 95)	71:29	1.3 $\pm$ 1.7 (9)
SW480 NEO12	1	52 (50-104)	64:36	0.9 $\pm$ 1.2 (10)

* Difference with SW480 and SW480 NEO12 is statistically significant ($P < 0.005$) as analyzed with the Student's t-test.

The three cell lines with increased expression of c-Ha-ras mRNA were further investigated. To determine the effects of the transfection procedure, two c-Ha-ras oncogene-transfected cell lines without increased levels of c-Ha-ras mRNA and one pSV₂neo-transfected cell line also were analyzed.

Modal chromosome number

The modal chromosome number of SW480 cells was 54, with a wide range (50-106). For all transfected cell lines, the range in chromosome number was similar to that observed in SW480, but in SW480 EJ1 it was increased, in parallel with a higher percentage of hypertetraploid cells (Table 1).

Figure 1. Karyotypes.

A. SW480: 52, X,X,-Y, add(1)(p36), del(2)(p24), +der(2)t(2;18)(q21;q11), del(5)(q12)(q32), der(7)t(5;7)(q15;p22), +ins(7;7)(q22;7), +der(7)t(5;7)(p1;p1), der(10)t(10;12)(p15;q11), +11, add(12)(q24), i(12)(p10), add(13)(p1),15p+, -18, add(19)(q13), der(20)t(5;20)(q22;p13), +der(20)t(5;20)(q22;p13)(q+), +21, +M1. Trisomy 21 is not apparent in this karyotype but see Table 4; B. SW480 E.J2: arrows indicate add(4)(p1?) and der(X)t(X;4)(p22.3;q?) described in the text and clonal chromosome abnormalities shown in Table 2.

Clonal chromosome changes

A representative karyogram of SW480 demonstrating most of the clonal chromosome abnormalities is shown in Figure 1. In addition to the rearranged chromosomes observed earlier (33, 34), new structurally rearranged chromosomes, including i(12)(p10) and add(12)(q24), were observed in all cells.

All transfected cell lines showed additional clonal abnormalities present in every cell, comprising numerical and structural chromosome alterations (Table 2). The number of clonal changes per cell line varied from eight in SW480 EJ4 to three in SW480 NEO12. SW480 EJ1 showed loss of two normal and two structurally rearranged chromosomes, but also a new marker chromosome. In SW480 EJ2 three new structurally rearranged chromosomes were observed (Fig. 1). Two of these new chromosomes probably were derived from the der(2) and der(10) present in SW480. Furthermore, trisomy 21, present in SW480, was not observed in SW480 EJ2, and the abnormal chromosome add(13)(p1) was lost, although this loss was compensated by gain of a chromosome 13 with cytogenetically normal appearance. The other two SW480 cell lines, SW480 EJ4 and SW480 EJ6, transfected with the c-Ha-ras oncogene but without increased c-Ha-ras mRNA levels, also showed additional clonal abnormalities in all cells. A der(19)t(1;19) was observed in most cells in SW480 EJ6 but this structurally rearranged chromosome was present in SW480 with a lower frequency (1 of 10).

Table 2. Clonal abnormalities in transfected cell lines, present in all cells, compared to SW480.

Cell line	No. of metaphases	Numerical changes in existing chromosomes	New structural rearrangements
SW480 EJ1	11	-3, -13p+, -19q+, -20	+M1
SW480 EJ2	14	-2p-, -13p+, -21 +13	der(2)t(2;18;?)(q21;q11;?) der(10)t(10;12;?)(p15;q11;?) +der(13)t(13p;14q?), +19q+
SW480 EJ4	10	-13p+, -18 +22	+(der7),t(1;7)(q2;q22), +15p+ 17q+, +20p+, +mar1
SW480 EJ6	8	+10, -12q+, -21	+12q-, 15p+
SW480 CO5	9	-13p+, -20, -21, -X +der(20)t(5;20)(q22;p13)	der(11q+) 21p+, der(X)t(X;10)(p11;p1)
SW480 NEO12	10	-X	del(3)(q13), i(15q)

In SW480 CO5, three new structurally rearranged chromosomes were present in all cells. They were most probably derived from chromosomes 11, 21, and X. Furthermore, der(20)t(5;20)(q2;p11), already present in SW480, was duplicated. Loss of chromosome 13p+ was observed.

After transfection with the pSV₂neo plasmid, SW480 NEO12 contained two additional abnormal chromosomes, a del(3)(q?1) and an i(15)(q2?) in all cells. Furthermore, an X chromosome had been lost (Table 2). The clonal abnormalities in the transfected cell lines were also present twice in hypertetraploid cells.

Various additional clonal chromosome abnormalities, not observed in all cells, were observed in all transfected cell lines; e.g., the cell line SW480 EJ2 demonstrated a.o. a der(4)t(4;?5)(p16;?q) in four of 14 cells and an add(4)(p1?) with a der(X)t(X;4)(p22.3;q?) in seven of 14 cells (Fig. 1).

4.3.4 Chromosome integration sites

The chromosome integration sites in SW480 cells transfected with Ras-containing plasmids were predominantly identified in new structurally rearranged chromosomes (Table 3). The visually observed intensity of the hybridization signal (Figs. 2, 3) appeared to vary along with the level of expression of c-Ha-ras mRNA and may reflect the number of integrated plasmid copies.

SW480 EJ1 showed one integration site in a marker chromosome, M1. SW480 EJ2 showed chromosome integration of pSV₂neoEJ in the telomeric region of the p-arm of a der(4)t(4;?5)(p16;?q) (Fig. 2), and at the translocation breakpoint of a der(X)t(X;4)(p22.3;q?) chromosome (Fig. 3)(30). SW480 EJ4 integration sites were observed in two different structurally abnormal chromosomes as well. One was identified as 15p+, already present in the parental SW480 cell line; the second was a der(7)t(1;7)(q2;q22), in which integration was observed at the translocation break-point (Fig. 3). SW480 EJ6 showed a chromosome integration site in a cytogenetically normal chromosome 11. Integration of the wild type c-Ha-ras gene in SW480 CO5 was observed in two different, structurally abnormal chromosomes. One chromosome was identified as a newly formed add(16)(q24) (Fig. 3); the other was one of the duplicated der(20)t(5;20)(q2;p11) chromosomes. Both chromosomes showed two integration sites, near each other, at the translocation breakpoint. Integration of pSV₂neo in SW480 NEO12 was identified in the centromeric region of a chromosome 16 with a normal appearance (Table 3).

Three of five integration sites in new structurally rearranged chromosomes occurred at translocation breakpoints, which involved telomeric bands, suggesting preferential integration at these regions. Integration was observed twice in subbands with known fragile sites (Table 3), and thus was not associated with fragile sites, when the number of known fragile sites (35) and subbands is considered: 107 and 321, respectively.

4.3.5 Karyotypic instability

The karyotypic abnormalities in SW480- and SW480-transfected cell lines, present in all cells (Fig. 1, Table 2), indicate that these cell lines originated from a single progenitor cell, and they were not considered a result of genetic instability. Only clonal chromosome abnormalities not observed in every cell, such as the

Figure 2. Combination of hot banding and fluorescence in situ hybridization (FISH).

A. Metaphase of SW480 EJ2 after hot banding; B. The same metaphase after FISH showing hybridization (arrow) in the telomeric region of the p-arm of der(4)t(4;75)(p16;q). Bar = 10 μ m.

Figure 3. Intensity of fluorescence in situ hybridization signals.

A, C, and E. Banded chromosomes;

B, D, and F. Same metaphases after FISH of SW480 EJ2, der(X)t(X;4)(p22.3;q?) (A,B); SW480 EJ4, der(7)t(1;7)(q2;q22) (C,D); SW480 CO5, add(16)(q24) (E,F). Photomicrographs show partial metaphases containing the hybridization signals indicated by arrows. Bar = 10 μ m.

der(4)t(4;75)(p16;q) in four of 14 SW480 EJ2 cells, were considered indicative of genetic instability because genetic alterations, not present in every cell, implied that these alterations occurred after selection. The number of these clonal genetic alterations, together with the number of non clonal changes, reflects the genetic instability of a cell line. To compare the genetic instability between cell lines, the karyotypic instability (Table 1) was determined.

The number of all clonal chromosome abnormalities not observed in every cell and all non clonal chromosome abnormalities in 10 SW480 cells was 14, all shown in Table 4. Thus, the karyotypic instability was 1.4.

Table 3. Chromosomal integration sites in transfected cell lines and nearest fragile sites.

Cell line	Integration in chromosome	Present in SW480	Integration in band	Nearest fragile site ^a
SW480 EJ1	M1	No	?	?
SW480 EJ2	der(X)t(X;4?)(p22.3;q?)	No	Xp22.3	Xp22.3
	der(4)t(4;?5)(p16;?q)	No	? ^b	?
SW480 EJ4	der(7)t(1;7)(q2;q22)	No	7q22	7q22
	15p+	Yes	15q15	15q22
SW480 EJ6	11	Yes	11q21	11q14.2
SW480 CO5	add(16)(q24)	No	16q24	16q23.2
	der(20)t(5;20)(q22;p13)	Yes	20p13	20p12.2
SW480 NEO12	16	Yes	16q12	16q22.1

a. Hecht et al. [35].

b. Integration was observed in the telomeric region.

Table 4. Chromosomal abnormalities in SW480 cells observed infrequently (n=10).

Numerical	Structural	Markers	Frequency
+13, +14	1q-, 2q-, 3q-, 6q-	1	1/10
	18q+, der(19),t(1;19)	2	1/10
-13p+, -21	8p-		2/10

Karyotypic instability was higher in the cell lines with increased expression of c-Ha-ras mRNA after transfection with pSV₂neoEJ. The significant increase in karyotypic instability of SW480 EJ1 was due predominantly to the presence of large marker chromosomes, which varied in number between one and five. The increase in karyotypic instability in SW480 EJ2 was due mainly to numerical and structural chromosome changes. Neither SW480 EJ4 nor SW480 EJ6 exhibited enhanced karyotypic instability, nor was karyotypic instability increased in SW480 CO5 and SW480 NEO12.

4.4 DISCUSSION

Our line of SW480 was cytogenetically slightly different from what has been reported in the literature (33, 34). The observed chromosome differences most likely represent ongoing karyotypic evolution in an unstable genome. Clonal selection after transfection of SW480 with the c-Ha-ras oncogene, the wild-type c-Ha-ras gene, and pSV₂neo resulted in cell lines with new chromosome changes, present in all cells. Such genetic alterations may explain the occasional metastatic ability of control transfectants (36, 37), and also may contribute to metastatic capacity after v-Ha-ras oncogene transfection (15).

It was surprising that five of eight integration sites were localized on new rearranged chromosomes, not observed in SW480, after transfection with Ras-containing plasmids. Integration of transfected plasmid DNA in new structurally rearranged chromosomes was reported previously (38, 39). In addition, integration of viruses such as hepatitis B is commonly associated with a chromosome rearrangement at or near the site of integration (40, 41). An explanation for the preferential occurrence of integration sites in new rearranged chromosomes may be that the chromosomes bearing integration sites become unstable at the site of integration after random integration into the transfected genome, leading to new chromosome rearrangements with the integrated DNA at the rearranged site. An unstable region may evolve after integration of plasmid DNA in a telomeric band, disrupting the telomeric structure, which is essential for the stability of chromosomes (42, 43), and leading to highly fusogenic chromosome regions involved in new rearrangements. Such a mechanism is supported by our observations, because three out of five integration sites in new rearranged chromosomes occurred at or near translocation breakpoints involving telomeric bands.

We did not observe chromosome integration sites in SW480 limited to specific regions (i.e. fragile sites), which contrasts with preferential integration of the c-Ha-ras oncogene in the long arm of chromosome 3 in rat embryo fibroblasts, as reported by McKenna et al. (20). There may be two reasons for the different results. First, the selection procedure should be considered, because McKenna et al. (20) selected morphologically altered fibroblasts after transfection whereas we selected transfected cells on the basis of G418-resistance. Second, the process of integration may differ between transformed human cells and untransformed rodent cells.

The presence of new clonal abnormalities in all cells after transfection should be considered the result of experimental interference with the genome of a karyotypically instable cell and as such should not be considered evidence of increased genetic instability. Therefore, we chose to determine the karyotypic instability of a cell line as a measure of the genetic instability. Control transfection with pSV₂neo did not yield increased karyotypic instability, which suggest that the transfection procedure is not an important factor, although the number of cell lines studied was limited. Neither did karyotypic instability increase in SW480 CO5, despite the high level of c-Ha-ras mRNA in this cell line. Indeed, increased karyotypic instability was found only in two c-Ha-ras oncogene-transfected cell lines, SW480 EJ1 and SW480 EJ2, both with moderately increased levels of c-Ha-ras mRNA. This finding suggests that the increased karyotypic instability, a measure for the genetic instability, may be a c-Ha-ras oncogene-specific effect.

How the c-Ha-ras oncogene might induce karyotypic instability is not clear. In general, karyotypic instability may result from chromosome non disjunction and mitotic recombination. This might be caused by incorrect segregation of chromosomes during mitosis or by the precocious entering of a dividing cell into mitosis. The correct segregation of chromosomes during mitosis requires topoisomerase II (44). Onset to mitosis is regulated by the activity of the M-phase-promoting factor (45). The activity

of both proteins was recently shown to be altered after introduction of the c-Ha-ras oncogene into the cell (46, 47). In c-Ha-ras oncogene-transformed NIH/3T3 cells, the activity of topoisomerase II is higher than in normal NIH/3T3 cells, in a form that appears to be less dependent on the proliferative state of cells (46). *Xenopus* oocytes injected with c-Ha-ras oncogene mRNA demonstrated a high level of M-phase-promoting factor activity, specifically induced by the oncogenic form of the c-Ha-ras gene (47). Furthermore, allelic overrepresentation of the c-Ha-ras oncogene has been associated with progression of skin tumors in mouse models (48, 49). Non disjunction and mitotic recombination events in these models may have led to overrepresentation of the c-Ha-ras oncogene (49) or to complete loss of the normal c-Ha-ras gene (48). Non disjunction and mitotic recombination were observed only in tumors with activated ras genes (48). Therefore, interaction of the c-Ha-ras oncogene with topoisomerase II or MPF activity might disturb mitosis or onset to mitosis, resulting in chromosome non disjunction and incorrect chromosome segregation and, in turn, increased karyotypic instability.

We showed that transfection of SW480 cells with the c-Ha-ras oncogene results in increased c-Ha-ras mRNA expression and enhanced karyotypic instability. This finding suggests that not only expression of the oncogene, but also the acquired genotypic instability might be responsible for acquisition of the metastatic phenotype. Furthermore, identification of chromosome integration sites showed predominant integration of Ras-containing plasmids in structurally rearranged chromosomes of SW480. Finally, integrations were observed especially associated with breakpoints in telomeric bands.

4.5 REFERENCES

1. Muschel RJ, Williams JE, Lowy DR, Liotta LA: **Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell.** *Am. J. Pathol.* 1985; 121: 1-8.
2. Egan SE, McClarty GA, Jarolim L, *et al*: **Expression of H-ras correlates with metastatic potential: evidence for direct regulation of the metastatic phenotype in 10T1/2 and NIH 3T3 cells.** *Mol. Cell. Biol.* 1987; 7: 830-837.
3. Bradley MO, Kraynak AR, Storer RD, Gibbs JB: **Experimental metastasis in nude mice of NIH 3T3 cells containing various ras genes.** *Proc. Natl. Acad. Sci. U. S. A.* 1986; 83: 5277-5281.
4. Thorgeirsson UP, Turpeenniemi-Hujanen T, Williams JE, *et al*: **NIH/3T3 cells transfected with human tumor DNA containing activated ras oncogenes express the metastatic phenotype in nude mice.** *Mol. Cell. Biol.* 1985; 5: 259-262.
5. Garbisa S, Pozzatti R, Muschel RJ, *et al*: **Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-E1a.** *Cancer. Res.* 1987; 47: 1523-1528.
6. Collier IE, Wilhelm SM, Eisen AZ, *et al*: **H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen.** *J. Biol. Chem.* 1988; 263: 6579-6587.
7. Testa JE, Medcalf RL, Cajot JF, Schleuning WD, Sordat B: **Urokinase-type plasminogen activator biosynthesis is induced by the EJ-Ha-ras oncogene in CL26 mouse colon carcinoma cells.** *Int. J. Cancer.* 1989; 43: 816-822.
8. Brunner G, Pohl J, Erkell LJ, Radler-Pohl A, Schirmmacher V: **Induction of urokinase activity and malignant phenotype in bladder carcinoma cells after transfection of the activated Ha-ras oncogene.** *J. Cancer. Res. Clin. Oncol.* 1989; 115: 139-144.
9. Bernhard EJ, Muschel RJ, Hughes EN: **Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells.** *Cancer. Res.* 1990; 50: 3872-3877.
10. Theodorescu D, Cornil I, Sheehan C, Man MS, Kerbel RS: **Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells.** *Cancer. Res.* 1991; 51: 4486-4491.
11. Klein G, Klein E: **Conditioned tumorigenicity of activated oncogenes.** *Cancer. Res.* 1986; 46: 3211-3224.
12. Pratt CL, Kao CH, Wu SQ, Gilchrist KW, Oyasu R, Reznikoff CA: **Neoplastic progression by EJ/ras at different steps of transformation in vitro of human uroepithelial cells.** *Cancer. Res.* 1992; 52: 688-695.
13. Bardwell L: **The mutagenic and carcinogenic effects of gene transfer.** *Mutagenesis.* 1989; 4: 245-253.
14. Ichikawa T, Kyprianou N, Isaacs JT: **Genetic instability and the acquisition of metastatic ability by rat mammary cancer cells following v-H-ras oncogene transfection.** *Cancer. Res.* 1990; 50: 6349-6357.
15. Ichikawa T, Schalken JA, Ichikawa Y, Steinberg GD, Isaacs JT: **H-ras expression, genetic instability, and acquisition of metastatic ability by rat prostatic cancer cells following v-H-ras oncogene transfection.** *Prostate.* 1991; 18: 163-172.
16. Hurlin PJ, Maher VM, McCormick JJ: **Malignant transformation of human fibroblasts caused by expression of a transfected T24 HRAS oncogene.** *Proc. Natl. Acad. Sci. U. S. A.* 1989; 86: 187-191.

17. Cooper GM, ed: **Oncogenes**. first ed. Boston: Jones and Bartlett Publishers; 1990
18. Wang J, Chenivresse X, Henglein B, Brechot C: **Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma**. *Nature*. 1990; 343: 555-557.
19. Hunter T, Pines J: **Cyclins and cancer**. *Cell*. 1991; 66: 1071-1074.
20. McKenna WG, Nakahara K, Muschel RJ: **Site-specific integration of H-ras in transformed rat embryo cells**. *Science*. 1988; 241: 1325-1328.
21. Leibovitz A, Stinson JC, McCombs WB, *et al*: **Classification of human colorectal adenocarcinoma cell lines**. *Cancer Research* 1976; 36: 4562-4569.
22. Southern PJ, Berg P: **Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter**. *J. Mol. Appl. Genet*. 1982; 1: 327-341.
23. Capon DJ, Chen EY, Levinson AD, Seeburg PH, Goeddel DV: **Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue**. *Nature*. 1983; 302: 33-37.
24. Parada LF, Tabin CJ, Shih C, Weinberg RA: **Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene**. *Nature*. 1982; 297: 474-478.
25. Sambrook J, Fritsch EF, Maniatis T: **Molecular cloning**. second ed. New York: Cold Spring Harbor Laboratory Press, 1989
26. Graham FL, van der Eb AJ: **A new technique for the assay of infectivity of human adenovirus 5 DNA**. *Virology* 1973; 52: 456-467.
27. Chen C, Okayama H: **High-efficiency transformation of mammalian cells by plasmid DNA**. *Mol. Cell. Biol*. 1987; 7: 2745-2752.
28. Mitelman F, ed: **ISCN (1991): Guidelines for Cancer Cytogenetics, Supplement to An International System for Human Cytogenetic Nomenclature**. Basel: Karger, S, 1991
29. Garson JA, van-den-Berghe JA, Kemshead JT: **Novel non-isotopic in situ hybridization technique detects small (1 Kb) unique sequences in routinely G-banded human chromosomes: fine mapping of N-myc and beta-NGF genes**. *Nucleic. Acids. Res*. 1987; 15: 4761-4770.
30. de Vries JE, Kornips FHAC, Wiegant J, *et al*: **Chromosomal localization of transfected genes by a combination of hot banding and fluorescence in situ hybridization**. *J. Histochem. Cytochem*. 1992; 40: 1053-1058.
31. Klever M, Grond-Ginsbach C, Scherthan H, Schroeder-Kurth TM: **Chromosomal in situ suppression hybridization after Giemsa banding**. *Hum. Genet*. 1991; 86: 484-486.
32. Wiegant J, Galjart NJ, Raap AK, d'Azzo A: **The gene encoding human protective protein (PPGB) is on chromosome 20**. *Genomics*. 1991; 10: 345-349.
33. Cherif D, Le-Coniat M, Suarez HG, Bernheim A, Berger R: **Chromosomal localization of amplified c-myc in a human colon adenocarcinoma cell line with a biotinylated probe**. *Cancer. Genet. Cytogenet*. 1988; 33: 245-249.
34. Yaseen NY, Watmore AE, Potter AM, Potter CW, Jacob G, Rees RC: **Chromosome studies in eleven colorectal tumors**. *Cancer. Genet. Cytogenet*. 1990; 44: 83-97.
35. Hecht F, Ramesh KH, Lockwood DH: **A guide to fragile sites on human chromosomes**. *Cancer. Genet. Cytogenet*. 1990; 44: 37-45.
36. Kerbel RS, Waghorne C, Man MS, Elliott B, Breitman ML: **Alteration of the tumorigenic and metastatic properties of neoplastic cells is associated with the process of calcium phosphate-mediated DNA transfection**. *Proc. Natl. Acad. Sci. U. S. A*. 1987; 84: 1263-1267.
37. Bell C, Frost P, Kerbel RS: **Cytogenetic heterogeneity of genetically marked and metastatically competent "dominant" tumor cell clones**. *Cancer. Genet. Cytogenet*. 1991; 54: 153-161.

38. Robins DM, Ripley S, Henderson AS, Axel R: **Transforming DNA integrates into the host genome.** *Cell.* 1981; 23: 29-39.
39. Popescu NC, DiPaolo JA: **Integration of human papillomavirus 16 DNA and genomic rearrangements in immortalized human keratinocyte lines.** *Cancer. Res.* 1990; 50: 1316-1323.
40. Tokino T, Fukushima S, Nakamura T, *et al*: **Chromosomal translocation and inverted duplication associated with integrated hepatitis B virus in hepatocellular carcinomas.** *J. Virol.* 1987; 61: 3848-3854.
41. Henderson AS, Ripley S, Hino O, Rogler CE: **Identification of a chromosomal aberration associated with a hepatitis B DNA integration site in human cells.** *Cancer. Genet. Cytogenet.* 1988; 30: 269-275.
42. Greider CW: **Chromosome first aid.** *Cell.* 1991; 67: 645-647.
43. Hecht F, Hecht BK: **The telomere in cancer.** *Cancer. Genet. Cytogenet.* 1991; 54: 245-246.
44. Holm C, Goto T, Wang JC, Botstein D: **DNA topoisomerase II is required at the time of mitosis in yeast.** *Cell.* 1985; 41: 553-563.
45. Lohka MJ, Hayes MK, Maller JL: **Purification of maturation-promoting factor, an intracellular regulator of early mitotic events.** *Proc. Natl. Acad. Sci. U. S. A.* 1988; 85: 3009-3013.
46. Woessner RD, Chung TD, Hofmann GA, *et al*: **Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II.** *Cancer. Res.* 1990; 50: 2901-2908.
47. Daar I, Nebreda AR, Yew N, *et al*: **The ras oncoprotein and M-phase activity.** *Science.* 1991; 253: 74-76.
48. Bremner R, Balmain A: **Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7.** *Cell.* 1990; 61: 407-417.
49. Bianchi AB, Aldaz CM, Conti CJ: **Nonrandom duplication of the chromosome bearing a mutated Ha-ras-1 allele in mouse skin tumors.** *Proc. Natl. Acad. Sci. U. S. A.* 1990; 87: 6902-6906.

CHAPTER 5

PHENOTYPIC ANALYSIS OF CACO 2 AND SW480 CELL LINES TRANSFECTED WITH THE C-HA-RAS ONCOGENE

J.E. de Vries, M. van Driel, P. Marx, E.P.M. van der Linden, L. de Bruin, P.M. Moerkerk,
H.W. Verspaget, F.T. Bosman, and J. ten Kate.

Parts of this chapter have been submitted for publication.

5.1 INTRODUCTION

It has been firmly established that oncogenes play a significant role in the dysregulation of cellular growth and differentiation, which characterizes neoplasia (1). The family of the ras genes, encoding the highly similar, N-, Ki- and Ha-ras proteins, was among the first to be identified (2-4). It has been suggested that the normal c-N-, c-Ki-, and c-Ha-ras genes may serve different functions, but when activated, the functional difference might be lost (5). This is supported by the induction of tumorigenic and invasive behavior in human immortal fibroblast MSU 1.1 cells after transfection with activated oncogenic forms of either the N-, Ki- or Ha-ras gene (6-8). However, activation of c-Ki-ras and c-Ha-ras proteins is catalyzed by different Guanine Nucleotide Releasing Proteins (9). These proteins convert inactive GDP-bound p21ras proteins into active GTP-bound p21ras proteins (10). Therefore, the protein products of the c-Ki-ras and c-Ha-ras oncogenes may exert different effects depending on the Guanine Nucleotide Releasing Protein available in the recipient type of cell. It is supported by the observation that c-Ha-ras oncogene transfection increases the genetic instability in SW480 cells (11), which contain a c-Ki-ras gene with a pointmutation in codon 12 (12). The frequent observation that many different human tumor types contain pointmutated c-ras genes, has suggested that oncogenic c-ras genes are involved in carcinogenesis. The presence of pointmutated c-ras genes, especially c-Ki-ras, in about 50% of human colorectal adenomas and carcinomas (5, 13) is one of the findings that has led to a genetic model of colorectal carcinogenesis, in which pointmutations in the c-ras genes are considered as early events, putatively playing a role in the transition from adenoma to carcinoma (14). This model has been based primarily on observational studies of series of colorectal adenomas and carcinomas. Additional supportive evidence might be provided by transfection studies, in which the effects of the introduction of pointmutated ras genes can be investigated.

Colorectal carcinoma cell lines have been used infrequently to investigate the effect of the introduction of pointmutated ras oncogenes. Studies indicate that the c-Ha-ras oncogene increased expression of differentiation markers (15, 16) and upregulated u-PA biosynthesis (17). Increased biosynthesis of u-PA has been associated with acquisition of invasive capacity of tumor cells (18-22) and might therefore be an important event in the progression towards invasion and metastasis (23). On the other hand, increased expression of differentiation markers is suggestive for a higher degree of differentiation, which is inversely related to malignancy.

In view of these contrasting reports on the effects of overexpression of the c-Ha-ras oncogene on colorectal carcinoma cells we transfected the c-Ha-ras oncogene, pointmutated in codon 12 (24), into the human colorectal carcinoma cell lines CaCo 2 (25), which is highly differentiated and non-tumorigenic (26-28), and SW480 (29), which is poorly differentiated, tumorigenic but non-invasive and non-metastatic *in vivo* (Chapter 2) to study the effects of the c-Ha-ras oncogene on differentiation, tumorigenic capacity, and invasive potential. The effect on differentiation was determined by

detecting the expression of differentiation markers specific for colonic epithelium, which included sucrase-isomaltase, chromogranine A and the production of mucin (30). The effects on tumor progression was analyzed by *in vivo* growth characteristics, invasion into embryonic chick heart fragments, *in vitro* production of the proteases t-PA and u-PA and gelatinase activity (31), the expression of the cell adhesion molecule E-cadherin and integrin receptors. The potential doubling time was determined as a measure for the proliferative potential (32, 33).

The results indicate that the c-Ha-ras oncogene might confer tumorigenic potential along with proteolytic activity to CaCo 2 cells, but does neither induce invasive behavior *in vivo* nor affect the degree of differentiation, the expression of cell adhesion molecules and the proliferative potential of CaCo 2 and SW480 cells.

5.2 MATERIALS AND METHODS

5.2.1 Cell culture and transfection.

CaCo 2 (25) and SW480 cells (29) were cultured in DMEM with 5% Fetal Calf Serum (Boehringer, Mannheim, Germany) at 37°C in a humidified atmosphere with 5% CO₂. The plasmid pSV₂neo (34) contains the neomycin gene, which provides resistance to the antibiotic gentamycin. The plasmid pSV₂neoEJ contains a 6.6 kb genomic Bam HI fragment of the c-Ha-Ras oncogene with a G to T transversion in codon 12 (24), pSV₂neoCO contains the 6.6 genomic Bam HI fragment of the wild type c-Ha-Ras gene (2), kindly provided by Dr. Cerutti (Swiss Institute for Experimental Cancer Research, CH-1066 Epalinges, Switzerland). Plasmids were isolated with the alkaline lysis method (35) and further purified by precipitation with NH₄Ac (7.5 M).

Cells were transfected with the calcium phosphate precipitation technique (36), as modified by Chen and Okayama (37). The addition of the plasmid/CaCl₂ mixture to N,N-bis(2-hydroxyethyl)-2-aminoethane-sulfonic acid (BES) buffered saline, was carried out in continuous airflow.

Cell lines were established using two procedures. For the first procedure, the cells were plated after transfection into 96 well plates, and selection was started by adding G418 (800 µg/ml, GIBCO, Gaithersburg, USA) to the culture medium. After three weeks, selection was completed and colonies started to grow in 96 well plates. This procedure yielded the cell lines CaCo 2 EJ1-EJ12 and SW480 EJ1, 2, 4. In the alternative procedure, two days after transfection cells were transferred into 75 cm² culture flasks and selection was started (G418, 800 µg/ml). Untransfected cells were no longer viable after three weeks and colonies of transfected cells started to grow. These were trypsinized and plated in 96 well plates by limiting dilution and yielded the cell lines CaCo 2 CO1-3, NEO1-5, and SW480 EJ3, 5-24, CO1-6, NEO1-16. All cell lines were obtained from wells with only one colony.

5.2.2 Southern and northern blotting.

Chromosomal DNA was isolated after lysis of cells with 1% SDS in the presence of proteinase K (Boehringer), extracted with phenol/chloroform mixture and precipitated with ethanol (35). It was digested with Bam HI (Boehringer), blotted on nylon filter and hybridized with the 3.8 PvuII kb fragment of pSV₂neo, or with the 3.0 kb SacI fragment of the wild type c-Ha-ras gene, containing the four coding sequences. Both probes were labeled with (³²P)dCTP (Amersham) by random priming.

Cytoplasmic mRNA was isolated from cells lysed with NP40 in the presence of vanadyl ribonucleoside complex. Nuclei were pelleted and discarded. The supernatant was extracted with phenol/chloroform mixture and mRNA was precipitated with ethanol (35). After gelelectrophoresis and blotting on nylon filter, it was hybridized with the 3.0 kb SacI fragment of the wild type c-Ha-ras gene, labeled with (³²P)dCTP (Amersham) by random priming. Hybridization signals were scanned with a densitometer (LKB Ultrascan XL, Uppsala, Sweden). The transfected cell lines were compared with the parental cell line, for which the hybridization signal was arbitrarily set to unity. Differences caused by unequal loading of mRNA were corrected for by hybridization with a probe specific for actin.

5.2.3 Xenografting.

Athymic CD-1 male nude mice, 3-4 weeks old, were obtained from Charles River Wiga (Freiburg, Germany) and maintained in a laminar air flow cabinet under specific pathogen free conditions.

Tumor cells were injected in nude mice under ether anesthesia, at four sites in the subcutis or in the cecal wall, which was approached through a small median abdominal incision, with 1×10^6 cells in 0.1 ml PBS. The mice were killed 7 weeks after injection. At autopsy, tumor tissue was removed and fixed in 4% formalin, embedded in paraplast for histology and immunohistochemical staining.

5.2.4 Potential doubling time, T_{POT} .

To determine the T_{POT} of the cell lines in vitro, cells were cultured in the presence of 10 μ M BrdU for 30 min, washed three times with PBS and refed with 5 ml culture medium ($t=0$). The cells were harvested after 3 hr by trypsinization, washed twice with PBS and fixed in 70% ethanol for flow cytometry as described previously (38). The T_{POT} was determined according to White et al. (39).

5.2.5 Protease assays.

Near confluent cells were provided with fresh medium and after 24h the amount of u-PA and t-PA in medium and cellular extracts was measured by sandwich ELISA as described previously (40, 41). Protein content of the cell extracts was determined according to Lowry et al. (42). The variability between data of independent samples from one cell line ranged from 10% to 50%. Intra sample variation did not exceed 3%.

Gelatinase activity was determined in serum free medium from near confluent cells, cultured in serum free medium 24 h. before harvesting (43). Gels were run in a BioRad mini protean system. Gelatinase activity bands were visualized by negative Coomassie brilliant blue staining.

5.2.6 Immunohistochemistry of cell adhesion molecules and differentiation markers.

CaCo 2 parental and transfected cells were cultured to confluency, whereupon medium was refreshed daily. Cells were harvested after two weeks. SW480 parental and transfected cells were cultured to near confluency, the medium was refreshed and the cells were harvested 24 h later. Cells, harvested by gentle scraping with a rubber policeman, were washed twice with PBS, diluted in PBS/1% BSA and centrifuged on a glass slide. Methanol, 1 min, -20°C, followed by acetone, 3x 1 sec., -20°C was used for fixation. Endogenous peroxidase was blocked by incubation in PBS/H₂O₂ (0.3%) for 20 min at RT, to detect cell adhesion molecules, or in methanol/H₂O₂ (0.3%) in case of differentiation markers. Monoclonal antibodies used are listed in Table 1. Monoclonal antibody binding was detected with rabbit anti-mouse horse radish peroxidase conjugate (Dako, Glostrup, Denmark). Peroxidase activity was visualized with diaminobenzidine and imidazol. Slides were counterstained with hematoxylin. As negative controls, specific antibodies were omitted. Normal human colon mucosa was used as a positive control. The results of the immunocytochemistry were scored independently by two observers (JdV, EvdL), providing largely concordant results. Photographs were taken with a Zeiss Axioplan (MC100).

Table 1. Monoclonal antibodies used.

Specific for	Clone	Source	Reference
E-cadherin	6F9	Eurodiagnostica ^a	44
Integrin $\alpha_2\beta_1$	10G11	A. Sonnenberg	45
Integrin $\alpha_3\beta_1$	J143	A.P. Albino	46
Integrin $\alpha_6\beta_1$	GoH3	A. Sonnenberg	47
Sucrase-isomaltase	HBB2/614/88	H.-P. Hauri	48
Mucin	Parlam 13	Our department	49
Chromogranin A	LK2H10	Sanbyo ^b	50

a. Eurodiagnostica BV, Apeldoorn, The Netherlands.

b. Sanbyo, Uden, The Netherlands.

5.3 RESULTS

Establishment of transfected cell lines

Transfection of CaCo 2 cells with the plasmids pSV₂neoEJ, pSV₂neoCO or pSV₂neo yielded 12, 3 and 5 clonal cell lines, respectively. Transfection of SW480 cells with the

same plasmids yielded 24, 6 and 16 clonal cell lines, respectively. Southern blotting showed integration of plasmid DNA in all but one (CaCo EJ5) of the transfected cell lines, each cell line demonstrating a unique pattern of restriction fragments (Fig. 1), indicative of integration of intact c-Ha-ras oncogene in CaCo 2 EJ3, EJ6, and EJ9, and in SW480 EJ1 and EJ2 cells. In SW480 CO5, but in none of the CaCo 2 CO cell lines, we observed integration of intact wild type c-Ha-ras gene. Northern blotting revealed increased expression of c-Ha-ras mRNA in the cell lines CaCo 2 EJ6 (51) and SW480 EJ1, EJ2, and CO5 (Fig. 2, Table 2). The level of expression roughly corresponded with the amount of plasmid DNA detected in these clonal cell lines (11). This was taken as indirect evidence that the increase in c-Ha-ras mRNA was due to transcription of the transfected c-Ha-ras genes.

Figure 1. Integration of plasmid DNA in transfected cell lines.

A. Hybridization with the 3.0 kb *SacI* fragment of the wild type c-Ha-ras gene. Note that the endogenous *BamHI* fragment of c-Ha-ras is 8.6 kb in CaCo 2 and 6.6 kb in SW480. **B.** The same blot hybridized with the 3.8 kb *PvuII* fragment of pSV2neo. Note the pSV2neo plasmid at 5.6 kb and the absence of specific hybridization in the CaCo 2 and SW480 parental cell lines. Lanes contain 10 μ g chromosomal DNA digested with *BamHI*. Lane 1: CaCo 2; 2: CaCo 2 EJ1; 3: CaCo 2 EJ2; 4: CaCo 2 EJ3; 5: CaCo 2 EJ5; 6: CaCo 2 EJ6; 7: CaCo 2 EJ7; 8: CaCo 2 EJ9; 9: CaCo 2 EJ10; 10: SW480; 11: SW480 EJ1; 12: SW480 EJ2.

Figure 2. Expression of c-Ha-ras mRNA in SW480 transfected cell lines.

A. Hybridization with the 3.0 kb *SacI* fragment of the wild type c-Ha-ras gene. All lanes demonstrated expression of c-Ha-ras mRNA upon longer exposure times (not shown). Note the increased expression of c-Ha-ras mRNA in SW480 EJ1

and SW480 EJ2 and the strong increased expression in SW480 CO5. **B.** The same blot hybridized with a probe specific for actin. Lanes contain 10 μ g cytoplasmic mRNA. Lane 1: SW480; 2: SW480 EJ1; 3: SW480 EJ2; 4: SW480 EJ4; 5: SW480 EJ17; 6: SW480 CO5; 7: SW480 NEO3; 8: SW480 NEO12.

A subset of transfected cell lines was further analyzed and included: (1) cell lines with increased expression of c-Ha-ras mRNA after transfection with pSV₂neoEJ or pSV₂neoCO; (2) cell lines with unaltered expression of c-Ha-ras mRNA after transfection with pSV₂neoEJ or pSV₂NEO; and (3) parental cell lines.

Behavior in nu/nu mice and in vitro invasion assay

CaCo 2. CaCo 2 cells were non-tumorigenic in xenograft experiments in the subcutis, as were the transfected CaCo 2 cells, with the exception of CaCo 2 EJ6 cells, which also demonstrated increased expression of c-Ha-ras mRNA after transfection with the c-Ha-ras oncogene (Table 2). This cell line yielded moderately well differentiated non-invasive adenocarcinomas with strong focal mucin production (51). Both CaCo 2 cells and CaCo 2 EJ6 cells injected in the cecal wall of nu/nu mice did not develop primary tumors (Table 2).

Parental CaCo 2 cells did not invade embryonic chick heart fragments. In vitro invasive potential was not induced in c-Ha-ras oncogene transfected CaCo 2 EJ6 cells (Table 2). **SW480.** The cell line SW480 was tumorigenic in the subcutis and remained tumorigenic after transfection (Table 2). All cell lines grew as non-invasive adenocarcinomas with areas of solid growth, intra- and extracellular lumina and focal mucin production. SW480 EJ2 demonstrated increased nuclear pleomorphism and intra- and extracellular lumina were more extensive. SW480 cells injected in the cecal wall of nu/nu mice demonstrated a low take-rate, in contrast with previous experiments (Chapter 2). The take-rate of the transfected SW480 cell lines was even lower, primary tumors were not observed after orthotopic xenografting (Table 2).

The parental SW480 cell line invaded embryonic chick heart fragments. Invasive potential was also observed in c-Ha-ras oncogene transfected SW480 cell lines (Table 2).

Morphology and potential doubling time

CaCo 2. In vitro morphology of all CaCo 2 transfected cell lines was identical to the parental CaCo 2 cell line. The potential doubling time appeared to be prolonged significantly in the transfected cell lines, but the increase was not correlated with an enhanced level of c-Ha-ras mRNA (Table 2).

SW480. Some of the transfected SW480 cell lines demonstrated morphological changes. In contrast with the spindle shaped form of parental SW480 cells, SW480 EJ4 and SW480 NEO3 grew in closed monolayers, and some SW480 EJ cell lines, including SW480 EJ17, grew predominantly in suspension (not shown). The morphotypes were maintained after prolonged culture.

The potential doubling time of transfected SW480 cell lines was either similar to the parental SW480 cell line or elevated. It was increased significantly in SW480 EJ1 and SW480 CO5 (Table 2). However, the increase in the potential doubling time did not correlate with an increased level of c-Ha-ras mRNA after transfection with the c-Ha-ras oncogene.

Table 2. Level of c-Ha-ras mRNA, behavior in vivo and in vitro, and potential doubling time of parental and transfected cell lines.

Cell line	c-Ha-ras mRNA level	Nu/nu mice		ECHF ^a	T _{POT} (hr) ± S _{DEV} (n)
		Subcutis	Cecum		
CaCo 2	1	0/5	0/5	- ^b	12.0 ± 2.5 (4)
CaCo 2 EJ6	4	5/5	0/5	-	15.9 ± 3.1 (7)*
CaCo 2 CO1	1	0/2	ND	ND	23.9 ± 7.5 (3)**
CaCo 2 NEO5	1	0/2	ND	ND	19 (2)
SW480	1	5/5	1/8	+	13.7 ± 4.9 (9)
SW480 EJ1	5	2/2	0/5	ND	18.0 ± 4.4 (8)*
SW480 EJ2	4	2/2	0/5	+	13.5 ± 3.0 (8)
SW480 EJ4	1	3/3	0/5	ND	13.2 ± 3.7 (9)
SW480 EJ17	1	2/2	0/5	+	14.7 ± 5.1 (8)
SW480 CO5	30	2/2	0/5	ND	20.4 ± 4.1 (6)**
SW480 NEO3	1	2/2	0/5	ND	17.1 ± 2.4 (4)

a. Embryonic chick heart fragment assay; b. - = non-invasive, + = invasive, ND = not done.

*. Difference with the parental cell lines is statistically significant as analyzed by Student's *t* test ($p < 0.05$).

**. Difference with the parental cell lines is statistically significant as analyzed by Student's *t* test ($p < 0.005$).

Protease production

CaCo 2. u-PA secretion was increased in CaCo 2 EJ6 cells in parallel with increased c-Ha-ras mRNA expression. The increase in u-PA secretion did not reach statistical significance. A similar trend was noted for u-PA in cell extracts, with values of 5% or less than recovered from the medium. The production of t-PA was not altered after transfection (Table 3).

Gelatinase activity was not observed in parental CaCo 2 cells. It was induced in CaCo 2 EJ6 and paralleled by an increased level of c-Ha-ras mRNA. Bands of gelatinase activity were visible at 107, 97, 81 and 18 kDa (Fig. 3).

SW480. The production of u-PA, either secreted or cell bound, varied in SW480 transfected cell lines and did not correlate with the level of c-Ha-ras mRNA. The amount of t-PA in the cell extracts of transfected and non-transfected cells was similar (Table 3).

Several bands with gelatinase activity were identified in parental SW480 cells, including one at 92 kDa. Consistent alterations in gelatinase activity were not observed in the SW480 transfected cell lines (not shown).

Table 3. In vitro production of proteases and in vitro expression of cell adhesion molecules in parental and transfected cell lines.

Cell line	u-PA ^a	u-PA ^b	t-PA ^b	Gelatinase activity	E-cadherin	Integrin		
	medium	cell	cell			$\alpha_2\beta_1$	$\alpha_3\beta_1$	$\alpha_6\beta_1$
CaCo 2	1012	37	579	-	+++ ^d	- ^d	$\pm$ ^d	++ ^d
CaCo 2 EJ6	2177	130	600	+	-	-	-	++
CaCo 2 CO1	1744	51	835	-	+++	-	$\pm$	-
CaCo 2 NEO5	586	36	497	-	$\pm$	-	-	-
SW480	641	404	908	+	-	-	++	++
SW480 EJ1	281	59	1057	+	-	-	++	+++
SW480 EJ2	610	225	1062	+	-	-	++	++
SW480 EJ4	484	277	1099	+	-	-	++	+++
SW480 EJ17	900	331	1142	+	-	-	++	+++
SW480 CO5	1099	318	1019	+	-	-	++	++
SW480 NEO3	272	139	1061	+	-	-	++	++

- a. Expressed in pg u-PA per mg protein cell extract, secreted into 1 ml medium.
b. Expressed in pg u-PA/t-PA per mg protein cell extract.
c. - = no gelatinase activity, + = gelatinase activity.
d. Percentage positive cells: - = 0%, $\pm$ = $\leq$, + = 1% - 10%, ++ = 10% - 75%, +++ = $\geq$ 75%.

Figure 3. Activity of gelatinases in CaCo 2 and CaCo 2 transfected cell lines.
Note the gelatinase activity bands at 107, 97, 81 and 18 kDa in CaCo 2 EJ6. Lane 1: CaCo 2 NEO5; 2: CaCo 2 CO2; 3: CaCo 2 CO1; 4: CaCo 2 EJ12; 5: CaCo 2 EJ6; 6: CaCo 2 EJ1; 7: CaCo 2.

Cell adhesion molecules

As cell adhesion molecules should be expressed at the surface of the cell in order to be functional, only membrane immunoreactivity of monoclonal antibodies specific for E-cadherin or integrins was taken into account.

CaCo 2. The parental CaCo 2 cell line showed abundant membranous expression of E-cadherin (Chapter 2), which was decreased in two transfected CaCo 2 cell lines (Table 3). The decrease in E-cadherin expression was not associated with increased level of c-Ha-ras mRNA. Membrane expression of $\alpha_2\beta_1$ integrin was not observed in CaCo 2 cells or in transfected CaCo 2 cells. The $\alpha_3\beta_1$ integrin was expressed at the membrane in less than 1% of the parental CaCo 2 cells. c-Ha-ras oncogene transfected CaCo 2 cells demonstrated a similar pattern of expression, in contrast to control transfected CaCo 2

cells, where expression was not detected (Table 3). Expression of the $\alpha_6\beta_1$ integrin was demonstrated at the plasma membrane in 50% of the CaCo 2 cells, both parental and transfected (Table 3).

SW480. Expression of E-cadherin was not detected in parental or transfected SW480 cells (Table 3). The $\alpha_2\beta_1$ integrin was not expressed at the plasma membrane in any of the SW480 cell lines. About 20% of the parental SW480 cells expressed $\alpha_3\beta_1$ integrin at the membrane. A similar percentage of the cells was positive after transfection with the c-Ha-ras oncogene and after control transfections of SW480 cells. Membrane expression of $\alpha_6\beta_1$ integrin was observed in 10% of the parental SW480 cells (Table 3). Increased expression of $\alpha_6\beta_1$ integrin was observed in several transfected SW480 cell lines, not related with an increased level of c-Ha-ras mRNA after transfection with the c-Ha-ras oncogene.

Markers of differentiation

CaCo 2. Expression of sucrase-isomaltase was observed in the brushborders of CaCo 2 cells (Fig. 4) and varied considerably after transfection (Table 4) without any relation to c-Ha-ras mRNA level. Mucin production was readily detected in the cytoplasm of parental CaCo 2 cells and to a similar degree after transfection (Fig. 4, Table 4). Chromogranine A was expressed in none of the CaCo 2 cell lines.

SW480. Cytoplasmic mucin production was observed in about 1% of the parental SW480 cells. The percentage of cells with cytoplasmic immunoreactivity increased to 10% in two transfected SW480 cell lines, but the increase was not associated with the level of c-Ha-ras mRNA (not shown). Sucrase-isomaltase and chromogranine A were neither detected in parental nor in transfected SW480 cell lines.

Figure 4. Immunohistochemistry of cell lines in vitro.

A. Mucin production demonstrated in CaCo 2 EJ6. Note the strong cytoplasmic reactivity. **B.** Expression of sucrase-isomaltase in CaCo 2. Note the highly polarized staining at one side of the cell. Arrows indicate cells to be held up as an example for cells with immunoreactivity for the monoclonal antibody used. Bar is 5 μ m.

Table 4. Expression of differentiation markers in CaCo 2 and CaCo 2 transfected cell lines.

Cell line	Sucrase isomaltase	Mucin	Chromogranine A
CaCo 2	+++ ^a	+ ^a	- ^a
CaCo 2 EJ6	-	+	-
CaCo 2 CO1	+++	+	-
CaCo 2 NEO5	-	±	-

a. Percentage positive cells: - = 0%, ± = ≤, + = 1% - 10%,
 ++ = 10% - 75%, +++ = ≥ 75%.

5.4 DISCUSSION

In this study we analyzed in c-Ha-ras oncogene transfected CaCo 2 and SW480 cells a broad spectrum of phenotypic characteristics. The effects of c-Ha-ras oncogene transfection can be grouped in two different categories. Firstly, phenotypic alterations such as the in vitro morphology of SW480 transfected cell lines, were found without any relation to increased c-Ha-ras mRNA levels, we therefore assume that these alterations are brought about by the transfection procedure. Also clonal variation might account for these alterations, as has been reported for the expression of sucrase isomaltase in CaCo 2 cells (52). The observed variation in sucrase isomaltase expression in the transfected CaCo 2 cell lines is also explained most likely by clonal variation. An explanation for such an effect of transfection could be insertional gene(in)activation.

The second category of phenotypic alterations are those coinciding with increased c-Ha-ras mRNA levels, which therefore, presumably result from the introduction and transcription of the c-Ha-ras oncogene. These alterations were found in CaCo 2 cells only and include induction of tumorigenicity of carcinoma cells injected in the subcutis and induction of gelatinase activity. Whether there is a functional relationship between tumorigenicity and gelatinase activity remains to be determined. The induction of tumorigenic potential was not accompanied by loss of differentiation. This corresponds with findings in Ha-ras transformed rat hepatocytes, which became tumorigenic and retained the ability to express liver specific genes (53, 54). Clonal variation cannot be excluded as a cause of the occurrence of tumorigenicity and increased gelatinase activity in transfected CaCo 2 cells. However, others also observed tumorigenicity after transfection of non-tumorigenic CaCo 2 cells with the c-Ha-ras oncogene (55), which makes clonal variation a less likely explanation.

Bearing in mind that tumor cells transfected with the c-Ha-ras oncogene frequently demonstrate a reduced requirement of growth factors in vitro (6, 56-61) it is conceivable that induction of tumorigenicity in vivo in c-Ha-ras oncogene transfected CaCo 2 cells might be caused also by a reduced requirement of growth factors. This

confers growth autonomy to tumor cells, and allows them to escape regulation by the microenvironment (62, 63). Growth autonomy can occur through two mechanisms. Firstly, the c-Ha-ras oncogene has been shown to induce expression of growth factors (57, 59, 60) and growth factor receptors (64). An autocrine loop is established when the induced growth factors can bind to endogenously expressed growth factor receptors. Secondly, normal cells increase the level of the active GTP.p21 ras complex after activation of the receptor for insulin, PDGF, or EGF (65-67). Which mechanism is effective remains to be established.

Contrary to what we expected in our experiments none of the CaCo 2 cells and none of the transfected SW480 cells developed primary tumors after orthotopic injection. Observations concerning the influence of the c-Ha-ras oncogene on orthotopic *in vivo* behavior could therefore not be made. However, the c-Ha-ras oncogene neither alters *in vitro* invasive capacities nor induces invasive capacity in CaCo 2 and SW480 cells in the subcutis. These observations could be taken as circumstantial evidence suggesting that the c-Ha-ras oncogene is not involved in the acquisition of invasive potential of human colorectal carcinoma cells.

In summary, our results suggest that; (1) The c-Ha-ras oncogene induces tumorigenic potential to non-tumorigenic CaCo 2 cells along with induction of gelatinase activity; (2) Neither in CaCo 2 cells nor in SW480 cells introduction of the c-Ha-ras oncogene confers invasive ability. These data are in keeping with an early position of the ras gene mutations in models of colorectal carcinogenesis.

5.5 REFERENCES

1. Cooper GM, ed: **Oncogenes**. first ed. Boston: Jones and Bartlett Publishers, 1990
2. Parada LF, Tabin CJ, Shih C, Weinberg RA: **Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene**. *Nature*. 1982; 297: 474-478.
3. Goldfarb M, Shimizu K, Perucho M, Wigler M: **Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells**. *Nature*. 1982; 296: 404-409.
4. Pulciani S, Santos E, Lauver AV, Long LK, Robbins KC, Barbacid M: **Oncogenes in human tumor cell lines: molecular cloning of a transforming gene from human bladder carcinoma cells**. *Proc. Natl. Acad. Sci. USA* 1982; 79: 2845-2849.
5. Fearon ER, Vogelstein B: **A genetic model for colorectal tumorigenesis**. *Cell*. 1990; 61: 759-767.
6. Hurlin PJ, Maher VM, McCormick JJ: **Malignant transformation of human fibroblasts caused by expression of a transfected T24 HRAS oncogene**. *Proc. Natl. Acad. Sci. U. S. A.* 1989; 86: 187-191.
7. Wilson DM, Yang DJ, Dillberger JE, Dietrich SE, Maher VM, McCormick JJ: **Malignant transformation of human fibroblasts by a transfected N-ras oncogene**. *Cancer. Res.* 1990; 50: 5587-5593.
8. Fry DG, Milam LD, Dillberger JE, Maher VM, McCormick JJ: **Malignant transformation of an infinite life span human fibroblast cell strain by transfection with v-Ki-ras**. *Oncogene*. 1990; 5: 1415-1418.
9. Mizuno T, Kaibuchi K, Yamamoto T, *et al*: **A stimulatory GDP/GTP exchange protein for smg p21 is active on the post-translationally processed form of c-Ki-ras p21 and rhoA p21**. *Proc. Natl. Acad. Sci. USA* 1991; 88: 6442-6446.
10. Bourne HR, Sanders DA, McCormick F: **The GTPase superfamily: conserved structure and molecular mechanism**. *Nature*. 1991; 349: 117-127.
11. de Vries JE, Kornips FHAC, Marx P, Bosman FT, Geraedts JPM, ten Kate J: **Transfected c-Ha-ras oncogene enhances karyotypic instability and integrates predominantly in aberrant chromosomes**. *Cancer. Genet. Cytogenet.* 1993; 65: 35-43.
12. Spandidos DA, Wilkie NM: **Malignant transformation of early passage rodent cells by a single mutated human oncogene**. *Nature*. 1984; 310: 469-475.
13. Vogelstein B, Fearon ER, Hamilton SR, *et al*: **Genetic alterations during colorectal-tumor development**. *N. Engl. J. Med.* 1988; 319: 525-532.
14. Bos JL: **Ras oncogenes in human cancer: A review**. *Cancer. Res.* 1989; 49: 4682-4689.
15. Bagli DJ, D'Emilia JC, Summerhayes IC, Steele GD, Barlozzari T: **c-Ha-ras-I oncogene-induced differentiation and natural killer cell resistance in a human colorectal carcinoma cell line**. *Cancer. Res.* 1990; 50: 2518-2523.
16. Celano P, Berchtold CM, Mabry M, *et al*: **Induction of markers of normal differentiation in human colon carcinoma cells by the v-ras oncogene**. *Cell Growth and Differentiation* 1993; 4: 341-347.
17. Testa JE, Medcalf RL, Cajot JF, Schleuning WD, Sordat B: **Urokinase-type plasminogen activator biosynthesis is induced by the EJ-Ha-ras oncogene in CL26 mouse colon carcinoma cells**. *Int. J. Cancer.* 1989; 43: 816-822.
18. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: **Plasminogen activators, tissue degradation, and cancer**. *Adv. Cancer. Res.* 1985; 44: 139-266.

19. Axelrod JH, Reich R, Miskin R: **Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells.** *Mol. Cell. Biol.* 1989; 9: 2133-2141.
20. Quax PHA, van Muijen GNP, Weening-Verhoeff EJD, *et al*: **Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase mediated matrix degradation.** *J. Cell. Biol.* 1991; 115: 191-199.
21. de Bruin PAF, Griffioen G, Verspaget HW, Verheijen JH, Lamers CBHW: **Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.** *Cancer. Res.* 1987; 47: 4654-4657.
22. Sier CFM, Verspaget HW, Griffioen G, *et al*: **Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia.** *Gastroenterology* 1991; 101: 1522-1528.
23. Liotta LA, Steeg PS, Stetler-Stevenson WG: **Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.** *Cell.* 1991; 64: 327-336.
24. Capon DJ, Chen EY, Levinson AD, Seeburg PH, Goeddel DV: **Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue.** *Nature.* 1983; 302: 33-37.
25. Fogh J, Fogh JM, Orfeo T: **One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.** *J. Natl. Cancer. Inst.* 1977; 59: 221-225.
26. Pinto M, Robine-Leon S, Appay M-D, *et al*: **Enterocyte-like differentiation and polarization of the human colon carcinoma cell line CaCo-2 in culture.** *Biol. Cell.* 1983; 47: 323-330.
27. Chantret I, Barbat A, Dussaulx E, Brattain MG, Zweibaum A: **Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines.** *Cancer. Res.* 1988; 48: 1936-1942.
28. de Vries JE, Dinjens WNM, Verspaget HW, *et al*: **Behavior of orthotopic human colorectal carcinoma xenografts in relation to in vitro invasion.** 100 1993; 100: 100.
29. Leibovitz A, Stinson JC, McCombs WB, *et al*: **Classification of human colorectal adenocarcinoma cell lines.** *Cancer Research* 1976; 36: 4562-4569.
30. Quaroni A: **Identification and biogenesis of intestinal cell-surface components.** *Progress in Cancer Research and Therapy* 1984; 29: 267-293.
31. Bernhard EJ, Muschel RJ, Hughes EN: **Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells.** *Cancer. Res.* 1990; 50: 3872-3877.
32. Stacey DW, Kung H-F: **Transformation of NIH 3T3 cells by microinjection of Ha-ras p21 protein.** *Nature.* 1984; 310: 508-511.
33. Feramisco JR, Gross M, Kamata T, Rosenberg M, Sweet RW: **Microinjection of the oncogene form of the human H-ras (T-24) protein results in rapid proliferation of quiescent cells.** *Cell.* 1984; 38: 109-117.
34. Southern PJ, Berg P: **Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.** *J. Mol. Appl. Genet.* 1982; 1: 327-341.
35. Sambrook J, Fritsch EF, Maniatis T: **Molecular cloning**, second ed. New York: Cold Spring Harbor Laboratory Press, 1989
36. Graham FL, van der Eb AJ: **A new technique for the assay of infectivity of human adenovirus 5 DNA.** *Virology* 1973; 52: 456-467.
37. Chen C, Okayama H: **High-efficiency transformation of mammalian cells by plasmid DNA.** *Mol. Cell. Biol.* 1987; 7: 2745-2752.

38. Schutte B, Reynders MM, van-Assche CL, Hupperets PS, Bosman FT, Blijham GH: **An improved method for the immunocytochemical detection of bromodeoxyuridine labeled nuclei using flow cytometry.** Cytometry. 1987; 8: 372-376.
39. White RA, Terry NH, Meistrich ML: **New methods for calculating kinetic properties of cells in vitro using pulse labelling with bromodeoxyuridine.** Cell. Tissue. Kinet. 1990; 23: 561-573.
40. Binnema DJ, van Iersel JJJ, Dooijewaard G: **Quantitation of urokinase antigen in plasma and culture media by use of an ELISA.** Thromb. Res. 1986; 43: 569-577.
41. Rijken DC, van Hinsbergh VWM, Sens EHC: **Quantitation of tissue-type plasminogen activator in human endothelial cell cultures by use of an enzyme immunoassay.** Thromb. Res. 1984; 33: 145-153.
42. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: **Protein measurement with the Folin phenol reagent.** J. Biol. Chem. 1951; 193: 265-275.
43. Zucker S, Wieman J, Lysik RM, *et al*: **Gelatin-degrading type IV collagenase isolated from human small cell lung cancer.** Invasion. Metastasis. 1989; 9: 167-181.
44. Behrens J, Birchmeier W, Goodman SL, Imhof BA: **Dissociation of Madin-Darby canine kidney epithelial cells by the monoclonal antibody anti-arc-1: mechanistic aspects and identification of the antigen as a component related to ovomorulin.** J. Cell. Biol. 1985; 101: 1307-1315.
45. Giltay JC, Brinkman HJ, Modderman PW, von-dem-Borne AE, van-Mourik JA: **Human vascular endothelial cells express a membrane protein complex immunochemically indistinguishable from the platelet VLA-2 (glycoprotein Ia-IIa) complex.** Blood. 1989; 73: 1235-1241.
46. Fradet Y, Cordon-Cardo C, Thomson T, *et al*: **Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies.** Proc. Natl. Acad. Sci. U. S. A. 1984; 81: 224-228.
47. Sonnenberg A, Hogervorst F, Osterop A, Veltman FE: **Identification and characterization of a novel antigen complex on mouse mammary tumor cells using a monoclonal antibody against platelet glycoprotein Ic.** J. Biol. Chem. 1988; 263: 14030-14038.
48. Zweibaum A, Hauri HP, Sterchi E, Haffen K, Bamat J, Sordat B: **Immunohistological evidence, obtained with monoclonal antibodies, of small intestinal brush border hydrolases in human colon cancers and foetal colons.** Int. J. Cancer. 1984; 34: 591-598.
49. Verstijnen CPHJ, Arends JW, Moerkerk PTM, Pijls M, Kuypers-Engelen B, Bosman FT: **Colonic epithelium reactive monoclonal antibodies. Identification and immunohistochemical localization of the target epitopes.** Histochemistry. 1989; 92: 397-406.
50. Lloyd RV, Wilson BS: **Specific endocrine tissue marker defined by a monoclonal antibody.** Science. 1983; 222: 628-630.
51. de Bruine AP, de Vries JE, Dinjens WNM, *et al*: **Human CaCo 2 cells transfected with c-Ha-ras as a model for endocrine differentiation in the large intestine.** Differentiation. 1993; 53: 51-60.
52. Beaulieu J-F, Quaroni A: **Clonal analysis of sucrase-isomaltase expression in the human colon adenocarcinoma CaCo-2 cells.** Biochem. J. 1991; 280: 599-608.
53. Fang XJ, Flowers M, Keating A, Cameron R, Sherman M: **ras transformation of simian virus 40-immortalized rat hepatocytes: an in vitro model of hepatocarcinogenesis.** Cancer. Res. 1992; 52: 173-180.
54. Isom HC, Woodworth CD, Meng Y, Kreider J, Miller T, Mengel L: **Introduction of the ras oncogene transforms a simian virus 40-immortalized hepatocyte cell line without loss of expression of albumin and other liver-specific genes.** Cancer. Res. 1992; 52: 940-948.

55. Delage S, Chastre E, Empereur S, *et al*: **Increased protein kinase C alpha expression in human colonic CaCo 2 cells after insertion of human Ha-ras or polyoma virus middle T oncogene.** *Cancer. Res.* 1993; 53: 2762-2770.
56. Yoakum GH, Lechner JF, Gabrielson EW, *et al*: **Transformation of human bronchial epithelial cells transfected by Harvey ras oncogene.** *Science.* 1985; 227: 1174-1179.
57. Andrejaskas E, Moroni C: **Reversible abrogation of IL-3 dependence by an inducible H-ras oncogene.** *Embo. J.* 1989; 8: 2575-2581.
58. Appleby MW, Greenfield IM, Crook T, Parkinson EK, Stanley MA: **In vivo and in vitro effects of v-fos and EJ-Ha-ras oncogene expression in murine epidermal keratinocytes.** *Oncogene.* 1989; 4: 1323-1330.
59. Ciardiello F, McGeedy ML, Kim N, *et al*: **Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation.** *Cell. Growth. Differ.* 1990; 1: 407-420.
60. Demetri GD, Ernst TJ, Pratt ES 2d, Zenzie BW, Rheinwald JG, Griffin JD: **Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes.** *J. Clin. Invest.* 1990; 86: 1261-1269.
61. Kinsella AR, Fiszler-Maliszewska L, Mitchell EL, Guo YP, Fox M, Scott D: **Introduction of the activated N-ras oncogene into human fibroblasts by retroviral vector induces morphological transformation and tumorigenicity.** *Carcinogenesis.* 1990; 11: 1803-1809.
62. Chadwick DE, Lagarde AE: **Coincidental acquisition of growth autonomy and metastatic potential during the malignant transformation of factor-dependent CCL39 lung fibroblasts.** *J. Natl. Cancer. Inst.* 1988; 80: 318-325.
63. Liotta LA: **Growth autonomy: The only requirement for metastasis?** *J. Natl. Cancer. Inst.* 1988; 86: 18.
64. Theodorescu D, Cornil I, Sheehan C, Man MS, Kerbel RS: **Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells.** *Cancer. Res.* 1991; 51: 4486-4491.
65. Burgering BMT, Medema RH, Maassen JA, *et al*: **Insulin stimulation of gene expression mediated by p21ras activation.** *The EMBO Journal* 1991; 10: 1103-1109.
66. Satoh T, Endo M, Nakafuku M, Nakamura S, Kaziro Y: **Platelet-derived growth factor stimulates formation of active p21ras.GTP complex in Swiss mouse 3T3 cells.** *Proc. Natl. Acad. Sci. U. S. A.* 1990; 87: 5993-5997.
67. Satoh T, Endo M, Nakafuku M, Akiyama T, Yamamoto T, Kaziro Y: **Accumulation of p21ras.GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity.** *Proc. Natl. Acad. Sci. U. S. A.* 1990; 87: 7926-7929.

CHAPTER 6

HUMAN CACO 2 CELLS TRANSFECTED WITH C-HA-RAS AS A MODEL FOR ENDOCRINE DIFFERENTIATION IN THE LARGE INTESTINE

A.P. de Bruijne, J.E. de Vries, W.N.M. Dinjens, P.M. Moerkerk, E.P.M. van der Linden, M. Pijls,
J. ten Kate, and F.T. Bosman.
Differentiation 1993; 53: 51-60.
(Reprinted with permission)

6.1 INTRODUCTION

In the colorectum, endocrine neoplasms in their most characteristic form are encountered as classical carcinoid tumors (1). However, endocrine differentiation in large intestinal epithelial tumors has been recognized to occur in a much wider spectrum of tumors, comprising poorly differentiated small cell undifferentiated carcinomas (2,3) and mixed exocrine/endocrine carcinomas with variable numbers of endocrine tumor cells (4). In colorectal adenocarcinomas, endocrine differentiation can be found in approximately 30% of cases (5). This relatively high frequency and the fact that some reports state a poorer prognosis for colon carcinomas with endocrine cells (6,7) is indicative for the potential importance of this phenomenon. The more aggressive behavior could be related to growth stimulatory effects of peptides and/or amines produced by endocrine tumor cells (8), which may act as autocrine or paracrine growth factors (9).

To study the biological relevance of endocrine differentiation in colorectal adenocarcinomas, well defined tumor models are of utmost importance. This has been hampered by the relative scarcity of colorectal adenocarcinoma cell lines with endocrine features. So far, only two colorectal cancer cell lines with endocrine differentiation have been well documented: HRA-19 (10) and NCI-H716 (11). In HRA-19 endocrine differentiation exclusively occurs in tumor xenografts, which are morphologically well differentiated adenocarcinomas. This finding suggests that stromal factors are involved in the induction of endocrine differentiation (12). NCI-H716 xenografts are morphologically poorly differentiated adenocarcinomas, not fully representative of the predominant type of colorectal adenocarcinoma. Endocrine differentiation is observed extensively in NCI-H716 xenografts, but can also be induced *in vitro* by specific extracellular matrix components (13). The availability of more cell lines, morphologically corresponding with the predominant (well differentiated) type of colorectal carcinoma and harboring all colorectal epithelial cell lineages, would be useful in order to elucidate the mechanism regulating endocrine differentiation.

In view of their high level of differentiation (14), we chose to investigate Caco-2 cells for endocrine characteristics. Initial experiments demonstrated that under standard conditions of xenografting a low take rate is attained. We therefore transfected these cells with a point mutated c-Harvey (Ha)-Ras-gene, as Ras overexpression has been associated with tumor progression (15), metastatic capacity (16,17), and endocrine differentiation (18,19). The present report describes the c-Ha-Ras transfection of Caco-2, the properties of the obtained cell lines and their use as a model to study endocrine differentiation in colorectal cancer.

6.2 MATERIALS AND METHODS

6.2.1 Tumor cells

Caco-2 cells were purchased from the American Type Culture Collection (ATCC, Rockville, Maryland, USA). Caco-2 EJ6 cells were established from this native cell line by transfection.

6.2.2 Transfection experiments

The plasmid pSV₂neo, containing the neomycin gene (20), the plasmid pSV₂neoEJ, containing a 6.6 kb genomic Bam HI fragment of the c-Ha-Ras oncogene with a G to T mutation in codon 12 (21), and the plasmid pSV₂neoCO, containing the 6.6 genomic Bam HI fragment of the c-Ha-Ras proto oncogene (22), were a kind gift of Prof.Dr. Cerutti (Swiss Institute for Experimental Cancer Research, CH-1066 Epalinges, Switzerland). Plasmids were isolated by the alkaline lysis method (23) and further purified by precipitation with 7.5 M ammoniumacetate (NH₄Ac).

For transfection, 5 µg of plasmid DNA was coprecipitated with calciumphosphate according to the protocol of Graham and van der Eb (24), with the modifications described by Chen and Okayama (25). The addition of the plasmid/calciumchloride mixture to N,N-bis(2-hydroxyethyl)-2-aminoethane-sulfonic acid buffered saline was carried out in continuous airflow. It was added to 2x10⁵ exponential growing Caco-2 cells in a 75 cm² culture flask with 10 ml medium. After two days, the cells were trypsinized and plated into 96-well plates, where selection was started by adding 800 µg/ml of gentamycin (G418, GIBCO, Paisley, Scotland) to the culture medium. After three weeks, selection was completed. Only wells containing one colony were used for further experiments. In the present study, the clones Caco-2 EJ6 (containing pSV₂neoEJ), Caco-2 CO1 and Caco-2 CO2 (containing pSV₂neoCO), and Caco-2 D5 Neo (containing pSV₂neo), were used (Table 1).

6.2.3 Southern blot analysis

After lysis of cells with 1% (v/v) proteinase K (10 mg/ml) and 0.5% sodiumdodecylsulfate (SDS) (1 hr., 56°C), DNA was extracted with a mixture of phenol, chloroform and isoamylalcohol (25:24:1 v/v), followed by chloroform and isoamylalcohol (24:1 v/v), and precipitated with isopropanol and 0.1 M sodiumacetate (NaAc). The pellet was washed with 70% ethanol, suspended in TE buffer (10 mM Tris pH 7.4, 0.1 mM ethylenediaminetetraacetic acid (EDTA)) and stored at 4°C.

Bam HI digested DNA was size-fractionated by overnight electrophoresis at 23V in 0.7% agarose gel in TAE buffer (0.04 M Tris-acetate, 0.001 M EDTA) and transferred to Hybond N+ filters by overnight blotting (RT). Filters were neutralized (30 sec. in 2xSSC, 0.5 M Tris-HCl, pH 7.4) and dried at RT.

Filters were prehybridized (overnight, 42°C) in 40% formamide, 1 M sodiumchloride (NaCl), 0.05 M sodiumphosphate, 1% SDS, 10% dextranulphate and 0.1 mg/ml denatured salmon sperm DNA. A 3 kb Sac I fragment containing the four coding

regions of the c-Ha-Ras gene was radiolabeled with ^{32}P by the random primer method (26,27), and added to the hybridization mixture. Hybridization took place overnight at 42°C . Washing steps were $2\times\text{SSC}$ ($2\times 5'$, RT), $0.1\times\text{SSC}$ and 1% SDS ($2\times 15'$, 60°C) and $2\times\text{SSC}$ ($2\times 15'$, RT). The filters were exposed to Kodak-XAR film, at -70°C with an Ilford intensifying screen.

6.2.4 Northern blot analysis

RNA was extracted with the cesiumchloride gradient method after lysing cells in a 4 M guanidinium thiocyanate solution, and precipitated with 96% ethanol/30 mM NaAc. RNA was size-fractionated by electrophoresis (3 hrs., RT) at 100V in 1% agarose/6% formaldehyde gel and transferred to Hybond N+ filters by overnight blotting.

Ras mRNA expression was detected using the same probe as in Southern blot analysis. Parallel hybridization for β actin mRNA was performed as an internal standard for the total amount of RNA, with a 1.3 kb cDNA probe (courtesy of Dr. T. Berkvens, University of Leiden). The Northern blots were prehybridized overnight at 42°C in 50% formamide, 1% SDS, 1M NaCl, 10% dextran sulphate and 0.1mg/ml denatured salmon sperm DNA. For hybridization, denatured Ras and β actin probes, radiolabeled with ^{32}P by the random primer method, were added to the hybridization mixture. After overnight incubation (42°C), the filters were washed in $2\times\text{SSC}$ ($2\times 5'$, RT), $2\times\text{SSC}$ and 1% SDS ($2\times 15'$, 60°C) and 0.1 SSC ($2\times 15'$, RT). Exposure of the filters was as described.

6.2.5 Cell culture

Cells were cultured at 37°C in a humidified atmosphere with 5% CO_2 . The medium consisted of Dulbecco's modified Eagles' minimal essential medium (DMEM, Flow Laboratories, Zwanenburg, The Netherlands), supplemented with 10% fetal bovine serum (FBS, Boehringer, Mannheim, FRG). Caco-2 EJ6 cells were maintained in selective medium containing 800 $\mu\text{g/ml}$ gentamycin.

Induction of endocrine differentiation in Caco-2 cells was attempted by supplementing the medium with glucose (final concentration 25 mM), sodium butyrate (NaBT, 2 mM), dimethylsulfoxide (DMSO, 2% v/v), or retinoic acid (RA, 35 μM). Cells were also cultured in serum free medium and in glucose free medium supplemented with 2.5 mM inosine. (DMSO was obtained from Merck, Darmstadt, FRG; all other chemicals from Sigma, St. Louis, USA).

Furthermore, both Caco-2 and Caco-2 EJ6 cells were cultured in serumfree, defined medium (DMEM with 50 nM hydrocortisone, 5 $\mu\text{g/ml}$ insulin, 5 $\mu\text{g/ml}$ transferrin, 5 nM sodiumselenite, 100 μM ethanolamine, 1 μM putrescine, 4 μM spermidine, 4 μM spermine and 0.1% bovine serum albumin (BSA)) in the presence or absence of basic fibroblast growth factor (bFGF, 10 ng/ml) and transforming growth factor β (TGFB, 1 ng/ml). Several modifications of the culturing substrate were tested for their capacity to induce endocrine differentiation. Cells were cultured on amnion membranes, prepared as described previously (28), on feeder layers of two types of human fibroblasts (adult fibroblasts, explanted from dermis of human skin obtained at autopsy, and embryonal

fibroblasts, purchased from the ATCC), and in two types of artificial extracellular matrix gels. Vitrogen 100 was purchased from the Collagen Corporation (Palo Alto, CA., USA), and basement membrane Matrigel from Collaborative Research Incorporated (Bedford, Mass., USA).

6.2.6 In vivo studies

For the xenografting experiments, immunodeficient female CD nu/nu mice (Charles River Wiga, Sulzfeld, FRG) aged 3-5 weeks, were inoculated subcutaneously (s.c.) with suspensions of $3\text{-}5 \times 10^6$ single tumor cells in phosphate buffered saline (PBS), obtained by gentle trypsinization (0.25% trypsin, DIFCO, Detroit, Mich., USA) at 37°C.

To enhance the take rate, s.c. injection of single tumor cell suspensions in soluble Vitrogen 100, or s.c. implantation of Vitrogen 100 gels containing 0.5×10^6 tumor cells cultured for 5 days (12) were attempted. Furthermore, animals were injected intraperitoneally every fifth day with 0.5 mg of polyclonal antibody against asialo GMI (α ASGM1, Wako Chemicals GmbH, Neuss, FRG), to eliminate natural killer (NK) cell activity (Table 2).

6.2.7 Cell and tissue processing

Cells were harvested by gentle scraping. After washing twice in icecold PBS, cells were immersed (3 hrs., 4°C) in fixative containing ethanol (100%), formalin (36%) and glacial acetic acid (97%) (15:14:1 v/v) or in ethanol 70%. Cells were resuspended in 4% agarose gel prior to routine tissue processing and paraffin embedding. Cells grown in Vitrogen 100 or basement membrane Matrigel and nude mouse xenografts were fixed and processed similarly. Xenografts were additionally snap frozen in liquid isopentane cooled to -70°C.

6.2.8 Histochemistry and immunohistochemistry

Paraffin sections (4 μ m) were screened for endocrine differentiation by combined histochemical staining for argyrophilia (Grimelius technique) and immunohistochemical staining with a monoclonal antibody against human chromogranin A (LK2H10, Hybritech, San Diego, CA., USA). For the latter, a standard indirect peroxidase labeled antibody technique was applied as was previously reported (29).

Phenotypical characterization of xenografts of Caco-2 and Caco-2 EJ6 was designed to identify the various intestinal epithelial cell lineages and to establish the neurohormonal profile of the endocrine lineage. The histochemical staining methods and the applied antibodies for immunohistochemistry are listed in Table 1. Immunohistochemical staining results were evaluated with appropriate positive and negative controls.

Table 1. Applied staining techniques.**Histochemistry**

Grimelius, Periodic-acid Schiff (PAS, with/without diastase pretreatment), Alcian Blue (pH 2.4), High-Iron-Diamine Alcian Blue (HID-AB)

Applied Antibodies (nature, source, type, dilution)**I. Intestinal Differentiation Markers**

-Enterocytes	Sucrase-Isomaltase*	HBB2/614/88-mc-1:16000
	Secretory Component	DAKO-pc-1:1000
-Goblet cells	Mucin (Parlam 3/9, 13)	own lab-mc-1:1000/2000
-Endocrine cells	Chromogranin A	Hybritech-mc-1:12500
	Chromogranin A/B	Milab-pc-1:2560
	Synaptophysin	Progen-mc-1:500
	NSE	DAKO-pc-1:1000
	Leu-7	BD-mc-1:50
	EGC	Milab-pc-1:400
-Paneth cells	Lysozyme	DAKO-pc-1:2500
-General marker	CEA (Parlam 4)	own lab-mc-1:1000

II. Hormonal Profile

-Gastrointestinal-Colon	Serotonin (5-HT)	own lab-pc-1:2000
	Somatostatin	own lab-pc-1:1500
	Glicentin	ED-pc-1:200
	Substance P	Milab-pc-1:600
	PYY	ED-pc-1:50
-Gastrointestinal-Other	Gastrin	own lab-pc-1:250
	Bombesin	ICN-pc-1:10000
	Insulin	own lab-pc-1:1500
	Glucagon	own lab-pc-1:500
	Pancreas Polypeptide	own lab-pc-1:250
	Neurotensin	Amersham-pc-1:2000
-Extra-intestinal	BHCG	DAKO-pc-1:2000
	α HCG	own lab-pc-1:3000
	ACTH	own lab-pc-1:100
	Growth Hormone	Progen-pc-1:8000

III. 2nd Antibodies

Swine-anti-rabbit	DAKO-1:150
Rabbit-anti-mouse	DAKO-1:200

*Generous gift of Dr. H.P. Hauri, Biozentrum der Universität, Basel, CH.

6.2.9 Electron microscopy

Tissues were fixed for 2 hours in 2.5% buffered glutaraldehyde, postfixed during 1 hour in 1.0% osmiumtetroxide (both in 0.1 M phosphate buffer), dehydrated in graded ethanol series and embedded in Epon. Ultrathin sections were stained with uranyl acetate and lead citrate.

6.2.10 Receptor assay

The presence of somatostatin receptors was determined on cultured Caco-2 and Caco-2 EJ6 cells. For this purpose, ^{125}I labeled octreotide (a long acting somatostatin analogue), with a tyrosine residue at position 3, was used (^{125}I -Tyr3-octreotide, courtesy of Prof.Dr. S.W.J. Lamberts, Dept. of Internal Medicine, Erasmus University, Rotterdam). Briefly, 5×10^5 tumor cells were seeded in a 6-well tissue culture dish and cultured for 3 days under standard conditions. After washing in PBS, the cells were incubated (2hrs., RT) with 400 μl of receptor stabilizing buffer (170 mM Tris, 5 mM MgCl_2 , 10 $\mu\text{g}/\text{ml}$ bacitracin, 1% BSA, pH 7.4) containing 1 nM radiolabeled ligand with or without a 5000-fold excess of unlabeled competitor (somatostatin-14). After washing steps (2x receptor stabilizing buffer, 1x PBS) the cells were trypsinized and again washed in PBS. Radioactivity was determined with a τ -counter. The receptor content was calculated from the amount of specifically bound radioligand, and expressed as the number of binding sites per cell.

6.2.11 Quantification and statistical analysis of endocrine cells

The number of endocrine cells in xenografts of Caco-2 and Caco-2 EJ6 was assessed by counting immunoreactive tumor cells in 4 μm thick sections of xenografts immunostained for chromogranin A. The density of endocrine cells was expressed per mm^2 surface area of tumor. Using a gridded eyepiece, at a magnification of 312.5x, 30 contiguous random fields of tumor were scored, representing a total surface area of 120 mm^2 per tumor ($n=3$ for both cell lines). Scores were statistically compared by t-tests for independent groups with separate variances.

6.3 RESULTS

6.3.1 Caco-2 cells

In vitro Caco-2 cells grew in monolayers of columnar cells with formation of domes (Fig. 1). In extracellular matrix gels glandular structures lined by flattened or cuboidal cells were formed (Fig. 2). In vitro, endocrine differentiation was not observed in Caco-2 cells. None of the applied tissue culture modifications induced endocrine differentiation.

Figure 1. Phase-contrast micrographs of Caco-2 cells in vitro.

Cells grown as confluent monolayers form domes. **A.** Focussed on the monolayer. **B.** Focussed on the surface of the dome. Caco-2 EJ6 shows identical morphology in vitro; *bar* = 120 μ m.

Figure 2. Three dimensional growth of Caco-2 EJ6 in Matrigel.

Cells are arranged in glandular formations lined by columnar cells. The same growth pattern was observed for Caco-2 cells. H&E, *bar* = 25 μ m.

Under standard xenografting conditions Caco-2 cells did not yield tumors (Table 2). The tumor take rate could be increased by inoculating Caco-2 cells in soluble Vitrogen 100 or as solid Vitrogen 100 collagen gels. Treatment of the animals with an antibody eliminating NK cell activity also improved the take rate. Xenografting of Caco-2 CO1

and Caco-2 CO2 cells (containing the wild type Ras oncogene) and of Caco-2 D5 Neo cells (containing the empty plasmid) did not result in tumor growth under standard conditions. The tumors obtained after xenografting Caco-2 cells were moderately-well differentiated adenocarcinomas with expansive growth, without evidence of invasion (Fig. 3).

Table 2. Tumor take rate upon xenografting under various conditions.

Cell line	Standard conditions	Vitrogen 100 gel	Vitrogen 100 soluble	Vitrogen + α ASGM1
Caco-2	0/8	3/3 (12)	1/1 (19)	2/2 (2)
Caco-2 EJ6	14/14 (4)	3/3 (4)	1/1 (5)	1/1 (2)
Caco-2 CO1	0/2	n.t.	n.t.	n.t.
Caco-2 CO2	0/2	n.t.	n.t.	n.t.
Caco-2 D5 Neo	0/3	n.t.	n.t.	n.t.

No. of animals with tumors obtained per total no. of animals inoculated; the latency time in weeks is indicated between brackets; n.t. = not tested.

Figure 3. Subcutaneous xenograft of Caco-2 EJ6 in nude mouse.

The histological pattern is representative for both native and transfected cells and shows a moderately well-differentiated adenocarcinoma with expansive growth, not invading neighbouring skeletal muscle. H&E, bar = 100 μ m.

6.3.2 Caco-2 EJ6 cells

Of the cell lines obtained after transfection of Caco-2 cells with point mutated c-Ha-Ras, Caco-2 EJ6 cells showed the highest level of Ras expression, and therefore these cells were further characterized. Southern blot analysis confirmed the integration of

Fig. 4. Integration and expression of pSV₂neoEJ in Caco-2 cells.
A. Southern blot. Lane 1. Caco-2; 2. Caco-2 EJ6; 3. Caco-2 EJ7; 4. Caco-2 EJ8. Chromosomal DNA was digested with Bam HI and hybridized with the 3.0 Sac I fragment of the c-Ha-ras gene. The 6.6 kb Bam HI fragment of pSV₂neoEJ in Caco-2 EJ6 can be distinguished from the endogenous 8.6 kb Bam HI fragment of Caco-2. B. Northern blot. Lane 1. Caco-2, 2; Caco-2 EJ6.

Figure 5. Enterocytic differentiation in vivo.
A. Frozen section of Caco-2 EJ6 xenograft showing apical luminal staining for the brush-border associated hydrolase sucrase-isomaltase. B. Caco-2 xenograft with focal cytoplasmic and apical staining of columnar cells for secretory component (arrows). Indirect immunoperoxidases with DAB; bars = 25 μ m.

the point mutated Ras oncogene (Fig. 4A). By Northern blot analysis, expression of c-Ha-Ras mRNA was clearly increased compared with normal Caco-2 cells (Fig. 4B). Caco-2 EJ6 cells in vitro were morphologically identical to native Caco-2 cells, and did not show endocrine differentiation either. As in Caco-2, the applied tissue culture variants did not induce endocrine differentiation in vitro.

In all xenografting conditions, except treatment with the α ASGM1 antibody, the growth properties of Caco-2 EJ6 were more favorable (higher take rate or shorter latency) than of untransfected Caco-2 (Table 2). Histologically, xenografts were identical to Caco-2 tumors, displaying the morphology of moderately well differentiated adenocarcinomas. Invasion was not observed. Cells representative of all intestinal cell lineages were present in xenografts from both the native and transfected cell line. Enterocytic differentiation in vivo was reflected in brush-border staining for sucrase-isomaltase and plasma membrane or cytoplasmic staining for secretory component (Fig. 5).

Both neutral (PAS staining after diastase pretreatment) and acid (Alcian Blue, pH 2.4) mucopolysaccharides could be demonstrated (Fig. 6). The HID-AB stains showed a combination of sulfo- and sialomucins. Immunohistochemically, the tumors showed reactivity for various mucin-associated antibodies. Both expression of Parlam 3/9, identifying a protein moiety of glycoproteins present in normal goblet cells, and of Parlam 13, identifying a carbohydrate epitope in glycoproteins increasingly expressed in neoplastic colonic epithelium (30), were found (Fig. 6).

Endocrine differentiation in Caco-2 EJ6 as well as Caco-2 xenografts was reflected in positive staining for several general neuroendocrine markers (Grimelius, chromogranin A, chromogranin A/B, synaptophysin, NSE) (Fig. 6). Variable numbers of endocrine cells were found, scattered between the other cells. No significant increase in the number of endocrine cells was noted in Caco-2 EJ6. (Endocrine cell density $2.04/\text{mm}^2$ (s.e.m. 0.42) for Caco-2 EJ6 vs. $1.76/\text{mm}^2$ (s.e.m. 1.10) for Caco-2; $p=0.83$). Most endocrine cells were located peripherally in the tumor lobules, in direct contact with the extracellular matrix (Fig. 6 and Fig. 7A). Ultrastructurally, a well formed basal lamina was present at the epithelial-stromal interface (Fig. 7B). Complete loss of endocrine differentiation occurred within three passages when Caco-2 EJ6 tumor xenografts were explanted in vitro. Endocrine differentiation was restored upon renewed xenografting of the cultured cells. This effect was consistently seen in both early and late in vitro passages of Caco-2 EJ6. Because of the difficulties in xenografting, these experiments were not performed for Caco-2.

The neurohormonal profile of the endocrine cells in Caco-2 EJ6 and Caco-2 was restricted to somatostatin (Fig. 6) and PYY, which both occur in normal colonic enteroendocrine cells (31,32). Other colorectal endocrine secretory products (5-HT, glicentin, substance-P) were not identified. Focal expression of α HCG was found. Neither hormone production indigenous to other gastrointestinal sites (gastrin, bombesin, neurotensin, glucagon, insulin, pancreatic polypeptide), nor ectopic hormone production (ACTH, growth hormone) were found. Both Caco-2 and Caco-2 EJ6 in vitro

Figure 6 A-H. Mucin production and endocrine differentiation in subcutaneous xenografts of both Caco-2 and Caco-2 EJ6.

A. Neutral mucopolysaccharides (PAS after diastase pretreatment) B. Acid mucopolysaccharides (Alcian Blue, pH 2.4) C. Sulfomucins (white arrows) and sialomucins (black arrows) (HID-AB) D. Goblet cell mucin glycoproteins (Parlun 3/9) E, F. Endocrine cells, peripherally in tumor lobules, in contact with stroma (s); Grimelius (E) and chromogranin A (F) G. Neuron specific enolase H. Focal immunoreactivity for somatostatin. Arrows indicate immunoreactivity; bar in C, 56 = μm ; all other bars = 28 μm .

Figure 7. Ultrastructural morphology of Caco-2 EJ6 xenograft.
A. Endocrine cell containing neurosecretory granules (arrow) in contact with extracellular matrix (s); *bar* = 2.3 μm . B. Well-developed basal lamina (arrows) at the interface of stroma (s) and tumor cells, of which one contains dense core granules; *bar* = 490 nm.

Figure 8. Cluster of Caco-2 cells with Paneth cell differentiation.
Lysozyme; *bar* = 25 μm .

demonstrated specific binding of the long-acting somatostatin analogue octreotide, with approximately 1900 and 800 binding sites per cell, respectively.

In addition to expression of markers for the three normal colorectal cell lineages, Paneth cell differentiation (lysozyme) (Fig. 8) and CEA production (Parlam 4)(33) (Fig. 9) were found.

Figure 9. Intraluminal staining for CEA in a xenograft of Caco-2.

Parlam 4; bar = 25 μ m.

6.4 DISCUSSION

The colon adenocarcinoma cell line Caco-2 in vitro forms monolayers of polarized enterocyte-like cells with tight junctions, well developed brush-border-membranes with associated hydrolases (34), and domes (35). The cell line has been frequently applied as a model to explore intestinal physiology and pathology, e.g. secretory processes (36); uptake and transport of electrolytes (37), nutrients (38-43) and drugs (44); activity, transport and organization of small and large intestinal enzymes (45-48); and intestinal infections (49-51). Under standard conditions in vitro, we did not find endocrine differentiation in Caco-2 cells. However, in xenografts, which only could be attained by inoculating tumor cells in collagen gel or by suppressing NK cell activity in recipient animals, large numbers of endocrine cells could be demonstrated. To our knowledge, endocrine differentiation has not been previously recorded in Caco-2 cells. In view of the difficulty encountered in obtaining Caco-2 xenografts, we decided to transfect Caco-2 cells with a point mutated c-Ha-Ras gene, because of the reported association between overexpression of the point mutated c-Ha-Ras gene and tumor progression (15-17). Furthermore, these experiments would allow us to test whether or not overexpression of a

point mutated Ras gene might induce or enhance endocrine differentiation. The latter question derived from experiments by Nakagawa et al. (18) and Mabry et al. (19), who demonstrated enhanced endocrine differentiation in medullary thyroid carcinoma cells and in small cell lung cancer cells respectively after transfection with v-Ha-Ras. After transfection and selection a cell line was obtained which showed overexpression of the c-Ha-Ras oncogene at the mRNA level: Caco-2 EJ6. This cell line showed improved growth *in vivo*: co-injection of extracellular matrix components was not necessary and the latency period was considerably shorter than that of Caco-2 cells.

We consider the improved take rate to be a result of the overexpression of the point mutated Ha-Ras oncogene and not the result of the transfection procedure, because xenografting of cells transfected with the wild type oncogene or the empty plasmid did not result in tumor formation under standard conditions.

In xenografts of Caco-2 and Caco-2 EJ6 endocrine differentiation occurred to a similar extent. Evidently, the potential for endocrine differentiation was not enhanced by overexpression of the c-Ha-ras oncogene. This finding supports an earlier report indicating that there is no correlation between increased Ras oncogene expression and endocrine differentiation in colonic neoplasms (52). The hormonal profile in both cell lines was identical and corresponded with hormone expression of normal colonic endocrine cells. In both cell lines endocrine cells produced immunohistochemically detectable somatostatin and specific somatostatin binding sites were found. Inhibition of growth of a colorectal adenocarcinoma cell line by somatostatin has been reported (53). This makes Caco-2 and Caco-2 EJ6 cells of potential interest to study autocrine or paracrine regulation of colorectal tumor growth.

On the basis of our observations we hypothesize that in Caco-2 and Caco-2 EJ6 cells, stromal factors in xenografts induce the endocrine phenotype, as has been observed for HRA-19 and NCI-H716 cells. Circumstantial evidence in favor of this hypothesis can be summarized as follows. Firstly, endocrine cells were found preferentially at the periphery of tumor lobules, apposed to the extracellular matrix, with a well developed basal lamina at the interface. Secondly, *in vitro* cell cultures of Caco-EJ6 xenografts indicate that endocrine differentiation *in vivo* is most likely a matter of differentiation induction and not of selection, because endocrine cells rapidly disappeared *in vitro* but reappeared when cells were again xenografted in nude mice. However, it is unclear which stromal components are involved. In preliminary experiments we were unable to induce endocrine differentiation *in vitro* by specific extracellular matrix components, which have been shown to enhance endocrine differentiation *in vitro* in NCI-H716 cells. The ability to induce endocrine differentiation *in vitro* therefore might depend on the level of differentiation of the cell line under investigation, because Caco-2 cells in this respect resemble HRA-19 cells, which also display a moderately well differentiated phenotype and do not show endocrine features *in vitro* either.

In conclusion, we have shown that endocrine differentiation occurs in xenografts of Caco-2 cells. Endocrine differentiation is not enhanced by overexpression of the c-Ha-Ras oncogene. Growth properties *in vivo*, however, are improved by overexpression of

a (transfected) c-Ha-Ras oncogene. The obtained cell line, Caco-2 EJ6, is a useful addition to the available colorectal cancer cell lines in which endocrine differentiation can be induced in vivo and/or in vitro.

6.5 REFERENCES

1. Oberndorfer S: **Über die kleinen Dunndarmcarcinome.** Verh. Dtsch. Ges. Path. 1907; 11: 113-116.
2. Damjanov I, Amenta PS, Bosman FT: **Undifferentiated carcinoma of the colon containing exocrine, neuroendocrine and squamous cells.** Virchows. Arch. A. 1983; 401: 57-66.
3. Redman BG, Pazdur R: **Colonic small cell undifferentiated carcinoma: a distinct pathological diagnosis with therapeutic implications.** Am. J. Gastroenterol. 1987; 82: 382-385.
4. Bosman FT, de Bruine A: **Endocrine cells in non-endocrine tumors of the gut and pancreas.** In: Dayal Y, ed. Endocrine pathology of the gut and pancreas. Boca Raton Ann Arbor Boston: CRC Press, 1991:319-338.
5. Ho SB, Itzkowitz SH, Frieri AM, Jiang SH, Kim YS: **Cell lineage markers in premalignant and malignant colonic mucosa.** Gastroenterology 1989; 97: 392-404.
6. Arends JW, Wiggers T, Verstijnen K, Bosman FT: **The occurrence and clinicopathological significance of serotonin immunoreactive cells in large bowel carcinoma.** J. Pathol. 1986; 149: 97-102.
7. Jansson D, Gould VE, Gooch GT, *et al*: **Immunohistochemical analysis of colon carcinomas applying exocrine and neuroendocrine markers.** Apmis. 1988; 96: 1129-1139.
8. Johnson LR: **Regulation of gastrointestinal mucosal growth.** Physiol. Rev. 1988; 68: 456-502.
9. Hoosein NM, Kiener PA, Curry RC, Brattain MG: **Evidence for autocrine growth stimulation of cultured colon tumor cells by a gastrin/cholecystokinin-like peptide.** Exp. Cell. Res. 1990; 186: 15-21.
10. Kirkland SC: **Endocrine differentiation by a human rectal adenocarcinoma cell line (HRA-19).** Differentiation. 1986; 33: 148-155.
11. de-Bruïne AP, Dinjens WN, Pijls MM, *et al*: **NCI-H716 cells as a model for endocrine differentiation in colorectal cancer.** Virchows. Arch. B. Cell. Pathol. 1992; 62: 311-320.
12. Del-Buono R, Pignatelli M, Hall PA: **Control of differentiation in a rectal adenocarcinoma cell line: the role of diffusable and cell-associated factors.** J. Pathol. 1991; 164: 59-66.
13. de-Bruïne AP, Dinjens WNM, van der Linden EPM, *et al*: **Extracellular matrix components induce endocrine differentiation in vitro in NCI-H716 cells.** Am. J. Pathol. 1993; 142: 773-782.
14. Rousset M: **The human colon carcinoma cell lines HT-29 and Caco-2: two in vitro models for the study of intestinal differentiation.** Biochimie. 1986; 68: 1035-1040.
15. Fearon ER, Vogelstein B: **A genetic model for colorectal tumorigenesis.** Cell. 1990; 61: 759-767.
16. Muschel RJ, Williams JE, Lowy DR, Liotta LA: **Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell.** Am. J. Pathol. 1985; 121: 1-8.
17. Lebeau J, Le-Chalony C, Prosperi MT, Goubin G: **Constitutive overexpression of a 89 kDa heat shock protein gene in the HBL100 human mammary cell line converted to a tumorigenic phenotype by the EJ/T24 Harvey-ras oncogene.** Oncogene. 1991; 6: 1125-1132.
18. Nakagawa T, Mabry M, de-Bustros A, Ihle JN, Nelkin BD, Baylin SB: **Introduction of v-Ha-ras oncogene induces differentiation of cultured human medullary thyroid carcinoma cells.** Proc. Natl. Acad. Sci. U. S. A. 1987; 84: 5923-5927.

19. Mabry M, Nakagawa T, Baylin S, Pettengill O, Sorenson G, Nelkin B: **Insertion of the c-Ha-ras oncogene induces differentiation of calcitonin-producing human small cell lung cancer.** J. Clin. Invest. 1989; 84: 194-199.
20. Southern PJ, Berg P: **Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.** J. Mol. Appl. Genet. 1982; 1: 327-341.
21. Capon DJ, Chen EY, Levinson AD, Seeburg PH, Goeddel DV: **Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue.** Nature. 1983; 302: 33-37.
22. Parada LF, Tabin CJ, Shih C, Weinberg RA: **Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene.** Nature. 1982; 297: 474-478.
23. Sambrook J, Fritsch EF, Maniatis T: **Molecular cloning.** second ed. New York: Cold Spring Harbor Laboratory Press, 1989.
24. Graham FL, van der Eb AJ: **A new technique for the assay of infectivity of human adenovirus 5 DNA.** Virology 1973; 52: 456-467.
25. Chen C, Okayama H: **High-efficiency transformation of mammalian cells by plasmid DNA.** Mol. Cell. Biol. 1987; 7: 2745-2752.
26. Feinberg AP, Vogelstein B: **"A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum.** Anal. Biochem. 1984; 137: 266-267.
27. Moerkerk PT, Kessels HJ, ten-Kate J, de-Goeij AF, Bosman FT: **Southern and dot blot analysis of DNA from formalin-fixed, paraffin-embedded tissue samples from colonic carcinomas.** Virchows. Arch. B. Cell. Pathol. 1990; 58: 351-355.
28. Liotta LA, Lee CW, Morakis DJ: **New method for preparing large surfaces of intact human basement membrane for tumor invasion studies.** Cancer. Lett. 1980; 11: 141-152.
29. Dinjens WN, Ten-Kate J, Kirch JA, *et al*: **Adenosine deaminase complexing protein (ADCP) expression and metastatic potential in prostatic adenocarcinomas.** J. Pathol. 1990; 160: 195-201.
30. Verstijnen CPHJ, Arends JW, Moerkerk PTM, Pijls M, Kuypers-Engelen B, Bosman FT: **Colonic epithelium reactive monoclonal antibodies. Identification and immunohistochemical localization of the target epitopes.** Histochemistry. 1989; 92: 397-406.
31. Sjolund K, Sanden G, Hakanson R, Sundler F: **Endocrine cells in human intestine: an immunocytochemical study.** Gastroenterology 1983; 85: 1120-1130.
32. Sundler F, Bottcher G, Ekblad E, Hakanson R: **The neuroendocrine system of the gut.** Acta. Oncol. 1989; 28: 303-314.
33. Verstijnen CP, Arends JW, Moerkerk PT, Warnaar S, Hilgers J, Bosman FT: **CEA-specificity of CEA-reactive monoclonal antibodies. Immunochemical and immunocytochemical studies.** Anticancer. Res. 1986; 6: 97-104.
34. Yoshioka M, Erickson RH, Matsumoto H, Gum E, Kim YS: **Expression of dipeptidyl aminopeptidase IV during enterocytic differentiation of human colon cancer (Caco-2) cells.** Int. J. Cancer. 1991; 47: 916-921.
35. Ramond MJ, Martinot-Peignoux M, Erlinger S: **Dome formation in the human colon carcinoma cell line Caco-2 in culture. Influence of ouabain and permeable supports.** Biol. Cell. 1985; 54: 89-92.
36. Chang EB, Bookstein C, Vaandrager A, DeJonge HR, Buse J, Musch MW: **Cystic fibrosis transmembrane regulator mRNA expression relative to ion-nutrient transport in spontaneously differentiating human intestinal CaCo-2 epithelial cells.** J. Lab. Clin. Med. 1991; 118: 377-381.

37. Watson AJ, Levine S, Donowitz M, Montrose MH: **Kinetics and regulation of a polarized Na(+)-H+ exchanger from Caco-2 cells, a human intestinal cell line.** *Am. J. Physiol.* 1991; 261: G229-G238.
38. Heyman M, Crain-Denoyelle AM, Nath SK, Desjeux JF: **Quantification of protein transcytosis in the human colon carcinoma cell line CaCo-2.** *J. Cell. Physiol.* 1990; 143: 391-395.
39. Field FJ, Albright E, Mathur S: **Inhibition of acylcoenzyme A: cholesterol acyltransferase activity by PD128042: effect on cholesterol metabolism and secretion in CaCo-2 cells.** *Lipids.* 1991; 26: 1-8.
40. Mason JB, Shoda R, Haskell M, Selhub J, Rosenberg IH: **Carrier affinity as a mechanism for the pH-dependence of folate transport in the small intestine.** *Biochim. Biophys. Acta.* 1990; 1024: 331-335.
41. Riley SA, Warhurst G, Crowe PT, Turnberg LA: **Active hexose transport across cultured human Caco-2 cells: characterisation and influence of culture conditions.** *Biochim. Biophys. Acta.* 1991; 1066: 175-182.
42. Smith TK, Gibson CL, Howlin BJ, Pratt JM: **Active transport of amino acids by gamma-glutamyl transpeptidase through Caco-2 cell monolayers.** *Biochem. Biophys. Res. Commun.* 1991; 178: 1028-1035.
43. Trotter PJ, Storch J: **Fatty acid uptake and metabolism in a human intestinal cell line (Caco-2): comparison of apical and basolateral incubation.** *J. Lipid. Res.* 1991; 32: 293-304.
44. Hilgers AR, Conradi RA, Burton PS: **Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa.** *Pharm. Res.* 1990; 7: 902-910.
45. Jumarie C, Malo C: **Caco-2 cells cultured in serum-free medium as a model for the study of enterocytic differentiation in vitro.** *J. Cell. Physiol.* 1991; 149: 24-33.
46. Klumperman J, Boekstijn JC, Mulder AM, Franssen JA, Ginsel LA: **Intracellular localization and endocytosis of brush border enzymes in the enterocyte-like cell line Caco-2.** *Eur. J. Cell. Biol.* 1991; 54: 76-84.
47. Malagolini N, Dall'Olio F, Serafini-Cessi F: **UDP-GalNAc:NeuAc alpha 2,3Gal beta-R (GalNAc to Gal) beta 1,4-N-acetylgalactosaminyltransferase responsible for the Sda specificity in human colon carcinoma CaCo-2 cell line.** *Biochem. Biophys. Res. Commun.* 1991; 180: 681-686.
48. Matter K, Stieger B, Klumperman J, Ginsel L, Hauri HP: **Endocytosis, recycling, and lysosomal delivery of brush border hydrolases in cultured human intestinal epithelial cells (Caco-2).** *J. Biol. Chem.* 1990; 265: 3503-3512.
49. Darfeuille-Michaud A, Aubel D, Chauviere G, *et al*: **Adhesion of enterotoxigenic Escherichia coli to the human colon carcinoma cell line Caco-2 in culture.** *Infect. Immun.* 1990; 58: 893-902.
50. Rigotherier MC, Coconnier MH, Servin AL, Gayral P: **A new in vitro model of Entamoeba histolytica adhesion, using the human colon carcinoma cell line Caco-2: scanning electron microscopic study.** *Infect. Immun.* 1991; 59: 4142-4146.
51. Svensson L, Finlay BB, Bass D, von-Bonsdorff CH, Greenberg HB: **Symmetric infection of rotavirus on polarized human intestinal epithelial (Caco-2) cells.** *J. Virol.* 1991; 65: 4190-4197.
52. Jansson DS, Radosevich JA, Carney WP, *et al*: **An immunohistochemical analysis of ras oncogene expression in epithelial neoplasms of the colon.** *Cancer.* 1990; 65: 1329-1337.
53. Smith JP, Solomon TE: **Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer.** *Gastroenterology* 1988; 95: 1541-1548.

CHAPTER 7

GENERAL DISCUSSION

7.1 INTRODUCTION

More insight in the mechanism(s) involved in metastasis of colorectal carcinoma cells might contribute to improved treatment of patients with colorectal cancer. To this effect relevant models must be employed to investigate the invasive and metastatic behavior of colorectal cancer. Orthotopic xenografting of human carcinoma cells in nude mice appears to be a promising model for the study of invasion and metastasis (1). We investigated whether or not this approach could be employed to study *in vivo* behavior of human colorectal carcinoma cells by xenografting these cells in the cecum of nude mice. Furthermore, it was investigated whether *in vitro* parameters, known to be involved in invasion and metastasis, predicted *in vivo* behavior of colorectal carcinoma cells.

Human colorectal carcinoma cell lines were selected, on account of their *in vivo* behavior in the cecum of nude mouse, to study progression in colorectal cancer by transfection experiments with the c-Ha-ras oncogene, which has been implicated in the carcinogenesis of and progression in colorectal carcinoma. The highly differentiated, poorly tumorigenic CaCo 2, and the undifferentiated, tumorigenic but non-invasive SW480 cell lines were chosen for this purpose. The association of tumor progression with karyotypic abnormalities prompted us to investigate the effects of transfection with the c-Ha-ras oncogene on the karyotype. Additionally, it was investigated whether or not changes were induced *in vitro* in cell functions, known to be involved in invasion and metastasis.

In this final chapter the results are briefly discussed in the context of the literature.

7.2 ORTHOTOPIC XENOGRAFTS: SUITABLE TO STUDY THE BEHAVIOR OF HUMAN COLORECTAL CARCINOMA CELLS?

Human tumor cells in nude mice may display metastatic behavior after orthotopic xenografting, e.g. the implantation of some human renal carcinoma cell lines in the kidney environment yields metastasizing tumors (1). Likewise xenografting of some human colorectal carcinoma cell lines in the wall of the cecum yields invasive and metastatic tumors (2). In contrast, we never observed metastases after xenografting human colorectal carcinoma cells in the subcutis, which suggests that local tissue factors may modulate the expression of genes responsible for invasion and metastasis. Proteases and cell adhesion molecules have been implicated in invasion and metastasis (3, 4), but in our model their expression *in vitro* did not predict malignant behavior *in vivo*, except for the expression of the $\alpha_2\beta_1$ integrin, which was found to be high in cells invasive *in vivo*. However, the number of proteins involved in invasion and metastasis is much larger than the limited set we have investigated. A recent example is CD44, which is a transmembrane receptor for extracellular matrix proteins and involved in homing of lymphocytes (5). A variant form of CD44 is expressed in colorectal neoplasia but not in normal colon tissue (6). This form confers metastatic

potential to rat carcinoma cells (7) and is expressed in metastatic human colorectal carcinoma HT29 cells, but not in non-metastatic SW620 cells (8). Therefore, additional parameters might be studied in the orthotopic xenograft model in order to further elucidate the mechanisms involved in metastasis.

A disadvantage in the use of cell lines may be that they are not fully representative of primary tumors and their metastases, because from only 30% of primary cancers, cell lines can be obtained (9). Further selection of cells may occur during in vitro culturing, implying that cells loose or acquire characteristics after prolonged culturing. Orthotopic grafting of tumor tissue fragments into nude mice may circumvent these disadvantages. The take rate improves to 60% by orthotopic grafting of fragments of intact colon cancer tissue (10). Moreover, orthotopic grafting of gastric cancer tumor tissue yielded xenografts with metastatic behavior, which closely correlated with the clinical course of the tumors in patients (11). However, a main restriction of model studies in nude mice is that effects of the immune system cannot be taken into account.

In conclusion, the mechanism(s) by which colorectal carcinoma cells metastasize can be studied with orthotopic xenografting of human colorectal carcinoma cell lines in nude mice. Further improvement is achieved by orthotopic grafting of intact primary tumor tissue.

7.3 GENETIC INSTABILITY IN COLORECTAL CARCINOMA: THE INFLUENCE OF THE c-HA-RAS ONCOGENE

Deviation of the DNA content from the diploid status to aneuploidy can be taken to indicate genetic instability. The incidence of aneuploidy, as measured by flow cytometry (12), is low (6%-27%) in colorectal adenomas and high (40%-70%) in colorectal carcinomas (13-16), which suggests that aneuploidy is a late phenomenon rather than a primary event in carcinogenesis. The clustering of high DNA-indices around a triploid- or tetraploid mode (12) suggests that aneuploidy may involve polyploidization with subsequent loss of chromosomes. Detailed cytogenetic analysis of short term cultures from colorectal carcinomas has shown two distinct types of karyotypic evolution (17). Most colorectal carcinomas demonstrated monosomy 17p and monosomy 18 along with additional monosomies due to either unbalanced rearrangements or additional losses of chromosomes. The other colorectal carcinomas demonstrated trisomies involving several chromosomes, most frequently trisomy 7, with either a monosomy 17p or a monosomy 18. The presence of trisomies also suggests involvement of polyploidization along the route to aneuploidy (17). The use of interphase cytogenetics (18) allows further elucidation of genetic abnormalities directly at the level of colorectal cancer tissue, thus avoiding bias induced by the culture of cancer cells before cytogenetic analysis. This approach confirmed that trisomy 7 is a frequently occurring phenomenon in colorectal cancer cells¹. A genetic model of colorectal carcinoma postulated a preferred order of genetic lesions, which included pointmutations in the p21^{ras} genes as early events in the adenoma stage, and monosomy 17p representing a late event in the carcinoma stage, the latter most likely

resulting in loss of one allele of the tumor suppressor gene p53 (19, 20). However, the total number of genetic lesions, rather than the order in which they accumulate, probably determines the biological properties of the tumor (20). This view is supported by the following observations; 1) Patients with multiple chromosomal abnormalities have a significantly shorter survival time than those with simple alterations (21); 2) Ki-ras pointmutation or p53 overexpression as single parameters does not correlate with survival in colorectal carcinoma, but together they predict a shorter survival time of patients (22).

The significantly higher presence of c-Ki-ras pointmutations in aneuploid colorectal carcinomas than in diploid colorectal carcinomas suggests that mutations in p21^{ras} proteins may be involved in the development of aneuploidy (23). This contention is supported by the increase in genetic instability observed in rat prostatic and mammary carcinoma cells and in our human colorectal carcinoma SW480 cells after introduction of the c-Ha-ras oncogene (24-26). However, pointmutated p21^{ras} genes are not invariably associated with increased genetic instability, because the karyotype of human MSU1.1 fibroblasts did not change after transfection with pointmutated p21^{ras} genes (27-29). Thus, the recipient cell is an important determinant of the effect of the c-Ha-ras oncogene on the karyotype.

We observed loss and gain of chromosomes, translocations, and acquisition of new marker chromosomes in SW480 cells transfected with ras-containing plasmids, which gave each transfectant a unique karyotype (26). The reported site-specific integration of the c-Ha-ras oncogene in rat embryo fibroblasts (30) prompted us to localize the chromosomal integration sites of plasmid DNA in SW480 transfected cell lines. To that effect, we developed a procedure by which chromosome banding was induced by either hot banding or a short trypsin treatment followed by fluorescence in situ hybridization (FISH). This combination allowed rapid and detailed identification of chromosome integration sites (26, 31). These were not associated with specific chromosomal regions but ras-containing plasmids were frequently located in new aberrant chromosomes. Most integration sites in aberrant chromosomes involved telomeric bands and were located at the translocation breakpoint. Our findings suggest that the introduction of exogenous DNA may destabilize chromatin locally, leading to new chromosome rearrangements, with plasmid DNA at the rearranged site (26). This also seems to be a likely scenario after integration in telomeric regions, where disruption of the telomeric structure results in fusogenic chromosome ends (32, 33).

In conclusion, genetic alterations in p21^{ras} genes are probably early events in the development of colorectal carcinoma, may increase the genetic instability of the tumor cells, and thus induce aneuploidy.

7.4 THE ROLE OF THE c-HA-RAS ONCOGENE IN COLORECTAL CARCINOMA: EFFECTS ON GROWTH AND DIFFERENTIATION

The normal function of the c-Ha-ras gene may differ between cells, and its role in signal transduction may be related with proliferation as well as differentiation (34). To fully understand the role of the c-Ha-ras oncogene in carcinogenesis, the normal function of the c-Ha-ras gene must be elucidated.

Increased levels of GTP.p21^{ras} are found in cells stimulated by growth factors, such as insulin (35), EGF (36-38), and PDGF (39), which stimulate mitogenesis (40). Thus, cells may divide continuously, thereby incorporating genetic errors (41) and in that way increase the genetic instability, if the level of GTP.p21^{ras} is constitutively high. GTP.p21^{ras} levels are regulated by proteins which stimulate the intrinsic GTPase activity of the GTP.p21^{ras} protein. As yet, GAP (42) and NF1 (43) are prototypes of these proteins. NF1 is a tumor suppressor gene (43), inactive in patients with neurofibromatosis type 1 (44). Cell lines derived from neurofibromatosis type 1 patients have increased levels of GTP.p21^{ras} (45), which suggests that NF-1 downregulates GTP.p21^{ras} levels. Pointmutations in codons 12, 13, and 61 of the p21^{ras} genes render mutant p21^{ras} proteins inactive to the GTPase activating activity of GAP and NF-1 (42, 43, 46). Thus, pointmutations in p21^{ras} genes might enable cells to divide continuously, thereby abrogating normal regulation by the microenvironment, which confers growth autonomy. Reduced requirement for growth factors has indeed repeatedly been observed after transfection with the c-Ha-ras oncogene (27, 28, 47-53). Also, growth autonomy has been reported to be one of the requirements for a carcinoma cell to metastasize (54, 55). In line with a role for the c-Ha-ras oncogene in conferring growth autonomy is the increase in tumorigenic potential of CaCo 2 cells (56, 57). SW480 cells are tumorigenic by themselves. The fact that phenotypic alterations did not occur and invasive capacity was not acquired after transfection of SW480 cells with the c-Ha-ras oncogene might be taken as circumstantial evidence that pointmutated p21^{ras} genes do not have a role in tumor progression in colorectal carcinoma. However, bearing in mind that functional differences between p21^{ras} proteins might be lost upon mutation (58), the presence of a pointmutated c-Ki-ras gene in the genome of SW480 cells (59) could be an alternative explanation for the lack of phenotypic changes in c-Ha-ras oncogene transfected SW480 cells.

Tumor growth results from an imbalance between cell birth and cell death. Therefore, not only increased proliferation but also decreased cell death may cause tumor growth. One mechanism of cell death, programmed cell death or apoptosis, has recently attracted wide attention. It is a normal regulatory mechanism in development, as has been extensively demonstrated in *C. elegans* (60) and *Drosophila* (61). Also, the human immune system eliminates self-antigen recognizing cells by apoptosis, which is induced by glucocorticoids and is mediated by the glucocorticoid receptor (62). The mechanism of apoptosis has not been fully elucidated yet. An interesting aspect is the observation that GAP associates with a putative transcriptional repressor of the glucocorticoid receptor gene in mitogenically stimulated cells (63, 64). Downregulation of the glucocorticoid receptor gene by a pointmutated GTP.p21^{ras}.GAP complex might

thus inhibit apoptosis. This may be an alternative explanation for the tumor inducing effect of pointmutated c-Ha-ras genes.

A role for the c-Ha-ras oncogene in the induction of endocrine differentiation, observed in human medullary thyroid carcinoma and small cell lung carcinoma cells (65, 66), was not supported by our results with the CaCo 2 cell line (57). Whether or not CaCo 2 cells were transfected with the c-Ha-ras oncogene, endocrine differentiated cells were noted *in vivo*, specifically at the periphery of tumor lobules. However, endocrine differentiated cells were not observed *in vitro*, which emphasizes the importance of the microenvironment in the regulation of gene expression (57).

In conclusion, our results with CaCo 2 and SW480 cells support the hypothesis that pointmutations in the c-Ha-ras gene may confer growth autonomy to colorectal cancer cells, but do not support a role for the pointmutated c-Ha-ras gene in the acquisition of invasive and metastatic potential of colorectal cancer cells.

7.5 CONCLUSIONS

To increase the knowledge about the mechanism(s) by which colorectal carcinoma cells invade and metastasize, we investigated whether or not the orthotopic xenograft model could be applied. Our results are in agreement with other studies (67-69) and show that a subset of the colorectal carcinoma cell lines investigated are invasive and metastatic. Therefore, this model is relevant for the study of invasive and metastatic human colorectal carcinoma cells. However, most *in vitro* parameters analyzed did not predict *in vivo* behavior of colorectal carcinoma cells. This can be attributed to the modulating influence of the microenvironment on gene expression, e.g. local tissue host factors in nude mice.

Pointmutations in p21^{ras} genes have been implicated in carcinogenesis and tumor progression. Therefore, it was of interest to investigate the effect of transfection with the c-Ha-ras oncogene upon cell behavior of human colorectal carcinoma cells. Our results indicated that the genetic instability increased and suggested that tumorigenic behavior was induced. Both phenomena might have a common cause, namely dysregulation of proliferation, which is likely to occur in view of the role of p21^{ras} proteins in mitogenic signal transduction pathways. Invasive capacity was not acquired after transfection with the c-Ha-ras oncogene. Taken together, these data suggest a role for pointmutated p21^{ras} proteins early in colorectal carcinogenesis rather than in progression.

7.6 REFERENCES

1. Fidler IJ, Naito S, Pathak S: **Orthotopic implantation is essential for the selection, growth and metastasis of human renal cell cancer in nude mice.** *Cancer. Metastasis. Rev.* 1990; 9: 149-165.
2. de Vries JE, Dinjens WNM, Verspaget HW, *et al*: **Behavior of orthotopic human colorectal carcinoma xenografts in relation to in vitro invasion.** Chapter 2, this thesis.
3. Liotta LA, Steeg PS, Stetler-Stevenson WG: **Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.** *Cell.* 1991; 64: 327-336.
4. Albelda SM: **Role of integrins and other cell adhesion molecules in tumor progression and metastasis.** *Lab. Invest.* 1993; 68: 4-17.
5. Haynes BF, Telen MJ, Hale LP, Denning SM: **CD-44 - A molecule involved in leukocyte adherence and T-cell activation.** *Immunology today* 1989; 10: 423-428.
6. Heider K-H, Hofmann M, Hors E, *et al*: **A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps.** *J. Cell. Biol.* 1993; 120: 227-233.
7. Gunthert U, Hofmann M, Rudy W, *et al*: **A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.** *Cell.* 1991; 65: 13-24.
8. Hofmann M, Rudy W, Zoller M, *et al*: **CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines.** *Cancer. Res.* 1991; 51: 5292-5297.
9. McBain JA, Weese JL, Meisner LF, Wolberg WH, Willson JK: **Establishment and characterization of human colorectal cancer cell lines.** *Cancer. Res.* 1984; 44: 5813-5821.
10. Fu XY, Besterman JM, Monosov A, Hoffman RM: **Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens.** *Proc. Natl. Acad. Sci. U. S. A.* 1991; 88: 9345-9349.
11. Furukawa T, Kubota T, Watanabe M, Kitajima M, Hoffman RM: **Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice: Correlation of metastatic sites in nude mouse and individual patient donors.** *Int. J. Cancer.* 1993; 53: 608-612.
12. Schutte B, Reynders MMJ, Wiggers T, *et al*: **Retrospective analysis of the prognostic significance of DNA content and proliferative activity in large bowel carcinoma.** *Cancer. Res.* 1987; 47: 5494-5496.
13. Armitage NC, Robins RA, Evans DF, Turner DR, Baldwin RW, Hardcastle JD: **The influence of tumour cell DNA abnormalities on survival in colorectal cancer.** *Br. J. Surg.* 1985; 72: 828-830.
14. van-den-Ingh HF, Griffioen G, Cornelisse CJ: **Flow cytometric detection of aneuploidy in colorectal adenomas.** *Cancer. Res.* 1985; 45: 3392-3397.
15. Wolley RC, Schreiber K, Koss LG, Karas M, Sherman A: **DNA distribution in human colon carcinomas and its relationship to clinical behavior.** *J. Natl. Cancer. Inst.* 1982; 69: 15-22.
16. Kokal W, Sheibani K, Terz J, Harada JR: **Tumor DNA content in the prognosis of colorectal carcinoma.** *Jama.* 1986; 255: 3123-3127.
17. Muleris M, Salmon RJ, Dutrillaux B: **Existence of two distinct processes of chromosomal evolution in near-diploid colorectal tumors.** *Cancer. Genet. Cytogenet.* 1988; 32: 43-50.
18. Poddighe PJ, Ramaekers FCS, Hopman AHN: **Interphase cytogenetics of tumours.** *J. Pathol.* 1992; 166: 215-224.
19. Vogelstein B, Fearon ER, Hamilton SR, *et al*: **Genetic alterations during colorectal-tumor development.** *N. Engl. J. Med.* 1988; 319: 525-532.
20. Fearon ER, Vogelstein B: **A genetic model for colorectal tumorigenesis.** *Cell.* 1990; 61: 759-767.

21. Bardi G, Johansson B, Pandis N, *et al*: **Cytogenetic aberrations in colorectal adenocarcinomas and their correlation with clinicopathological features.** *Cancer.* 1993; 71: 306-314.
22. Bell SM, Scott N, Cross D, *et al*: **Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer.** *Gastroenterology* 1993; 104: 57-64.
23. Suchy B, Zietz C, Rabes HM: **K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis.** *Int. J. Cancer.* 1992; 52: 30-33.
24. Ichikawa T, Kyprianou N, Isaacs JT: **Genetic instability and the acquisition of metastatic ability by rat mammary cancer cells following v-H-ras oncogene transfection.** *Cancer. Res.* 1990; 50: 6349-6357.
25. Ichikawa T, Schalken JA, Ichikawa Y, Steinberg GD, Isaacs JT: **H-ras expression, genetic instability, and acquisition of metastatic ability by rat prostatic cancer cells following v-H-ras oncogene transfection.** *Prostate.* 1991; 18: 163-172.
26. de Vries JE, Kornips FHAC, Marx P, Bosman FT, Geraedts JPM, ten Kate J: **Transfected c-Ha-ras oncogene enhances karyotypic instability and integrates predominantly in aberrant chromosomes.** *Cancer. Genet. Cytogenet.* 1993; 100: 100.
27. Hurlin PJ, Maher VM, McCormick JJ: **Malignant transformation of human fibroblasts caused by expression of a transfected T24 HRAS oncogene.** *Proc. Natl. Acad. Sci. U. S. A.* 1989; 86: 187-191.
28. Wilson DM, Yang DJ, Dillberger JE, Dietrich SE, Maher VM, McCormick JJ: **Malignant transformation of human fibroblasts by a transfected N-ras oncogene.** *Cancer. Res.* 1990; 50: 5587-5593.
29. Fry DG, Milam LD, Dillberger JE, Maher VM, McCormick JJ: **Malignant transformation of an infinite life span human fibroblast cell strain by transfection with v-Ki-ras.** *Oncogene.* 1990; 5: 1415-1418.
30. McKenna WG, Nakahara K, Muschel RJ: **Site-specific integration of H-ras in transformed rat embryo cells.** *Science.* 1988; 241: 1325-1328.
31. de Vries JE, Kornips FHAC, Wiegant J, *et al*: **Chromosomal localization of transfected genes by a combination of hot banding and fluorescence in situ hybridization.** *J. Histochem. Cytochem.* 1992; 40: 1053-1058.
32. Hecht F, Hecht BK: **The telomere in cancer.** *Cancer. Genet. Cytogenet.* 1991; 54: 245-246.
33. Greider CW: **Chromosome first aid.** *Cell.* 1991; 67: 645-647.
34. Furth ME, Aldrich TH, Cordon-Cardo C: **Expression of ras proto-oncogene proteins in normal human tissues.** *Oncogene.* 1987; 1: 47-58.
35. Burgering BMT, Medema RH, Maassen JA, *et al*: **Insulin stimulation of gene expression mediated by p21ras activation.** *The EMBO Journal* 1991; 10: 1103-1109.
36. Buday L, Downward J: **Epidermal growth factor regulates the exchange rate of guanine nucleotides on p21ras in fibroblasts.** *Mol. Cell. Biol.* 1993; 13: 1903-1910.
37. Satoh T, Endo M, Nakafuku M, Akiyama T, Yamamoto T, Kaziro Y: **Accumulation of p21ras.GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity.** *Proc. Natl. Acad. Sci. U. S. A.* 1990; 87: 7926-7929.
38. Satoh T, Endo M, Nakafuku M, Nakamura S, Kaziro Y: **Platelet-derived growth factor stimulates formation of active p21ras.GTP complex in Swiss mouse 3T3 cells.** *Proc. Natl. Acad. Sci. U. S. A.* 1990; 87: 5993-5997.
39. Gibbs JB, Marshall MS, Scolnick EM, Dixon RA, Vogel US: **Modulation of guanine nucleotides bound to Ras in NIH3T3 cells by oncogenes, growth factors, and the GTPase activating protein (GAP).** *J. Biol. Chem.* 1990; 265: 20437-20442.
40. Pusztai L, Lewis CE, Lorenzen J, McGee JO'D: **Growth factors: Regulation of normal and neoplastic growth.** *J. Pathol.* 1993; 169: 191-201.
41. Cohen SM, Ellwein LB: **Genetic errors, cell proliferation, and carcinogenesis.** *Cancer. Res.* 1991; 51: 6493-6505.

42. Vogel US, Dixon RA, Schaber MD, *et al*: Cloning of bovine GAP and its interaction with oncogenic ras p21. *Nature*. 1988; 335: 90-93.
43. Xu GF, O'Connell P, Viskochil D, *et al*: The neurofibromatosis type 1 gene encodes a protein related to GAP. *Cell*. 1990; 62: 599-608.
44. Legius E, Marchuk DA, Collins FS, Glover TW: Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. *Nature Genetics* 1993; 3: 122-125.
45. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J: Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. *Nature*. 1992; 356: 713-715.
46. Ballester R, Marchuk D, Boguski M, *et al*: The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. *Cell*. 1990; 63: 851-859.
47. Sirinian MI, Marchetti A, Rocco GD, Starace G, Jucker R, Nasi S: Ras oncogene transformation of human B lymphoblasts is associated with lymphocyte activation and with a block of differentiation. *Oncogene*. 1993; 8: 157-163.
48. Feramisco JR, Gross M, Kamata T, Rosenberg M, Sweet RW: Microinjection of the oncogene form of the human H-ras (T-24) protein results in rapid proliferation of quiescent cells. *Cell*. 1984; 38: 109-117.
49. Stacey DW, Kung H-F: Transformation of NIH 3T3 cells by microinjection of Ha-ras p21 protein. *Nature*. 1984; 310: 508-511.
50. Ricketts MH, Levinson AD: High-level expression of c-H-ras1 fails to fully transform rat-1 cells. *Mol. Cell. Biol*. 1988; 8: 1460-1468.
51. Jankun J, Maher VM, McCormick JJ: Malignant transformation of human fibroblasts correlates with increased activity of receptor-bound plasminogen activator. *Cancer. Res*. 1991; 51: 1221-1226.
52. Ciardiello F, McGeedy ML, Kim N, *et al*: Transforming growth factor- α expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor- α complementary DNA leads to transformation. *Cell. Growth. Differ*. 1990; 1: 407-420.
53. Andrejauskas E, Moroni C: Reversible abrogation of IL-3 dependence by an inducible H-ras oncogene. *Embo. J*. 1989; 8: 2575-2581.
54. Chadwick DE, Lagarde AE: Coincidental acquisition of growth autonomy and metastatic potential during the malignant transformation of factor-dependent CCL39 lung fibroblasts. *J. Natl. Cancer. Inst*. 1988; 80: 318-325.
55. Liotta LA: Growth autonomy: The only requirement for metastasis? *J. Natl. Cancer. Inst*. 1988; 86: 18.
56. de Vries JE, van Driel M, Marx P *et al*: Phenotypic analysis of CaCo 2 and SW480 cell lines transfected with the c-Ha-ras oncogene. Chapter 5, this thesis.
57. de Bruine AP, de Vries JE, Dinjens WNM, *et al*: Human CaCo 2 cells transfected with c-Ha-ras as a model for endocrine differentiation in the large intestine. *Differentiation*. 1993; 53: 51-60.
58. Bos JL: Ras oncogenes in human cancer: A review. *Cancer. Res*. 1989; 49: 4682-4689.
59. Capon DJ, Seeburg PH, McGrath JP, *et al*: Activation of Ki-ras 2 gene in human colon and lung carcinomas by two different point mutations. *Nature*. 1983; 304: 507-513.
60. Vaux DL, Weissman IL, Kim SK: Prevention of programmed cell death in *Caenorhabditis elegans* by human Bcl-2. *Science*. 1992; 258: 1955-1957.
61. Abrams JM, White K, Fessler LI, Steller H: Programmed cell death during *Drosophila* embryogenesis. *Development* 1993; 117: 29-43.
62. Cohen JJ: Glucocorticoid-induced apoptosis in the thymus. *Seminars in Immunology* 1992; 4: 363-369.

63. Moran MF, Polakis P, McCormick F, Pawson T, Ellis C: **Protein-tyrosine kinases regulate the phosphorylation, protein interactions, subcellular distribution, and activity of p21ras GTPase-activating protein.** *Mol. Cell. Biol.* 1991; 11: 1804-1812.
64. Settleman J, Narasimhan V, Foster LC, Weinberg RA: **Molecular cloning of cDNAs encoding the GAP-associated protein p190: implications for a signaling pathway from ras to the nucleus.** *Cell.* 1992; 69: 539-549.
65. Mabry M, Nakagawa T, Baylin S, Pettengill O, Sorenson G, Nelkin B: **Insertion of the c-Ha-ras oncogene induces differentiation of calcitonin-producing human small cell lung cancer.** *J. Clin. Invest.* 1989; 84: 194-199.
66. Nakagawa T, Mabry M, de-Bustros A, Ihle JN, Nelkin BD, Baylin SB: **Introduction of v-Ha-ras oncogene induces differentiation of cultured human medullary thyroid carcinoma cells.** *Proc. Natl. Acad. Sci. U. S. A.* 1987; 84: 5923-5927.
67. Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ: **Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice.** *Cancer. Res.* 1988; 48: 6863-6871.
68. Morikawa K, Walker SM, Jessup JM, Fidler IJ: **In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice.** *Cancer. Res.* 1988; 48: 1943-1948.
69. Bresalier RS, Raper SE, Hujanen ES, Kim YS: **A new animal model for human colon cancer metastasis.** *Int. J. Cancer.* 1987; 39: 625-630.

SUMMARY

The subject of this thesis has been the biological behavior of human colorectal carcinoma cells in various models and the influence of the c-Ha-ras oncogene on this behavior.

In **Chapter 1** the characteristics of invasive and metastatic cells and their interactions with the microenvironment are reviewed, and a survey is presented of the structure, regulation and putative (dys)function of the c-Ha-ras (onco)protein and its effects on tumor cell lines after transfection.

In **Chapter 2** experiments are described in which nine human colorectal carcinoma cell lines were xenografted in nu/nu mice, either hetero- or orthotopically. Different modes of in vivo behavior, ranging from non-tumorigenic to tumorigenic, invasive and metastatic, were observed, depending on the site of xenografting. Because E-cadherin, urokinase- or tissue type-plasminogen activator, and integrin receptors have a role in intercellular adhesion, extracellular matrix degradation and cell-matrix interactions and are of importance for the invasive and metastatic cascade, the expression of these proteins was analyzed. With the exception of high expression of the $\alpha_2\beta_1$ integrin receptor, expression did not correlate with the in vivo invasive and metastatic behavior of tumor cells. Also, the ability to invade chick heart embryonic tissue, did not correlate with in vivo invasive and metastatic behavior. From these results, it was concluded that local tissue factors, in casu the microenvironment, play a role in the induction of genes responsible for invasion and metastasis.

Based on these results highly differentiated poorly tumorigenic CaCo 2 cells and undifferentiated, tumorigenic but non-invasive SW480 cells were selected to evaluate the genotypic and phenotypic consequences of transfection experiments with the c-Ha-ras oncogene, particularly with regard to genetic instability, chromosomal integration site, tumorigenic and invasive potential, and differentiation.

In **Chapter 3** the use of fluorescence in situ hybridization after chromosomal banding, induced by either hot banding or short trypsin treatment, is described in order to identify chromosomal integration sites of transfected plasmid DNA. Nick translated DNA-probes labeled with digoxigenin-dUTP gave optimal fluorescence in situ hybridization signals in our hands. This method allowed rapid identification of chromosomal integration sites.

In **Chapter 4** a cytogenetic analysis is described of transfected SW480 cells. All cell lines demonstrated new clonal chromosomal abnormalities, but genetic instability was significantly increased only in c-Ha-ras oncogene transfected SW480 cells with an increased level of c-Ha-ras mRNA. The application of the method developed in chapter 3 demonstrated that Ras-containing plasmids integrated predominantly in new structurally rearranged chromosomes (five of eight). Three of five integration sites in new structurally rearranged chromosomes were localized at or near translocation breakpoints situated in telomeric regions. However, specific chromosomes were not involved in the chromosome rearrangements. It was concluded that the c-Ha-ras

oncogene might increase the genetic instability and that chromosomal integration sites were especially associated with breakpoints in telomeric bands.

In **Chapter 5** the phenotypic effects of c-Ha-ras oncogene transfection on CaCo 2 and SW480 cells are described. CaCo 2 cells became highly tumorigenic, but not invasive, in nu/nu mice and induction of gelatinase activity was observed along with a possible increase in urokinase-plasminogen activator production. Specific changes in vitro in invasive capacity, tissue-type plasminogen activator production, proliferative potential, expression of β_1 integrin receptors, and differentiation were not noted. None of these parameters was altered in c-Ha-ras oncogene transfected SW480 cells, nor did the transfected cells become invasive. These results suggested that the c-Ha-ras oncogene might be involved in the progression of colorectal cancer, particularly in the induction of tumorigenic potential, but is most likely not required for the acquisition of invasive potential.

Chapter 6 describes in detail phenotypic characteristics of parental and c-Ha-ras oncogene transfected CaCo 2 cells in vivo. The routine xenograft procedures with the parental CaCo 2 cells did not yield xenografts in nu/nu mice. Therefore, CaCo 2 cells were inoculated in collagen gel and by suppressing natural killer cell activity to obtain xenografts. Both CaCo 2 and c-Ha-ras oncogene transfected CaCo 2 cells displayed in vivo goblet cell, enterocytic, Paneth cell, and endocrine differentiation. The latter is of interest because of the scarcity of colorectal cancer cell lines with endocrine differentiation. Endocrine differentiation was not observed in vitro, neither under standard conditions nor with extracellular matrix components as differentiation inducers. It was concluded that CaCo 2 cells and its c-Ha-ras oncogene transfected CaCo 2 subline display in vivo similar differentiation characteristics, which included endocrine features. Therefore, ras overexpression does not alter the pattern of differentiation, but due to the favorable growth properties of the c-Ha-ras oncogene transfected CaCo 2 cells in vivo, this subline may be a suitable model to study endocrine differentiation in colorectal cancer.

In **Chapter 7** the results of the studies presented in the previous chapters are integrated with regard to current models employed to study colorectal carcinoma, and to the role of the c-Ha-ras oncogene in: 1. Genetic instability in colorectal carcinoma and 2. Intracellular proliferation and differentiation pathways.

SAMENVATTING VOOR DE LEEK

Kanker ontstaat als het evenwicht tussen celaanmaak en celsterfte verstoord is. In normale omstandigheden is celsterfte gelijk aan celaanmaak, bij kanker is de laatste hoger dan de eerste, waardoor plaatselijk te veel weefsel ontstaat, een tumor. Suksevolle behandeling van kanker is in hoge mate afhankelijk van het groeigedrag van de tumor. Is de groei alleen plaatselijk dan kan de tumor goed behandeld worden, bijvoorbeeld door volledige verwijdering via chirurgisch ingrijpen, en is de kans op genezing groot. Is de tumor echter ook doorgedrongen in omringend weefsel, zogenaamd invasief groeigedrag, dan is het waarschijnlijk dat door middel van behandeling niet alle tumorcellen verwijderd kunnen worden. Achtergebleven tumorcellen kunnen vervolgens weer uitgroeien tot tumoren. Bereiken invasieve tumorcellen de bloedbaan, dan kunnen ze verspreid worden naar andere delen van het lichaam, en daar uitgroeien tot nieuwe tumoren. Dit proces heet metastasering en is vaak verantwoordelijk voor de fatale afloop van kanker. Het groeigedrag van de tumor is dus van groot belang voor een succesvolle behandeling van kanker. Inzicht in de factoren betrokken bij: (1) het ontstaan van kanker; (2) de overgang van niet-invasieve naar invasieve tumorgroei en; (3) het metastaserings proces kunnen de behandeling van kanker mogelijk verbeteren.

Het ontstaan van kanker is waarschijnlijk toe te schrijven aan afwijkingen in eiwitten die normaal celgroei en celdeling reguleren. Een belangrijk groeiregulerend eiwit is het Ha-ras eiwit. Bepaalde afwijkingen in het Ha-ras eiwit resulteren in een eiwit dat continu actief is en in staat blijkt te zijn om groei en deling van verschillende typen cellen te stimuleren. Het is mogelijk dat het afwijkende of mutante Ha-ras eiwit kanker veroorzaakt doordat het een cel continu prikkelt tot groei en deling, onafhankelijk van regulerende signalen van buitenaf. Deze visie wordt ondersteund door de aanwezigheid van genetische afwijkingen in het Ha-ras gen in verschillende typen tumoren, wat betekent dat deze tumorcellen afwijkende Ha-ras eiwitten produceren.

De overgang van niet-invasieve groei naar invasieve groei betekent dat een tumor cel in staat is zijn normale omgeving te verlaten. Cellen blijven op hun plaats doordat speciale eiwitten op het oppervlak van een cel, zogenaamde cel-adhesie molekulen, binden aan andere cel-adhesie molekulen op naast gelegen cellen. Tumorcellen met een verminderde expressie van deze eiwitten kunnen hun directe omgeving waarschijnlijk makkelijker verlaten doordat ze minder hard plakken aan naast gelegen cellen. Daarnaast is elk orgaan van het lichaam ingekapseld in een mengsel van grote eiwitten, de extracellulaire matrix, die voornamelijk bestaat uit collageen en laminine. De extracellulaire matrix geeft steun aan weefsels en scheidt organen van elkaar en van omringend weefsel. Bepaalde klassen van eiwitten, met name collagenases en plasmine en hun aktivatoren, kunnen de bouwstenen van de extracellulaire matrix afbreken. Vermoedelijk vergemakkelijkt een hoge expressie van collagenases en/of plasmine en hun aktivatoren de passage van een tumorcel door de extracellulaire

matrix, wat nodig is om omringend weefsel te kunnen binnendringen. Dit wordt ondersteund door de waarneming dat hoge expressie van collagenases gepaard gaat met een verhoogd invasief vermogen van verschillende typen tumorcellen. Mogelijk speelt het Ha-ras eiwit ook een rol in de overgang van niet-invasieve naar invasieve groei, want een verhoogde expressie van mutant Ha-ras eiwit in bepaalde tumorcel typen is ook gekoppeld aan verhoogd invasief vermogen en aan verhoogde expressie van collagenase.

Metastasering is een nog grotendeels onbegrepen proces. Kenmerkend voor een groot aantal metastaserende tumor typen is een sterke toename in genetische afwijkingen. Dit betekent dat mutante eiwitten worden geproduceerd, en/of dat de produktie van bepaalde eiwitten verhoogd, verminderd of volledig stilgelegd kan zijn. Dit kan de groei en deling van cellen ingrijpend veranderen als het eiwitten betreft met een functie in de regulering van groei en deling. Hiermee mogelijk verband houdend is het feit dat metastaserende tumoren vaak een lage differentiatiegraad vertonen. Dit betekent dat veel van de specifieke kenmerken van bijvoorbeeld darmcellen niet meer aanwezig zijn in cellen van een metastaserende darmtumor. Ook in dit aspect heeft het Ha-ras eiwit mogelijk een functie, want mutant Ha-ras eiwit kan de differentiatiegraad van tumorcellen beïnvloeden, maar ook de genetische instabiliteit verhogen, waardoor de toename in het aantal genetische afwijkingen in tumorcellen wordt versneld.

In de vakgroep Pathologie houdt een onderzoeksgroep zich bezig met darmkanker. Dit is de meest voorkomende vorm van kanker in West Europa en de Verenigde Staten na longkanker en prostaatkanker bij mannen en borstkanker bij vrouwen, en is verantwoordelijk voor 10% van de sterfte aan kanker bij mannen en voor 14% van de sterfte aan kanker bij vrouwen. De behandeling van darmkanker is in de afgelopen decennia niet of nauwelijks verbeterd. Meer inzicht in het mechanisme van invasie en metastasering van darmtumorcellen kan behandeling van kwaadaardige tumoren verbeteren. De mogelijke relaties tussen mutant Ha-ras eiwit en (1) het ontstaan van kanker, (2) invasief, en (3) metastaserend gedrag in verschillen typen tumorcellen is reden om te veronderstellen dat het mutante Ha-ras eiwit eenzelfde betrokkenheid kan hebben bij darmtumoren. Ten einde dit nader te onderzoeken is het mutante Ha-ras eiwit ingebracht in humane darmtumorcellen en zijn de effecten bekeken op de genetische stabiliteit en op het gedrag van darmtumorcellen.

Hoofdstuk 1 beschrijft de kenmerken van invasieve en metastaserende cellen, en de structuur en mogelijke functie van het Ha-ras eiwit. Tevens worden de effecten van het mutante Ha-ras eiwit op verschillende typen tumorcellen beschreven.

Hoofdstuk 2 beschrijft het gedrag van menselijke darmtumor cellijnen onder verschillende kondities. Tumor cellijnen ontstaan uit tumorcellen, die verwijderd zijn uit een patiënt, en buiten het lichaam (= in vitro) doorgroeien en delen onder optimale voedings kondities. Het gedrag van verschillende darmtumor cellijnen werd bekeken na injectie van tumorcellen in het lichaam (= in vivo) van een speciaal soort muis zonder immunologisch afweersysteem. Een gedeelte van de darmtumor cellijnen was

invasief en metastaseerde, een gedeelte was invasief maar metastaseerde niet, en een gedeelte vormde tumoren die niet invasief en niet metastaserend waren. Het waarnemen van invasief groeigedrag en metastasering betekent dat dit model gehanteerd kan worden om invasie en metastasering te onderzoeken.

Vervolgens werd gekeken of er een verband was tussen in vivo invasief vermogen en in vitro expressie van cel-adhesie molekulen en plasminogeen aktivator. Er werd geen verband gevonden, wel bleek er een verband te zijn tussen in vitro expressie van zowel cel-adhesie molekulen als een plasminogeen aktivator met invasie in vitro. Uit de bovenstaande experimenten werd gekonkludeerd dat de direkte omgeving van een tumorcel een faktor is die invasief en metastaserend gedrag beïnvloedt.

Twee menselijke cellijnen werden geselecteerd voor verdere experimenten. CaCo 2, een cellijn die geen tumoren vormde in de muis, en SW480, een cellijn die niet-invasieve tumoren vormde in de muis. Het mutant Ha-ras gen werd ingebracht in CaCo 2 en SW480 cellen. Voor blijvende expressie van het Ha-ras eiwit moet het Ha-ras gen ingebouwd worden in het genetisch materiaal. Dit betekent dat het gen moet integreren in een chromosoom. Om na te gaan of integratie willekeurig plaatsvond of niet, werd de chromosomale integratie plaats zichtbaar gemaakt.

Hoofdstuk 3 beschrijft een methode waarmee de chromosomale integratie plaats bepaald kan worden van het ingebrachte mutante Ha-ras gen.

Hoofdstuk 4 beschrijft de toepassing van deze methode op verschillende cellijnen van SW480 waar een mutant Ha-ras gen is ingebracht. Het blijkt dat het ingebrachte Ha-ras gen voornamelijk aangetoond wordt op nieuwe afwijkende chromosomen. De resultaten suggereren eveneens dat het inbrengen van het mutante Ha-ras gen de genetische instabiliteit van SW480 verhoogt.

Hoofdstuk 5 beschrijft het gedrag en de expressie in vitro van verschillende eiwitten met een mogelijke rol in invasie en metastasering van CaCo 2 en SW480 cellen na het inbrengen van het mutante Ha-ras gen. Het blijkt dat CaCo 2 cellen collagenases verhoogd tot expressie brengen en nu wel tumoren vormen in de muis. Deze tumoren zijn niet-invasief. Het inbrengen van het mutante Ha-ras eiwit sorteert geen effect op het gedrag van SW480 cellen en brengt ook geen veranderingen teweeg in de expressie van de onderzochte eiwitten.

Hoofdstuk 6 beschrijft in detail de differentiatiegraad van de CaCo 2 tumoren in vivo. Het blijkt dat de differentiatie van de tumorcellen ondermeer afhangt van de direkte omgeving, maar lijkt niet beïnvloedt te worden door het inbrengen van een mutant Ha-ras eiwit.

Hoofdstuk 7 integreert de data gepresenteerd in de voorgaande hoofdstukken. De belangrijkste effekten van het inbrengen van het mutante Ha-ras gen op menselijke darmtumorcellen is een verhoging van de genetische instabiliteit en een verhoging van het vermogen tot niet-invasieve tumor vorming in de muis. Deze resultaten suggereren een rol voor het mutante Ha-ras eiwit in het ontstaan van darmkanker, maar geen rol in de overgang van niet-invasief naar invasief groeigedrag en van niet naar wel metastaserend gedrag.

DANKWOORD

Dit proefschrift vormt de afronding van een periode die ik met veel plezier heb doorgebracht bij de Pathologie. Mijn hartelijke dank en grote waardering gaat uit naar diegenen die op enigerlei wijze hun steen(tje) hebben bijgedragen. Een aantal wil ik graag bij naam noemen, zonder de andere mensen tekort te willen doen.

Beste Joop, zonder jou was dit proefschrift er niet gekomen. Het kwam tot stand in een zeer prettige samenwerking waar ik veel van heb opgestoken. De hartverwarmende steun en onvermoeibare inzet (ook na werktijd) zal ik niet vergeten. Fré, het proefschrift had zijn huidige vorm niet gekregen zonder de scherp analyserende inbreng van jou. De ontspannen wijze waarop deze inbreng werd geleverd maakte je tot de ideale supervisor op het promotie traject. Joep, jouw bijdrage was essentieel om de genetische data korrekt te interpreteren.

Met veel plezier denk ik terug aan de genetische sessies met Frank. Onder rook, muziek en verzuchtingen heb je de genetische afwijkingen in kaart gebracht. Beste Peter, met hetzelfde plezier denk ik terug aan de humorvolle en soepele samenwerking met jou op velerlei gebieden.

Grote bewondering heb ik voor Edith, jouw grenzeloze bekwaamheid gekoppeld aan uiterste hulpvaardigheid heeft het onderzoek veel goed gedaan. Deze eigenschappen bezaten meer mensen van de Pathologie (Orthopaedie), zoals Jacques Cleutjens, (Roel Kuijer), Cor Beek, Mat Rousch, Miek Havenith, Bert Schutte, Ton de Goeij, en het secretariaat door de jaren heen. De positieve opstelling van Jan-Willem Arends heeft de laatste loodjes lichter gemaakt.

Adriaan en Winand, jullie beider dynamische voortvarendheid resulteerde in hoofdstuk 6, waarvan akte.

Verder hebben de "Mannen van Jan" (Marc Oosterloo, Wessel Wittenburg, Marc Fischer) hun bijdrage geleverd. Patrick Marx, bedankt voor het aan elkaar knopen van veel losse eindjes in de laatste fase van het onderzoek. Léon en Marjolein, het was een genot om met jullie samen te werken. De enorme hoeveelheid kweekwerk kon ik rustig in jullie betrouwbare handen achterlaten (hetgeen ook gebeurde). Nicole, de vrouw die metafase preparaten sneller hybridiseert dan ze gespat kunnen worden. Blanka en Petra, jullie bijdrage kwam op een cruciaal moment.

Beste Marc Mareel en Hein Verspaget, de samenwerking gebeurde op een *plezante* wijze, waar ik veel van heb opgestoken. Joop Wiegant, je bent een onovertroffen leermeester geweest in het bijbrengen van niet-radioactieve in situ hybridisatie technieken.

Beste Marc Stuart en Paul Bomans, jullie inbreng in de doka bleef me soms duister maar hielp wel degelijk om goede foto's te verkrijgen. Ook de audiovisuele dienst is zeer gewaardeerd voor het geleverde fotowerk, met name Francis van der Lubbe. Tevens bedank ik de Dienst Automatisering en Orthopaedie voor het beschikbaar stellen van HPL4's. Ruud Leliveld gaf op plezierige wijze de goede tips om het proefschrift drukklaar te krijgen.

De beoordelingskommissie, aangevuld met Goos van Muijen, bedank ik voor het doornemen van het manuscript en het geleverde kommentaar. Frans, bedankt voor het voorzitterschap.

Uiteindelijk is onderzoek een groepsgebeuren. Een goede sfeer is daarbij een eerste vereiste. Die ontstaat natuurlijk door de inbreng van alle mensen van de Pathologie, maar voor mij in het bijzonder door Ellen als ideale werkkamergenote, bovenbuurvrouw, en mede-promovenda, Robert als biljarter, en Anneke ondermeer als "Zuidelijk Toneel" fan. Tenslotte wil ik benadrukken, Mieke, dat jouw steun in de afgelopen jaren erg belangrijk is geweest voor mij.

Het zijn de mensen die 't 'm doen, dit waren de mensen die 't 'm deden.

Curriculum vitae

- 1963 Geboren te Drachten
- 1982 Eindexamen Atheneum B
Het Drachtster Lyceum, Drachten
- 1982-1988 Studie Scheikunde, Afstudeerrichting Biochemie
Rijks Universiteit Groningen
- 1988-1992 Assistent In Opleiding bij de vakgroep Pathologie
Rijksuniversiteit Limburg
- 1992-1993 Afronding proefschrift
- 1993-1994 Vervulling van de gewone vervangende dienst bij de vakgroep
Fysiologie, Rijksuniversiteit Limburg

PUBLICATIONS

Artikelen

B. Neuteboom, W. Dokter, J. van Gijsen, H. Rensink, J.E. de Vries and J.J. Beintema. **Partial amino acid sequence of a hemocyanin subunit from *PALINURUS VULGARIS***. Comp. Biochem. Physiol. 94B: 593-597, 1989.

J.N.J. Philipsen, J.E. de Vries, J. Samallo, C. van Dijk, A.C. Arnberg, and G. AB. **Characterization of a polymorphism in the 3' part of the chicken vitellogenin gene**. J. Mol. Evol. 28: 185-190, 1989.

J.E. de Vries, F.H.A.C. Kornips, J. Wiegant, P.M. Moerkerk, N. Senden, B. Schutte, J.P.M. Geraedts, F.T. Bosman, and J. ten Kate. **Chromosomal localization of transfected genes by a combination of hot banding and fluorescence in situ hybridization**. J. Histochem. Cytochem. 40: 1053-1058, 1992.

A.P. de Bruïne, J.E. de Vries, W.N.M. Dinjens, E.P.M. van der Linden, M. Pijls, J. ten Kate, and F.T. Bosman. **Human Ha-Ras transfected CaCo-2 cells as a model for endocrine differentiation in the large intestine**. Differentiation, 53: 51-60, 1993.

J.E. de Vries, F.H.A.C. Kornips, P. Marx, F.T. Bosman, J.P.M. Geraedts, and J. ten Kate. **Transfected c-Ha-ras oncogene enhances karyotypic instability and integrates predominantly in aberrant chromosomes**. Cancer Genet. Cytogenet, 65: 35-43, 1993.

J.E. de Vries, M. van Driel, P. Marx, E.P.M. van der Linden, L.G.A. de Bruin, P.M. Moerkerk, H.W. Verspaget, F.T. Bosman, and J. ten Kate. **Phenotypic analysis of CaCo 2 and SW480 cell lines transfected with the c-Ha-ras oncogene**. Submitted.

J.E. de Vries, W.N.M. Dinjens, H.W. Verspaget, E.P.M. van der Linden, A.P. de Bruïne, M.M. Mareel, F.T. Bosman, and J. ten Kate. **Behavior of orthotopic human colorectal carcinoma xenografts in relation to in vitro invasion**. Submitted.

Abstracts.

J.E. de Vries, P.M. Moerkerk, L.G.A. de Bruïne, W.N.M. Dinjens, E.P.M. van der Linden, J. Wiegant, M. van Driel, J. ten Kate and F.T. Bosman. **Characterization of colon cancer cell lines after transfection with the c-Ha-ras oncogene**. Clin. Exp. Metast. 8 (suppl. 1): 39, 1990.

J.E. de Vries, P.M. Moerkerk, L.G.A. de Bruïne, W.N.M. Dinjens, E.P.M. van der Linden, J. Wiegant, M. van Driel, J. ten Kate and F.T. Bosman. **Growth characteristics of colon tumor cell lines after transfection with the c-Ha-ras oncogene**. Eur. J. Cell Biol. 53 (suppl. 1): 34, 1990.

A. de Bruïne, J. de Vries, W. Dinjens, E. van der Linden, M. Pijls, J. ten Kate, F. Bosman. **RAS-transfected CaCo-2 cells: A model for endocrine differentiation in the large intestine**. Histochemical J. 24: 612, 1992.

J.E. de Vries, A.P. de Bruïne, W.N.M. Dinjens, E.P.M. van der Linden, H.W. Verspaget, F.T. Bosman and J. ten Kate. **In Vitro expression of L-CAM and u-PA of human colorectal carcinoma cells is not related to their In Vivo growth behavior**. Histochemical J. 24: 613, 1992.